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Both HIV-1 and HIV-2 cause AIDS, but HIV-1 is found worldwide, whereas HIV-2 is 
found primarily in West Africa.  
It is estimated that approximately 40 million people worldwide are infected with HIV, 
and two-thirds of them live in the sub-Saharan Africa. Three regions, Africa, Asia, and 
Latin America, have the highest rates of new infections, and AIDS is the fourth leading 
cause of death worldwide. Since 1981, more than 980,000 cases of AIDS have been 
reported in the US alone, and according to CDC, more than 1,000,000 Americans may 
be infected with HIV. 
HIV preferentially infects and kills CD4+ T lymphocytes, and by killing or damaging 
CD4+ T cells of the body's immune system, HIV progressively destroys the body's 
ability to fight infections. People diagnosed with AIDS often suffer from life-
threatening diseases caused by opportunistic infections. HIV also infects other cells, 
such as macrophages, monocytes and dendritic cells. 
This book provides a detailed overview on the HIV transmission, how HIV infection 
alters the host immune responses, and on the prevention and treatment of AIDS 
related diseases. 
 
Vishwanath Venketaraman Ph.D.,  
Assistant Professor 
Microbiology/Immunology,  
Department of Basic Medical Sciences, 
College of Osteopathic Medicine of the Pacific,  
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Infection for Mycobacterium tuberculosis and 
Nontuberculous Mycobacteria in the  
HIV/AIDS Patients 
Lilian María Mederos Cuervo 
National Reference Laboratory TB/Mycobacteria Collaborate Center PAHO / WHO 
Tropical Medicine Institute Pedro Kourí (IPK) 
Cuba 
1. Introduction 
Tuberculosis (TB) is a disease also know as consumption, wasting disease, and the white 
plague, it has affected humans for centuries. Until the mid-1800s, people thought that 
tuberculosis, or TB, was hereditary. They did not realize that it could be spread from person 
to person through the air. Also, until the 1940s and 1950s there was no cure for TB. For 
many people, a diagnosis of TB was a slow death sentence 1-4. 
In 1865 a French surgeon, Jean-Antoine Villemin, proved that TB was contagious, and in 
1882 a german scientist named Robert Koch discovered the bacteria causes TB, denominated 
as Mycobacterium tuberculosis. Yet half a century passed before drugs were discovered that 
could cure TB, until then, many people with TB were sent to sanatoriums, special rest homes 
where they followed a prescribed routine every day. A breakthrough came in 1943, an 
american scientist, Selman Waksman discovered a drug that could kill TB bacteria. Between 
1943 and 1952, two more drugs were found, after these discoveries, many people with TB 
were cured and the death rate for TB in the United States dropped dramatically, and fewer 
and fewer people got TB 5.  
A global health emergency 6, 7: 
 Someone in the world is newly infected with TB bacilli every second. 
 Overall, one-third of the world's population is currently infected with the TB bacillus. 
 5-10 % of people who are infected with TB bacilli become sick or infectious at some time 
during their life.  
TB program activities, reinforced by successful chemotherapy, resulted in a pronounced 
reduction of infection and death rates. The disease became greatly controlled but it never 
quite disappeared. Then, in around 1985, cases of TB began to rise again in industrialized 
countries. Several inter-related forces drove this resurgence, including increase in prison 
populations, homelessness, injection drug use, crowded housing and increased immigration 
from countries where TB continued to be endemic. Above all, the decline in TB control 
activities and the human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) epidemic were two major factors fuelling each other in the re-emergence of TB.  
People with HIV and TB infection are much more likely to develop TB. The HIV/AIDS 
epidemic has produced a devastating effect on TB control worldwide. While one out of ten 
 1 
Infection for Mycobacterium tuberculosis and 
Nontuberculous Mycobacteria in the  
HIV/AIDS Patients 
Lilian María Mederos Cuervo 
National Reference Laboratory TB/Mycobacteria Collaborate Center PAHO / WHO 
Tropical Medicine Institute Pedro Kourí (IPK) 
Cuba 
1. Introduction 
Tuberculosis (TB) is a disease also know as consumption, wasting disease, and the white 
plague, it has affected humans for centuries. Until the mid-1800s, people thought that 
tuberculosis, or TB, was hereditary. They did not realize that it could be spread from person 
to person through the air. Also, until the 1940s and 1950s there was no cure for TB. For 
many people, a diagnosis of TB was a slow death sentence 1-4. 
In 1865 a French surgeon, Jean-Antoine Villemin, proved that TB was contagious, and in 
1882 a german scientist named Robert Koch discovered the bacteria causes TB, denominated 
as Mycobacterium tuberculosis. Yet half a century passed before drugs were discovered that 
could cure TB, until then, many people with TB were sent to sanatoriums, special rest homes 
where they followed a prescribed routine every day. A breakthrough came in 1943, an 
american scientist, Selman Waksman discovered a drug that could kill TB bacteria. Between 
1943 and 1952, two more drugs were found, after these discoveries, many people with TB 
were cured and the death rate for TB in the United States dropped dramatically, and fewer 
and fewer people got TB 5.  
A global health emergency 6, 7: 
 Someone in the world is newly infected with TB bacilli every second. 
 Overall, one-third of the world's population is currently infected with the TB bacillus. 
 5-10 % of people who are infected with TB bacilli become sick or infectious at some time 
during their life.  
TB program activities, reinforced by successful chemotherapy, resulted in a pronounced 
reduction of infection and death rates. The disease became greatly controlled but it never 
quite disappeared. Then, in around 1985, cases of TB began to rise again in industrialized 
countries. Several inter-related forces drove this resurgence, including increase in prison 
populations, homelessness, injection drug use, crowded housing and increased immigration 
from countries where TB continued to be endemic. Above all, the decline in TB control 
activities and the human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) epidemic were two major factors fuelling each other in the re-emergence of TB.  
People with HIV and TB infection are much more likely to develop TB. The HIV/AIDS 
epidemic has produced a devastating effect on TB control worldwide. While one out of ten 
  
Global View of HIV Infection 
 
4 
immunocompetent people infected with M. tuberculosis will fall sick in their lifetimes, 
among those with HIV infection, one in ten per year will develop active TB. In developing 
countries, the impact of HIV infection on the TB situation, especially in the 20-35 age groups, 
is overwhelming. While wealthy industrialized countries with good public health care 
systems can be expected to keep TB under control, in much of the developing world a 
catastrophe awaits. In poorly developed countries, TB remains a significant threat to public 
health, as incidences remain high, even after the introduction of vaccination and drug 
treatment. The registered number of new cases of TB worldwide roughly correlates with 
economic conditions: highest incidences are seen in the countries of Africa, Asia, and Latin 
America with the lowest gross national products. Supervised treatment, including 
sometimes direct observation of therapy (DOT), was proposed as a means of helping 
patients to take their drugs regularly and complete treatment, thus achieving cure and 
preventing the development of drug resistance 5-7. 
2. Transmission and pathogenesis 
TB is spread from person through the air. When a person with pulmonary or laryngeal TB 
coughs, sneezes, speaks, or sings, droplet nuclei containing Mycobacterium tuberculosis are 
expelled into the air. Depending on the environment, these tiny particles (1-5 microns in 
diameter) can remain suspended in the air for several hours. If another person inhales air 
containing droplet nuclei, transmission may occur. The probability that TB will be 
transmitted depends on these factors 4, 5: 
 The infectiousness of the person with TB (the number of organisms expelled into the air). 
 The environment in which exposure occurred. 
 The duration of exposure and the virulence of the organism. 
The best way to stop transmission is to isolate patients with infectious TB immediately and 
start effective TB therapy. Infectiousness declines rapidly after adequate therapy is started, 
as long as the patient adheres to the prescribed regimen. Persons at the highest risk of 
becoming infected with Mycobacterium tuberculosis are close contacts, the persons who had 
prolonged, frequent, or intense contact with a person with infectious TB. Close contacts may 
be family members, roommates, friends, coworkers, or others. Data collected by CDC since 
1987 show that infection rates have been relatively stable, ranging form 21-23% for the 
contacts of infectious TB patients 6-9. Some people with infection develop TB disease. This 
disease develops when the immune system cannot keep the tubercle bacilli under control 
and the bacilli begin to multiply rapidly. The risk that TB disease will develop is higher for 
some people than for others 3, 10-12. Among contacts of persons with drug-resistant TB, 
infection rates seem to be similar. However, because they may have a poor response to 
treatment persons with drug-resistant disease are often infectious for longer periods and 
therefore have the potential to infect more contacts 10-13.  
Extra pulmonary TB is rarely contagious; however, transmission from extrapulmonary sites 
has been reported during aerosol-producing procedures, such as autopsies and tissue 
irrigation 14-16. 
3. Pathogenesis  
The tubercle bacilli that alveoli are ingested by alveolar macrophages, the majority of these 
bacilli are destroyed or inhibited. A small number multiply intracellulary and are released 
Infection for Mycobacterium tuberculosis and  
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when the macrophages die. These bacilli can spread through the lymphatic channels to 
regional lymph nodes and then through the bloodstream to more distant tissues and organs, 
including areas in which TB disease is most likely to develop: the apices of the  lung, the 
kidneys, the brain, and bone.  Extracellular bacilli attract macrophages form the 
bloodstream. The immune response kills most of the bacilli, leading to the formation of a 
granuloma. At this point the person has TB infection, which can be detected by using the 
tuberculin skin test. It may take 2-10 weeks for the infected person to develop a positive 
reaction to the tuberculin skin test. Immune responses soon develop to kill the bacilli. 
Within 2-10 weeks after infection, the immune system is usually able to halt the 
multiplication of the tubercle bacilli, preventing further spread 4, 17-19. 
In persons infected with Mycobacterium tuberculosis  but that don’t  have TB disease cannot 
spread the infection to other people. TB infection in persons who does not have TB disease 
is not considered a case of TB and referred to as ¨latent TB infection¨. In some persons, TB 
bacilli overcome the defenses or the immune system and begin to multiply, resulting in 
the progression from TB infection to TB disease.  This process may occur soon after or 
many years after infection. Some study demonstrated that approximately 5% of person 
who have been infected with Mycobacterium tuberculosis  will develop TB disease in the 
first year or two after infection and another 5% will develop disease some time later in 
life. Recent infection (with the past 2 years) with Mycobacterium tuberculosis is therefore an 
important risk factor for progression to TB disease and in approximately 10% of persons 
with normal immune system who are infected with Mycobacterium tuberculosis , TB disease 
will develop at some point 5-7.  
Some medical conditions increase the risk that TB infection will progress to disease. Some 
studies suggest that the risk  is mayor in inmmunosuppressed patients, for example persons 
with Diabetes mellitus, prolonged therapy with corticosteroids, immunosuppressive 
therapy, certain types of cancer,  severe kidney disease, injection of illicit drugs, and 
infection with Human Immunodeficient  Virus (HIV) 2,3,12. 
TB disease most commomly affects the lung,  73% of TB cases are exclusively pulmonary, 
and however, TB is a systemic disease and may also commonly occur in the following 
ways;  as pleural effusion in the central nervous, lymphatic, or genitourinary systems, as 
disseminated disease (military TB). Also the infection for Mycobacterium tuberculosis can 
occur in the other body sites; in the breast, skin, or peritoneum 16,20-23. Extrapulmonary TB 
is more common in immunosuppressed persons and in young children; 
meningoencephalitis TB, lymphatic TB and military disease are particularly common in 
immunosuppressed persons, in some case the extrapulmonary TB is often accompanied 
by pulmonary TB 3, 8, 16-23.  
4. Epidemiology of TB 
TB infection is one of the most common infections in the world. It is estimated that 30-60% 
of adults in developing countries have TB infection. Annually about 8-10 million people 
develop TB disease and 2-3 million people die of the disease. TB disease is the leading cause 
of death due to infectious disease around the world 24, 25.  When the health department 
learns about a new case of TB, it should take steps to ensure that the person receives 
appropriate treatment. Is very important that the health authorities should also start a 
contact investigation, this means interviewing a person who has TB disease to determinate 
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who may have been exposed to TB, this person are screened for TB infection and disease 8, 26-
28. 
In order to the decrease in the number of TB cases reported annually is very important to 
comply three factors 29: 
 To increase federal resources for TB control and other public health efforts. 
 To improve prevention and TB control programs in state and local health department. 
 To Increase attention to ensuring that patients complete drug therapy through directly 
observed therapy (DOT). 
In the control of TB disease is also important to know the Groups at High Risk for TB 29, 30: 
People at Higher Risk for Exposure or Infection: 
 Close contacts of people with infectious TB disease. 
 People born in areas of the world where TB is common. 
 Elderly people. 
 Low-income groups with poor access to health care, including homeless people. 
 People who inject illicit drugs. 
 People who live or work in residential facilities (Example: nursing correctional 
facilities). 
 Other people who may be exposed to TB on the job. 
 People in other groups as identified by local public health officials. 
People at Higher Risk for TB disease: 
 People with other medical conditions that can increase the risk for TB. 
 People recently infected with Mycobacterium tuberculosis. 
 People with chest x-ray  suggestive of previous TB disease. 
 People who inject illicit drugs. 
 People with HIV infection. 
Infection with HIV makes people susceptible to rapidly progressive tuberculosis; over 10 
millions peoples are infected with both HIV and Mycobacterium tuberculosis 8. 
TB in Children:  
The occurrence of TB infection and disease in children provide important information about 
the spread of TB in homes and communities. When a child has TB infection or disease is 
important to learn if 29-31 : 
 Recent TB transmition. 
 Other adults and children in the household or community have probably been exposed 
to TB; if they are infected, they may develop TB disease in the future. 
4.1 Drug-resistant tuberculosis 
Drug-resistant TB is transmitted in the same way as drug-susceptible TB. The earlier outbreaks 
of multidrugs-resistant (MDR) TB support the findings that drug-resistant TB is no less 
infectious than drug-susceptible TB, although prolonged periods of infectiousness that often 
occur in the patients with drug-resistant TB may facililate transmission. Drug resistance was 
divided in two types; primary resistance and secondary or acquired resistance. Primary 
resistance develops in persons who are initially infected, with resistant organisms. Second 
resistance, or acquired resistance develops during TB therapy, either because the patient was 
treated with an inadequate regimen or because the patient did not take the prescribed regimen 
appropriately 27, 29, 32.  The MDR-TB are resistant to rifampicin and isoniazid drugs. Recently 
drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis caused by a Mycobacterium 
Infection for Mycobacterium tuberculosis and  
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tuberculosis strain that is resistant to at least rifampicin and isoniazid among the first-line 
antitubercular drugs (MDR-TB) in addition to resistance to any fluroquinolones and at least 
one of three  second-line drugs, namely amikacin, kanamycin and/or capreomycin. Current 
studies have described XDR-TB strains from all continents. Worldwide prevalence of XDR-TB 
is estimated in 6.6% in all the studied countries among MDR-TB strains. The emergence of 
XDR-TB strains is a reflection of poor tuberculosis management, and controlling its emergence 
constitutes an urgent global health reality and a challenge to tuberculosis control activities in 
all parts of the world, especially in developing countries and those lacking resources and as 
well as in countries with increasing prevalence of HIV/AIDS 32-34 . 
5. Diagnosis of tuberculosis 
The systemic symptom of Tuberculosis include fever, chills, night sweats, appetite loss, 
weigh loss, and easy fatigability,   the symptoms of pulmonary TB are productive and  
prolonged cough (>14-21 week) , chest pain and in some case the patient present 
hemoptysis. It is important to ask persons suspected of having tuberculosis about their 
history of TB exposure, infection, or disease. The clinicians may also contact the local health 
department for information about whether a patient has received tuberculosis treatment in 
the past, if the drug regimen was inadequate or if the patient may did not adhere to therapy, 
this disease may recur and may be drug resistant. Also is important to consider 
demographic factors; country of origin, age, ethnic or racial group and occupation, this 
factors may increase the patient’s risk for exposure to TB or drug-resistant TB disease.  
Clinicians should determinate whether the patient has medical conditions, especially HIV 
infection, because this infection increases the risk for TB disease. All patients who do not 
know their current HIV status should be referred for HIV counseling and testing 26, 27. 
The tuberculin skin test and the chest radiography,  are two probes  that help in the 
diagnostic for TB disease. Tuberculin skin testing useful for 29: 
 To examine a person who is not ill but may be infected with Mycobacterium tuberculosis, 
such as a person who has been exposed to someone who has TB. This test is the only 
way to diagnose tuberculosis infection before it has progressed to tuberculosis disease. 
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 To examine person who has symptoms of TB. 
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response to tuberculin. In children younger than 6 months of age may not react to the 
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 To detect abnormalities often seen in apical or posterior segments of upper lobe or 
superior segments of lower lobe. 
 To detect atypical images in immunosuppressed persons an in HIV-positive persons. 
In HIV-infected persons, pulmonary TB may appear in the chets radiograph. For example; 
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diagnostic for TB disease. Tuberculin skin testing useful for 29: 
 To examine a person who is not ill but may be infected with Mycobacterium tuberculosis, 
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mediastinal or hiliar lymphadenophaty with or without accompanying infiltrates and/or 
cavities. In HIV-positive persons, almost any abnormality on a chest radiographic may 
indicate TB. In fact, the radiograph of an HIV-positive person with TB disease may even 
appear entirely normal. Abnormalities on chest radiographs may be suggestive of, but are 
never diagnostic of TB.  However, chest radiographic  may be used to rule out the 
possibility of pulmonary TB in a person who has a positive reaction to the tuberculin skin 
test and no symptoms of disease 29, 31, 32, 34. 
Summarizing the possibility of TB should be considered in persons who have these 
symptoms, person suspected of having this disease should be referred for a medical 
evaluation, which should include a medical history, a physical examination, a Mantoux 
tuberculin skin test or tuberculosis purified protein derivate (PPD) skin test, a chest 
radiograph. Also, it is very important any appropriate bacteriologic or histological 
examinations in this patients, principally in all inmmunosuppressed patients, of course 
including the HIV patients 29.  
Person with symptoms of TB pulmonary disease should have at least three sputum 
specimens examined by smear and culture. The bets way would be to get serial specimens 
collected early in the morning on 3 consecutive days. A health care worked should be 
prepared and directly supervise at least during the first time sputum collection. This 
personal should give properly instructed in how to produce a good specimen, the patients 
should be informed that sputum is the material brought up form the lungs and that mucus 
from the nose or throat and saliva are not good specimens 35, 36.  
Recommends for Specimen Collection: 
 Get 3 sputum specimens for smear examination and culture.  
 In persons unable to cough up sputum, induce sputum, bronchoscopy or gastric 
aspiration. 
 Before chemotherapy and drug therapy is started. 
 To use clean, sterile, one-use, plastic, disposable containers  that have been washed with 
dichromate sulfuric acid and sterilized. 
 To transport specimens to the laboratory as soon as possible. 
5.2 Laboratory examination  
Detection of acid-fast bacilli (AFB) in stained smears examined microscopically may provide 
the first bacteriologic of TB. The traditional method for to detect AFB is the Zielh-Neelsen 
coloration, it is a method more economic. There are other methods that increased sensitivity 
as fluorescent methods. Smear examination is an easy and quick procedure, because the 
results should be available within 24 hours of specimen collection. However, smear 
examination permits only the presumptive diagnosis of TB because many TB patients have 
negative AFB smears. The sensitivity of smear examination may be reduced if the directed 
inflammatory response and relative absence of cavitary lesions results in fewer organisms 
expectorated in sputum. There has been concern that the utility of sputum acid-fast smears 
may be reduced in HIV-infected populations 36, 37.  
5.3 Extrapulmonary TB disease  
This disease is not taking in account as causative agent of an extrapulmonary disease 
because the chest radiography is normal or tuberculin skin test is negative, or both. 
Mycobacteria may infect almost any organ in the body, the laboratory should expect to 
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receive a variety of extrapulmonary specimens: aseptically collected body fluids, surgically 
excised tissue, aspirated or draining pus, and urine. Others ascetically collected specimens 
are the body fluids as spinal, pleural, pericardial, synovial, ascetic, blood, pus, and bone 
marrow are aseptically collected by the physician using aspiration techniques or surgical 
procedure. Acid-fast bacilli may be difficult to isolate from some of these specimens because 
they often are diluted by the large fluid volume 16-19, 37-39.  
The identification of TB can be done by traditional culture materials include egg-based solid 
media, such as Löwenstein-Jensen medium, and synthetic solid media as Middlebrook  
7H10 and 7H11 agars. The identification depends on the visualization of mycobacterial 
colonies and is limited by the slow growth rate of these organisms. A major advance in 
laboratory diagnosis of TB has been the development of systems based on detecting growth 
in liquid media with the use of radiometric methods as Bactec System. In this, the medium 
contains palmitic acid labeled with carbon-14. The metabolism of this fatty acid by growing 
mycobacteria liberates radioactive carbon dioxide, periodic sampling of the gasses in the 
culture-containing flask permits rapid detection of mycobacterial growth 40-41.  
Species identification was accomplished with biochemical test that often involved additional 
diagnostic delays. Others techniques, currently being evaluated in a number of clinical 
settings include identification based on chromatography techniques for the studies of some 
specific lipids present in the wall of Mycobacterium 42, 43. Also genetic probes are now availed 
for the identification of Mycobacterium tuberculosis and several other common mycobacterial 
species. These probes recognize species-specific sequences of ribosomal RNA. Theoretically, 
genetic probe as polymerase chain reaction (PCR), may permit diagnosis directly form 
patients specimens, eliminating the need for culture of organism. In practice, the utility of 
PCR has been limited by problems with the sensitivity and particularly, the specificity of 
results. In some laboratories, the sensitivity and specificity have been reported to exceed 
85%. However, in several laboratories, false-positive rates ranged from 3% to 20%, and in 
one, 77% of positive results were false. In the last time the Genotype Mycobacteria Direct 
Assay (GTMD), a novel commercial assay based on nucleic acid sequence-based 
amplification technology, was evaluated for detection of Mycobacterium tuberculosis complex 
and some atypical mycobacterial species from clinical samples, and your sensitivity, 
specificity, positive predictive, and negative predictive were evaluated and these results 
were more better 44-46. 
6. Nontuberculous mycobacteria in the environment 
Environmental opportunistic mycobacteria are those that are recovered form natural and 
human influenced environments and can infect and cause disease in humans, animals, and 
birds. Other names for these mycobacteria are nontuberculous, however, they cause 
tuberculous lesions, also other name is atypical mycobacterial, it distinguish from ¨typical¨ 
Mycobacterium tuberculosis, and them nontuberculous mycobacteria (NTM). The 
environmental opportunistic mycobacteria are normal inhabitants of natural waters, 
drinking water, and soils. They can be isolated from biofilms, aerosol, and dusts. The 
distribution of NTM and the incidence of disease caused by them is perhaps are not fully 
understood in most parts of the world. NTM are widely distributed in nature and have been 
isolated from natural water, rap water, tap water, and water used in showers and surgical 
solutions 47-51. 
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radiograph. Also, it is very important any appropriate bacteriologic or histological 
examinations in this patients, principally in all inmmunosuppressed patients, of course 
including the HIV patients 29.  
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prepared and directly supervise at least during the first time sputum collection. This 
personal should give properly instructed in how to produce a good specimen, the patients 
should be informed that sputum is the material brought up form the lungs and that mucus 
from the nose or throat and saliva are not good specimens 35, 36.  
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 To use clean, sterile, one-use, plastic, disposable containers  that have been washed with 
dichromate sulfuric acid and sterilized. 
 To transport specimens to the laboratory as soon as possible. 
5.2 Laboratory examination  
Detection of acid-fast bacilli (AFB) in stained smears examined microscopically may provide 
the first bacteriologic of TB. The traditional method for to detect AFB is the Zielh-Neelsen 
coloration, it is a method more economic. There are other methods that increased sensitivity 
as fluorescent methods. Smear examination is an easy and quick procedure, because the 
results should be available within 24 hours of specimen collection. However, smear 
examination permits only the presumptive diagnosis of TB because many TB patients have 
negative AFB smears. The sensitivity of smear examination may be reduced if the directed 
inflammatory response and relative absence of cavitary lesions results in fewer organisms 
expectorated in sputum. There has been concern that the utility of sputum acid-fast smears 
may be reduced in HIV-infected populations 36, 37.  
5.3 Extrapulmonary TB disease  
This disease is not taking in account as causative agent of an extrapulmonary disease 
because the chest radiography is normal or tuberculin skin test is negative, or both. 
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receive a variety of extrapulmonary specimens: aseptically collected body fluids, surgically 
excised tissue, aspirated or draining pus, and urine. Others ascetically collected specimens 
are the body fluids as spinal, pleural, pericardial, synovial, ascetic, blood, pus, and bone 
marrow are aseptically collected by the physician using aspiration techniques or surgical 
procedure. Acid-fast bacilli may be difficult to isolate from some of these specimens because 
they often are diluted by the large fluid volume 16-19, 37-39.  
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7H10 and 7H11 agars. The identification depends on the visualization of mycobacterial 
colonies and is limited by the slow growth rate of these organisms. A major advance in 
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in liquid media with the use of radiometric methods as Bactec System. In this, the medium 
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mycobacteria liberates radioactive carbon dioxide, periodic sampling of the gasses in the 
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specific lipids present in the wall of Mycobacterium 42, 43. Also genetic probes are now availed 
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It is common observation that environmental mycobacteria cause disease in individuals who 
offer some opportunity due to altered local or systemic immunity. Chronic obstructive 
pulmonary diseases, emphysema, pneumoconiosis, bronchiectasis, cystic fibrosis, thoracic 
scoliosis, aspiration due to esophageal disease, previous gastrectomy and chronic 
alcoholism  are some of conditions which have been linked to disease due to NTM. While 
the reasons may be less clear in conditions like adenitis in children, such factors may be 
quite obvious in other conditions like bronchiectasis, surgical procedures, injections, break 
in skin surface due to wounds and generalized immune deficiency states like AIDS, use of 
immunosuppressive agents as used in transplant patients, etc 50, 51. 
6.1 Pathogenesis  
The mechanisms of pathogenesis of NTM are not very clear and have not been adequately 
investigated. Very low CD4 counts and defective cytokine response have been linked to 
severe infections in AIDS patients 50.  
Nontuberculous mycobacteria have been reported to cause localized or disseminated 
disease depending on local predisposition and/or degree of immune deficit. In non-HIV 
patients, different NTM may cause localized pulmonary disease, adenitis, soft tissue 
infections, infections of joints and bones, bursae, skin ulcers and generalized disease in 
individuals like leukemia, transplant patients, etc. In AIDS patients the manifestations may 
range from localized to disseminated disease. Clinical features will include local organ 
specific signs and symptoms to persistent high grade fever, night sweats, anemia and 
weight loss in addition to nonspecific symptoms of malaise, anorexia, diarrhea, myalgia and 
occasional painful adenopathy 52-57. 
7. Epidemiology of human infection with nontuberculous mycobacteria 
The frequency of NTM pulmonary disease has been reported to be increasing on several 
continents. Changing patient populations, most notably from infection with HIV, have 
greatly increased the numbers of people at risk 57-60. Studies addressing the epidemiology of 
NTM infection may be broadly divided into three types: cutaneous delayed-type 
hypersensitivity to NTM antigens has been used to study large samples of people in many 
countries. These studies have the strength of providing information regarding simple 
infection in large groups of people but suffer from the lack of information regarding the 
prevalence of disease. Another drawback of this study type reflects the relatively poor 
specificity of the skin test, as well as overlap in reactivity among various Mycobacterial 
species. The second useful type of epidemiologic study of NMT infection includes 
investigations reviewing consecutive isolates from a mycobacterial laboratory. In the 
presence of adequate laboratory protocols to avoid contamination with environmental 
organisms, these studies provide unequivocal evidence of infection but have the obvious 
shortcoming of a lack of clinical data, preventing the assessment regarding the presence or 
absence of disease. The final and most useful study type combines information from the 
mycobacterial laboratory and the clinician’s assessment 55-62.  
A true increase in rates of infection and disease could be related to the host, the pathogen, or 
some interaction between the two. Host changes leading to increased numbers of 
susceptibility could play an important role, with increased numbers of patients with 
inadequate defenses from diseases such as HIV infection, malignancy, or simply advanced 
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age. Many investigations have observed decreasing rates of TB concomitant with the 
increases in NTM. Finally, an interaction between the host and pathogen could involve a 
major increase in pathogen exposure or potential inoculum size 63-67.  
7.1 Clinical manifestations  
Environmental opportunist or nontuberculous mycobacteria (NMT) include both slowly 
and rapidly growing. The range of infections caused by environmental opportunist 
mycobacteria is quite broad 8, 51. 
7.2 Pulmonary infections 
Mycobacterium avium-intracellulare complex (MAC) strains have been a major cause of 
pulmonary and other infections, principally in the HIV patients. MAC infections were 
commonly seen in chronic obstructive airway disease and in the in the geriatric patients too. 
Mycobacterium kansasii and Mycobacterium scrofulaceum have been considered an important 
cause of pulmonary infections. Mycobacterium xenopi, an unusual specie has been 
encountered as a pathogen in patients with other underlying lung diseases. Others  species  
of slow grown as Mycobacterium simiae (Mycobacterium ´habana´), Mycobacterium szulgai, 
Mycobacterium  malmoense  and Mycobacterium fortuitum of rapid grown are other pathogens 
reported to be associated with pulmonary infections 51, 65-68. 
7.3 Cutaneous infection 
Mycobacterium szulgai, Mycobacterium marinum, Mycobacterium ulcerans and Mycobacterium 
vaccae have been reported to be a cause of skin infectious. Mycobacterium marinum, specie has 
been recognized as a causative organism of swimming pool granuloma or fish tank 
granuloma. It causes papular lesions in the extremities and may be confused with 
sporotricosis. Mycobacterium ulcerans is established cause of buruli ulcer, Mycobacterium 
vaccae has also been reported to be a cause of skin infections 51-56.   
7.4 Wound infection bone, joints and bursae and sepsis 
Mycobacterium fortuitum causes pyogenic lesions in the soft tissue, joints, bursae and 
injection abscesses, while Mycobacterium chelonae abscessus is a well known cause of wound 
infections, a new related species Mycobacterum immunogenum has been recently been 
recognized as a cause of sepsis. Mycobacterium marinum also causes infections of bones, 
joints, tendon sheaths especially in AIDS patients. Mycobacterium smegmatis, and more 
recently Mycobacterium wolinskyi and Mycobacterium thermoresistible have been reported to 
cause wound infection and also bacteraemia. Mycobacterium terrae complex (Mycobacterium 
terrae, Mycobacterium nonchromogenicum and Mycobacterium triviale) may be associated with 
mycobacterial disease. Also occasionally Mycobacterium nonchromogenicum and 
Mycobacterium chelonae have been identified as causes of acupuncture induced infections. 
Mycobacterium septicum a new rapidly growing species has been reported to be associated 
with catheter related bacteremia 49, 51, 57,58.  
7.5 Lymphadenitis 
Infection of the submaxillar, cervical, inguinal or preauricular lymph nodes is the most 
common presentation of NTM lymphadenitis. The involved lymph nodes are generally 
unilateral (95%) and not tender 54-57. The nodes may enlarge rapidly, and even rupture, with 
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unilateral (95%) and not tender 54-57. The nodes may enlarge rapidly, and even rupture, with 
  
Global View of HIV Infection 
 
12
formation of sinus tracts that result in prolonged local drainage. Other nodal groups outside 
of the head and neck may be involved occasionally. Distinguishing tuberculous from 
nontuberculous lymphadenitis is key because the former requires drug therapy and public 
health tracking, whereas the latter does not. A definitive diagnosis of NTM lymphadenitis is 
made by recovery of the causative organism form lymph node cultures. A simple diagnostic 
biopsy or incision and drainage of the involved lymph nodes should be avoided, since most 
of these procedures will be followed by fistulae formation with chronic drainage. However, 
even with excised nodes with compatible histopathology, only about 50% will yield positive 
cultures, because in some case these smear-positive, culture-negative cases may be due to 
fastidious species such as Mycobacterium haemophilum or Mycobacterium genavence. 
Approximately 80% of culture-proven cases of NTM lymphadenitis are due to MAC. It´s 
predominance is due to a change approximately from 20-30 years ago, when most 
geographic areas reported Mycobacterium scrofulaceum as the most common etiologic agent, 
only about 10% of the culture-proved mycobacterial cervical lymphadenitis in children is 
due to Mycobacterium avium  complex and Mycobacterium scrofulaceum. Also Mycobacterium 
haemophilum, Mycobacterium malmoense, Mycobacterium fortuitum and others have been 
isolated from cases of lymphadenitis including HIV patients. In contrast, in adults more 
than 90% of the culture-proven mycobacterial lymphadenitis is due to Mycobacterium 
tuberculosis  8, 67, 70-76. 
7.6 Disseminated disease in immunocompromized individuals 
Disseminated disease due to NTM in AIDS patients usually occurs only in those with very 
advanced immunosuppressant, because these patients frequently have other complications, 
the diagnosis of mycobacterial infection may be confused or delayed. The diagnosis is 
exceedingly rare in person with >100 CD4 cells, and it should usually be suspected only in 
persons with <50 CD4 cells 53. MAC have been found to be more commonly isolated from 
HIV-positive and HIV-negative patients, in their the portal of entry mainly through the gut 
31  67,69. Persistent high grade fever, night sweats, anemia and weight loss in addition to 
nonspecific symptoms of malaise, anorexia, diarrhoea, myalgia and occasional 
painfuladenopathy are common signs and symptoms associated with MAC disease in AIDS 
cases. Others pulmonary and extrapulmonary mycobacterial infections in AIDS patients are 
for  Mycobacterium kansasii , Mycobacterium scrofulaceum, Mycobacterium xenopi, Mycobacterium 
simiae, Mycobacterium fortuitum-Mycobacterium chelonei complex, Mycobacterium malmoense, 
Mycobacterium szulgai, and more recently Mycobacterium genavense, Mycobacterium 
haemophilum and Mycobacterium celatum 74-82. 
8. Identification of nontuberculous mycobacteria 
Traditional identification of NTM, as well as Mycobacterium tuberculosis, has relied upon 
statistical probabilities of presenting a characteristic reaction pattern in battery biochemical 
test. The niacin test was the most useful for separating NTM and Mycobacterium tuberculosis 
because the former is usually negative, whereas isolates of  Mycobacterium tuberculosis  are 
positive. Runyon devised the first good scheme for grouping NTM based on growth rates 
and colony pigmentation. For the diagnostic of NTM is very important to know the growth 
rates  and  colony pigmentation, and biochemical test such as,  niacin production, nitrate 
reduction, tween-80 hydrolysis, arylsulphatase, urease, tellurite reduction, catalase 
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qualitative and quantitative, grown on MaConkey agar, sodium chloride tolerance, etc, are 
adequate to identify majority of clinically relevant mycobacteria. This strategy is very 
necessary and important for the diagnostic of NTM, however, some time consuming and is 
not conclusive for many isolates with variable characters. For this reason others  alternative 
diagnostic techniques are recommended, for example, the analysis of the mycolic acids of 
mycobacteria by thin layer chromatography (TLC) and high performance liquid 
chromatography (HPLC), and more recently the identification and characterization of NTM 
by molecular methods, based on new knowledge about the gene sequences of mycobacteria 
many gene probes for the identification of isolates as well as amplification of specific gene 
fragments from the lesions and mycobacterial culture isolates have  been developed; gene 
probes, polymerase chain reaction (PCR) techniques, DNA fingerprinting techniques, etc, 35-
40, 43,44,48, 83, 84 
9. Mycobacterium tuberculosis and nontuberculous mycobacteria diseases 
in the HIV/AIDS patients 
After years of worldwide decline of tuberculosis (TB), this disease has returned as a big 
problem in the Public Health. The resurgence of TB in the past decades is closely linked to 
acquired immunodeficiency syndrome (AIDS) pandemic. The high susceptibility of patients 
infected with the human immunodeficiency virus (HIV) to TB and others mycobacterial 
infections is unique, creating a lot of diagnostic and therapeutic challenges for clinicians 
12,32,24. Pulmonary tuberculosis is the most common manifestation of tuberculosis in adults 
infected with HIV 53,85,86.  
HIV/TB co-infection occurs in various stages of HIV infection, with the clinical pattern 
correlating with the patient’s immune status. In the early stages of HIV infection, when 
immunity is only partially compromised, the features are more typical of tuberculosis, 
commonly with upper lobe cavitations, and the disease resembles that seen in the pre-HIV 
era. HIV-infected patients present with atypical pulmonary disease due to immune 
deficiency advances, resembling primary tuberculosis or extra pulmonary and disseminated 
disease, commonly with hilar adenopathy and lower lobe infection 87. 
9.1 Clinical symptoms in pulmonary tuberculosis 
The clinical symptoms are severally similar in HIV-infected and HIV-negative patients. 
However, cough is reported less frequently by HIV-infected patients, probably because 
there is less cavitations, inflammation and endobronchial irritation as a result of a reduction 
in cell-mediated immunity. Similarly, haemoptysis, which results from caseous necrosis of 
the bronchial arteries, is less common in HIV-infected patients 87.88. 
In general, the traits that characterize HIV-TB co-infection include the potential for rapid 
progression from primary infection to disseminated disease, atypical radiographic features 
of pulmonary disease, increased frequency of extrapulmonary disease and involvement of 
unusual sites of infection. All of these atypical features seem to occur more commonly with 
more advance stages of immunosuppression and the paradigm that emerges is one of 
typical TB early in the course of HIV infection and atypical manifestation with advanced 
HIV disease, in this case the atypical features included lower lobe alveolar opacities, 
multifocal alveolar opacities, interstitial infiltrates, mediastinal adenopathy and pleural 
effusions 24,30,67,69,89. 
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9.2 Clinical symptoms in extrapulmonary tuberculosis 
The main manifestation of extrapulmonary tuberculosis in AIDS patients are 
lymphadenopathy, pleural effusion, meningitis, pericardial effusion and miliary 
tuberculosis. This diagnostic is often difficult because the patients with HIV are prone to all 
of the usual bacterial and viral infection that affect a non-HIV infected patients, so, the 
presentation of extrapulmonary tuberculosis in HIV-infected patients is generally no 
different 8, 69. 
9.3 Nontuberculous mycobacterial infection in HIV/AIDS patients 
The clinical relevant of NMT infection in HIV/AIDS patients are very frequent, this 
infection can be pulmonary and extrapulmonary and their symptoms are the same that 
Mycobacterium tuberculosis 51-54, 69. Recently, the nontuberculous mycobacterial are also 
denominated as environmental opportunist mycobacterial. Normally, they live as 
environmental saprophytes and they cause opportunist disease in human. Many cases of 
NTM are associated with some form of immune deficiency in special HIV/AIDS patients. In 
this group of patients is frequently to find this mycobacterial species as etiological agent for 
this reason is very important their microbiology diagnostic which is different to 
Mycobacterium tuberculosis 90, 91.  
Disseminate Mycobacterium avium complex (MAC) diseases was one of the first opportunist 
infections recognized in the syndrome of AIDS since 20 years ago. The interest of the 
diagnostic of disseminated MAC and others species of nontuberculous mycobacteria 
infection have been increased as a result of the HIV pandemic. The prevention and 
treatment in nontuberculous mycobacteria are life long because cure of them were not 
achievable in AIDS patients with profound immune suppression. The precise immune 
defect predisposing HIV/AIDS patients to disseminated diseases is unknown 92 . 
The main manifestation of pulmonary and extrapulmonary infections for Mycobacterium 
tuberculosis  and nontuberculous mycobacterial are the same affecting lung, pleura, skin, 
lymphatic system and producing dissemination infection (Figure 1, Figure 2), (Figure 3A-
3B-3C, Figure 4A-4B) 8, 63,69.  For this reason is very important the highly active antiretroviral 
therapy (HAART) for treatment of AIDS patients that has been associated with a market 
reduction in the incidence of most opportunistic infection 82,89,92. 
So, is very important that the mycobacteriology laboratory should give a definitive 
diagnostic,  because in immunosuppressed patients is important to find resistant alcohol 
acid bacillus in order to detect the co-infection with Mycobacterium tuberculosis which is the 
most frequently agent found. Nevertheless, others species of mycobacteria may be causing 
infection and should be search for. 
 
 
Fig. 1. Messenteric lymph nodes for Mycobacterium tuberculosis in AIDS patients. 
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Fig. 2. Biopsy of liver pedicle lymph nodes for Mycobacterium tuberculosis in AIDS patients. 
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Fig. 3. AIDS patients with skin lesions from Mycobacterium avium complex (Figure 3A, Figure 
3B) and Mycobacterium fortuitum (Figure 3C)  
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Fig. 4. Lymphadenitis cervical from Mycobacterium tuberculosis (Figure 4A), inguinal-testes 
lesions from Mycobacterium avium complex in lymphatic system (Figure 4B, Figure 4C). 
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HIV/AIDS scourge has been and still is a devastating disease since its advent in the late 
70’s, claiming up to 25 million lives globally (WHO, 2010). The United Nations program on 
AIDS (UNAIDS) estimated that 39.5 million people were living with HIV/AIDS by the end 
of 2006, 63% of these were in Sub Saharan Africa. Furthermore, 4.3 million people were 
reported to be newly infected with HIV while 2.9 million had lost their lives to AIDS in 2006 
alone (UNAIDS, 2010). It is also reported that young people of age 15 and above account for 
40% of new infections (CWYF, 2007). Epidemiological models predict a growing trend of the 
disease most notably the alarming incidence of new infections in sub-Saharan Africa, 
Western Europe and Asia (UNAIDS, 2010).  
1.2 HIV/AIDS in Uganda: Past and current situation 
In many regards, Uganda is considered a global role model in awareness, prevention and 
control of HIV/AIDS (Aidsmap, 2006; Kaiser family foundation, 2005). The first cases of 
AIDS in Uganda were identified in Rakai district off the shores of Lake Victoria in 1982 
(Serwadda et al 1985; MOH, 2006). AIDS was clinically characterized by wasting, this is why 
it is popularly known as ‘slim disease’ (Serwadda et al., 1985). Just as before, this disease is 
still characterized by opportunistic infections, notable are Mycobacterium avium complex 
infections which are usually the causes of fatality in victims (Serwadda et al., 1985; MOH, 
2006). In the late 1980’s a famous Ugandan Musician Philly Bongole Lutaaya paved the way 
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HIV/AIDS scourge has been and still is a devastating disease since its advent in the late 
70’s, claiming up to 25 million lives globally (WHO, 2010). The United Nations program on 
AIDS (UNAIDS) estimated that 39.5 million people were living with HIV/AIDS by the end 
of 2006, 63% of these were in Sub Saharan Africa. Furthermore, 4.3 million people were 
reported to be newly infected with HIV while 2.9 million had lost their lives to AIDS in 2006 
alone (UNAIDS, 2010). It is also reported that young people of age 15 and above account for 
40% of new infections (CWYF, 2007). Epidemiological models predict a growing trend of the 
disease most notably the alarming incidence of new infections in sub-Saharan Africa, 
Western Europe and Asia (UNAIDS, 2010).  
1.2 HIV/AIDS in Uganda: Past and current situation 
In many regards, Uganda is considered a global role model in awareness, prevention and 
control of HIV/AIDS (Aidsmap, 2006; Kaiser family foundation, 2005). The first cases of 
AIDS in Uganda were identified in Rakai district off the shores of Lake Victoria in 1982 
(Serwadda et al 1985; MOH, 2006). AIDS was clinically characterized by wasting, this is why 
it is popularly known as ‘slim disease’ (Serwadda et al., 1985). Just as before, this disease is 
still characterized by opportunistic infections, notable are Mycobacterium avium complex 
infections which are usually the causes of fatality in victims (Serwadda et al., 1985; MOH, 
2006). In the late 1980’s a famous Ugandan Musician Philly Bongole Lutaaya paved the way 
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for the awareness campaign by publically disclosing his sero-positive status at a time when 
the epidemic prevalence was up to 29% in peri-urban and urban areas of Uganda (Open 
Vision Club, 2004; Hooper, 1990; Hogle, 2002). 
This campaign later evolved into the first ever control programme designed to educate the 
general population on measures of avoidance coined in the abbreviation ABC; 1) 
Abstinence, 2) being faithful to your partner and 3) the use of condoms (Hooper, 1990; 
Hogle, 2002).  The success of this open campaign was characterized by a drastic fall in the 
incidence and prevalence of HIV/AIDS among young adults as well as pregnant women 
(Stoneburner, 2004; STI/AIDS, 2002). This prevalence has been kept at a record low in part 
due to this awareness, global funds and subsidies on anti-retroviral therapy in addition to a 
steady development in palliative treatment and counseling offered by nongovernmental 
organizations like ‘The AIDS support organization’ (TASO) (Hogle, 
2002;UAC,2004;Ashemeire,2010). Unfortunately this effort together with the evolving life 
style trends today have bred an army of complacent and risk taking youth (Chinaview, 
2008), therefore the resilience of this control strategy is yet to be fully tested.  Early age at 
first sex is reported to be among the key risk factors for HIV infection. In this regard, records 
from the ministries of health and Gender Labour and Social Development estimates age at 
first sex being 16.7 and 18.8 for girls & boys respectively in 2005 (MGLSD,2004; MOH,2006).  
Furthermore, by age 17, half of young women are sexually active and 62.7% have already begun 
child bearing by the age of 19 (MOH, 2006). This explains the current prevalence estimated at 
7% (UNAIDS, 2010) with the highest records of 17% and 18% in HIV/AIDS hot-spot districts of 
Mubende and Nakasongola, respectively (Anonymous, 2004 and Anonymous, 2008).  
 
 
Fig. 1. Median HIV prevalence among pregnant women in Uganda (Hogle, 2002) 
Likewise the Ministry of Health’s indices in Uganda also indicate that to date this disease 
has affected approximately 7.4 % of the total national population and that 3.2% of the deaths 
that have occurred since its advent globally have been in Uganda ( MOH,2006; UNAIDS, 
2010).  The socio-economic effects of AIDS on communities have recently been documented 
in a study conducted among public service officers with AIDS. It showed a significant 
increase in direct and indirect costs on HIV/AIDS related illness in addition to claiming the 
lives of family breadwinners. This has given rise to orphans who are left at the mercy of 
nongovernmental support groups (MOH report, 2010).  
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2. Mycobacterial infections in Uganda  
Tuberculosis (TB) caused by M. tuberculosis complex group remains a major public health 
problem in Uganda. It is documented to be endemic in poor peri- urban and urban areas 
mainly due to; 1) congested living conditions (Banerjee, 1999; Tupasi, 2000; Asimwe et al., 
2009), 2) high prevalence of HIV, malnutrition and use of immunesupressive therapy in 
use today (Cosivi, 1998; Asimwe, 2009).  Uganda is ranked 16th among the countries with 
the highest burden of TB in Sub-Saharan Africa, with an estimated incidence rate of 559 
cases per 100,000 per year (WHO, 2007). There are other pathogenic mycobacteria other 
than M.tuberculosis and M.bovis that have been documented in Uganda, and these include 
M. ulcerans and M. leprae (Giuseppe et al, 1997). M. ulcerans, the cause of Buruli Ulcer is a 
skin infection clinically characterized by a nodular skin lesion that busts open into a non 
healing ulcer (Giuseppe et al, 1997). In the 60’s and 70’s Buruli ulcer was reported  in the 
Busoga District on the east side of the Victoria Nile, north of Lake Victoria (Barker, 1971). 
Although cases were known in the other parts of the country, it was unknown in the 
district before 1965. In this study Barker postulated that the outbreaks were related to the 
unprecedented flooding of the lakes of Uganda from 1962 to 1964 as a result of heavy 
rainfall (Barker, 1971). Leprosy in comparison to TB is an old disease documented in the 
Bible as affecting people even before Christ. It is caused by M. leprae, which damages the 
skin and the peripheral nervous system resulting in skin lesions and deformities, most 
often affecting the cooler places on the body for example, eyes, nose, earlobes, hands, feet, 
and testicles (Giuseppe et al, 1997). In Uganda, it was first documented in the South 
Eastern part in 1978 by a Christian based hospital (Kawuma, 1999). Currently, the 
prevalence of leprosy is 2.8 cases per 100,000 population, with a case detection rate of 2.5 per 
100,000 (WHO, 2002&2004). In 2004, new cases were reported in Iganga, Hoima, Kabarole, 
Kyenjonjo, Rukungiri and Lira district. The latter had has as high as 86 new cases reported 
(Nation TB and Leprosy, 2004). Recent incidence reports on leprosy in Uganda showed a 
slight increase in the years 2004/05, but case detection rate continues to decline. It is 
therefore too early to envisage a Uganda free of leprosy.  
At the beginning of the AIDS pandemic, Non-Tuberculous Mycobacteria (NTM) were 
reported as emerging  pathogens responsible for opportunistic infections, found in almost 
half of HIV/AIDS infected patients, usually associated with CD4 cell counts B/100/ml and 
a survival of less than one year (Masur,1993). The species documented to cause 
opportunistic human infections are : Mycobacterium avium, M. intracellulare, M. kansasii,  M. 
paratuberculosis, M. scrofulaceum,  M. simiae, M. habana, M. interjectum, M. xenopi, M. 
heckeshornense,   M. szulgai, M. fortuitum,   M. immunogenum,   M.chelonae, M. marinum, M. 
genavense, M. haemophilum, M. celatum, M. conspicuum, M. malmoense, M. ulcerans, M. 
smegmatis, M. wolinskyi, M. goodii, M. thermoresistible, M. neoaurum, M. vaccae, M.palustre, M. 
elephantis, M. bohemicam  and M. septicum (Katoch, 2004). It has previously been estimated 
that up to one-quarter of all patients with AIDS will acquire this infection during their 
lifetime (Horsburgh, 1991). It is difficult to accurately describe the situation in Sub Saharan 
Africa since most of the data on which these inferences are made comes from northern 
Europe or North America (Horsburgh, 1989). Notably, these regions have experienced a 
gradual decline in the prevalence of TB and increase in mycobacterial infection caused by 
NTM’s in the past several years (Claudio et al., 2008). It is still unclear if this trend is real or 
is the result of technologic developments in diagnostics (Claudio et al., 2008). Worse so, little 
has been done in developing countries especially in the sub Saharan Africa to capture this 
  
Global View of HIV Infection 
 
22
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is the result of technologic developments in diagnostics (Claudio et al., 2008). Worse so, little 
has been done in developing countries especially in the sub Saharan Africa to capture this 
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trend (Narang, 2008). Studies in 1990’s in Kenya, Uganda, Tanzania, and the Ivory Coast 
(Gilks et al., 1995; Okello et al., 1990; Archibald et al., 1998; Lucas et al., 1993) concluded that 
disseminated NTM infections were relatively uncommon in Africa. On the contrary, recent 
studies in Zambia and South Africa using better diagnostic tools have actually reported a 
high prevalence of NTM infections in HIV/AIDS patients. These dismissed the previous 
notion and warned that the problem was bigger than previously documented (Clive, 2001; 
Buijtels, 2009). 
3. Non tuberculous mycobacteria in the environment  
The distribution of NTM and the incidence of NTM diseases is still an enigma in most 
parts of the world however; consistent reports show that NTM are widely distributed in 
nature. Therefore, the environment is regarded to the biggest reservoir and source of 
NTMs for animal and human hosts (Falkinham, 1996; Falkinham, 2009; Van ingen 2009). 
This is in resonance with earlier studies done in Ugandan environments, in which 
Stanford et al., in 1972 reported that areas around Kampala and Kyoga had 67%, 34% and 
98%, 56% of NTM isolation from mud and grass respectively. Of the districts from which 
mud samples were taken, the isolation rate and the greatest variety of mycobacteria 
species recovered was from east Bunyoro (present day Kibaale District), southern Lango ( 
present day Oyam, Apac and Dokolo districts) and northern Busoga (present day Kamuli 
district). Species isolated included M. chelonae, M. fortuitum, M. avium and others which 
were more prevalent in areas with surface water pH values between 5.5 and 5.7 (Barker et 
al., 1972).   Subsequent studies showed that Mycobacterium avium complex (MAC) was the 
most prevalent in urban environments, these accounted for 43% of the recovered NTM 
from water and soil environments in Kampala, Uganda (Eaton et al., 1995).These were 
mostly recovered from water and soil with pH ranges (6.0, 6.0-6.9, and > 7.0) respectively. 
Meanwhile, the most recent studies in pastoral environments have shown that MAC 
accounted for 29% of NTM recovered in Mubende and Nakasongola (Kankya et al 2011).  
M. gordonae, M. nonchromogenicum  M. engbaekii,  M. hiberniae, M. kubicae, M. simiae, M. 
arupense, M. terrae, M. parafortuitum were some of the other NTM isolated from pastoral 
ecosystems of Uganda (Table 1).  Water is considered to be the primary source of NTM 
infections in humans while domestic and wild animals may be reservoirs (Biet et al., 
2005). In the highly mobile pastoral systems of Uganda, humans, livestock domestic and 
wildlife share open natural water sources. The sharing of these stagnant open water 
sources provides yet another NTM infection challenge at the human- environment- 
domestic/ wildlife interface (HELI) (Kankya et al 2010). Subsequent studies on these 
natural water sources and follow up of this water that was being used in households 
revealed a high prevalence of Mycobacterium species including those known to be 
pathogenic (Kankya et al., 2011). Host-environment interaction is a key element in 
colonization and maintenance of Mycobacterium in a niche (Falkinham 1996; Biet al , 2005). 
This is held true by the vast amounts of mycobacteria that were recently isolated from 
animal environments (Krizova et al., 2010; Ofukwu et al., 2010). Kankya et al 2011a also 
recovered a wide variety of NTMs from swine and cattle environments, which included 
M. fortuitum peregrinum complex, M. avium complex, M. parafortuitum, M. hiberniae and M. 
engbaekii (table 1). 
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Table 1. Non-tuberculous mycobacteria isolated from Human, Animals and environments in 
Uganda 
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4. Non tuberculous mycobacteria in animals 
The subject of NTM in humans and animals in the sub-Saharan Africa has received 
increasing attention in the recent past. Major concerns in the NTM transmission especially in 
immuno-compromised individuals has been associated with high levels of interactions 
occurring at the human-environment-livestock-wildlife interface. 
4.1 Poultry  
Avian tuberculosis is caused by M. avium, it is mostly known to occur in temperate zones and 
has been widely documented in North and South America and Australia (Barnes et al., 2003). In 
the United states Avian tuberculosis has been reported to be responsible the condemnation  of 
1870 per 100,000 birds slaughtered however the figures here were anticipated to be higher than 
this given that only visual inspection was used (Barnes et al., 2003). The incidence is reported to 
be low in South Africa while in Kenya it has only been documented in lesser flamingoes (Barnes 
et al., 2003).  Uganda has 37 million chickens and about half a million turkey’s. Unfortunately 
there has not been any studies done to document the prevalence of fowl tuberculosis despite the 
constant reports of clinical signs typical of this disease in poultry in the east and central region 
of Uganda (rural poultry farmers’ personal communication). 
4.2 Cattle  
Bovine tuberculosis just like its human cousin M. tuberculosis has been given top priority in 
Uganda, simply because it is a well-documented zoonosis. Worldwide, the proportion of 
human cases caused by Mycobacterium bovis is estimated to be 3.1% of all forms of TB 
(Cosivi, 1998). In the most recent studies on the prevalence of bovine TB in pastoral areas of 
Uganda, tuberculin reactors were reported to be 6% of cattle in Mbarara district, an 
important dairy cattle area in the south west (Bernard et al., 2005), and a prevalence of 2·8% 
in nomadic cattle of Karamoja in the north east of the country (Oloya et al., 2006). Cattle 
herds in Uganda are concentrated along the cattle corridor that stretches from the south 
west to the north east through the central parts of the country. In another study done by 
Oloya (2007) in the same area gave the initial indication that Non tuberculous mycobacteria 
could be a public health force to reckon. This study found that NTMs were an integral part 
of bacteria isolated from disseminated tuberculous lesions and surprisingly these were 
almost equal in proportions (48.6:51.4) to M.bovis (Oloya et al 2007). Similarly a study done 
by Asimwe et al., 2009 on slaughtered cattle in Kampala revealed a similar pattern of 
isolation with M.bovis and NTMs accounting for 64.7% and 35.3% of the mycobacterium 
isolated from various tuberculous lymph node lesions respectively. 
These finding further reaffirm the key role played by NTM in the tuberculosis pathogenesis. 
In two separate studies by Oloya et al., 2006 and Inangolet et al., 2007, shared water sources 
were identified as the responsible factor for a high prevalence of high avian reactors to the 
purified protein derivative ( PPD) skin test.   
The highest response to avian purified protein derivative (PPD) was observed in cattle 7-9 
years old (figure 1) which was attributed to non specific immune response to environmental 
mycobacteria of the Mycobacterium avium complex prevalent in the natural water sources 
animals drink from. Therefore it is no longer disputable that NTMs are prevalent in cattle in 
Uganda but rather the effort should be on the role if any played by cattle in disseminating 
them to human populations. 
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Species Host Environmental source Geographical location Reported by 
M. arupense  Household water Mubende and Nakasongola Kankya et al 2011  
M. asiaticum Swine  Mubende Muwonge et 
al.,2011 under 
review 
M. parascrofulaceum Swine  Mubende Muwonge et 
al.,2011 under 
review 
M. bejali Swine  Mubende and Nakasongola Muwonge et 
al.,2011 under 
review 
















M. smegmitis Swine  Mubende Muwonge et 
al.,2011 under 
review 
M. salmonphilum Swine  Mubende Muwonge et 
al.,2011 under 
review 
M. rhodesia Swine  Mubende Muwonge et 
al.,2011 under 
review 
M. septicum Swine  Mubende Muwonge et 
al.,2011 under 
review 




M. marinum swine  Mubende Muwonge et 
al.,2011 under 
review 
M. komamatonse Swine  Mubende Muwonge et 
al.,2011 under 
review 
Unidentified NTM Cattle, 
human, 
swine 




review; Oloya et 
al.,2007; Assimwe 
et al 2009 
Table 1. Non-tuberculous mycobacteria isolated from Human, Animals and environments in 
Uganda 
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Fig. 2. Variation of skin reactions to comparative intradermal tuberculin test with age 
adapted from Oloya et al.,2006 
 




Swine tuberculosis is a chronic infectious disease characterized by inflammatory reactions in 
various body parts but mostly in the digestive system. Calcification prone tubercles, 
inflamed lymph nodes and sarcoid-like granulomas are the most common features of this 
disease (Cvetnic, 2007; Coetzer, 2004; Ofukwu, 2010). The disease in swine is caused by M. 
bohemicum, M. intracellulare, M. avium, M. hemophilum, M. malmose, M. szulgai, M. kansasii, M. 
scrofuleceum, M. tuberculosis, M.simiae, M. palustre, M. gordonae, M. terrae, M. xenopi and  M. 
heckershornense and other potentially pathogenic mycobacteria (PPM) (Jakko van Ingen, 
2010, Cvetnic, 2007).  
The only study in Uganda  done on swine mycobacterial infection showed 9.3% and 3.1% 
prevalence based on necropsy examination and culture isolation, respectively (Muwonge 
et al 2010). A seasonal variation in prevalence of lesions typical of mycobacterial 
infections was also found in which lesions tended to increase after the rain season (figure 
3).In a follow up molecular study on slaughter pigs in Mubende (Muwonge et al., 2011), 
Mycobacterium avium was the most prevalent mycobacterium specie accounting for 18% of 
the isolates from lymph nodes. Other species isolated included; M. senuense, M. terrae, M. 
asiaticum, M. parascrofulaceum, M. bejali and M. neoaurum, M. simie, M. duvalii, M. 
smegmitis and M. parafortuitum,M.salmonphilum, M. rhodesia, M. septicum, M. chelonae, M. 
marinum,M. parafinicum, M. komamatonse and M. gordona (Table 1).In general these 
findings are reflective of the NTMs load (infection/colonization) in swine reared in  





Fig. 3. Temperal occurrence of pathological lesions in slaughtered pigs in Mubende district 
(Muwonge et al., 2010) 
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5. Non-tuberculous mycobacteria in human 
The absence of documented human to human transmission in the last 30 years has led to the 
conclusion that the environment is the source of NTM for human (Falkinham, 2009). In 
comparison to developed countries, NTM infections in humans are not well documented in 
Uganda. The few earlier studies did not show that disseminated Mycobacterium avium complex 
(MAC) infections was a problem in terminally sick AIDS patients unlike in the western world 
(Okello, 1990; Valadas, 2004; Chih-Cheng Lai, 2006). Subsequent studies further seem to 
support the absence of M. avium in HIV-infected Ugandans (Eaton et al., 1995). On the other 
hand Ugandan immigrants with AIDS in London had previously been diagnosed with 
symptomatic mycobacterium avium complex (MAC) infections (Nigel, 1993). These patients at 
the time of diagnosis had a CD4 count of 10X106/L and some had been receiving treatment for 
extra pulmonary tuberculosis (Nigel, 1993). This disparity in prevalence at the time was 
explained by the speculation that temperate areas were preferential niches for NTMs and the 
superiority in diagnostics. It is now known that it was the latter, Nambuya et al., (1988) 
documented the prevalence of tuberculous lymphadenitis (which today is known to be caused 
by MTCs and NTM) but surprisingly they were unable to culture specimen to prove the cause. 
In 1998 Ssali et al reported for the first time presence of disseminated MAC and Mycobacterium 
simiae infections in HIV/AIDS patients in Mulago hospital in Uganda. This study showed that 
mycobacteriamia among febrile HIV-infected Ugandan adults accounted for 13% (Ssali et al., 
1998). M. avium is also known to be one of the leading causes of infant lymphadenitis 
worldwide (Coetzer, 2004; Johansen, 2007; Van Ingen et al., 2009). This is in agreement with a 
study done in Uganda on the cause of cervical lymphadenitis. In that study the prevalence was 
highest among infants below 7 years of age and M. avium was the most frequently isolated 
NTM in this group (Oloya et al 2007). It is a common observation that NTM cause disease in 
individuals whose immunity has been compromised (Wolinsky, 1979; Wallace et al.,1990; von 
Reyn et al 1994; Falkinham et al 2009). Pneumoconiosis, cystic fibrosis, bronchiestasis , 
smoking and chronic alcoholism are some of the predisposing factors to NTM infections. The 
current technological advancements in diagnostics seem to indicate a possible further 
identification of more NTM zoonoses. In Netherland, Komjin et al., (1999) showed a close 
genetic relatedness between M. avium subsp. hominissuis isolated from swine and humans. 
Since then many scholars have continued to document more evidence re affirming the role 
pigs play in the transmission of mycobacterial infections to immunecompromised and 
immunecompetent indivuals. In 2007, Oloya et al isolated M. avium subsp.hominissuis from 
tuberculous lesions in cattle and T.B patients with cervical lymphadenitis in pastoral areas of 
Karamoja in Uganda. The molecular findings showed a very high genetic relatedness between 
animal and human isolates (figure 4 and 5). Although the true source of human infection is 
still a matter of dispute, these findings tend to point us to zoonotic scenario, with shared 
environment, in this case water, playing an important role. The true picture of human non 
tuberculous infections in Uganda is yet to be unveiled, but studies done elsewhere in Africa 
have indicated that this problem is bigger than previously documented (Buitjel, 2009). 
5.1 Diagnostics and therapeutics  
The greatest mistake in disease treatment arises when a physician is not well armed with 
facts about the cause of visible clinical signs, in other words a good diagnosis precedes a 
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better treatment. Given the ubiquitous presence of NTMs in the environment and animal 
hosts, establishing the true causal relationship is highly dependent on representative 
sampling and stringent laboratory practices as contamination can easily occur. Another 
important problem is the overlapping of clinical manifestation of the disease caused by 
M.tuberculosis   which makes the specific diagnosis of NTM disease practically impossible in 
poor health care settings. In Uganda, definitive NTM diagnosis in clinical setting is rarely 
done therefore, at the time of treatment commencement the only diagnosis available is 
presence/absence of acid fast rod like bacteria. This diagnosis is arrived at with the use of 
Ziehl-Neelsen (ZN) staining (Nation leprosy and tuberculosis programme). Literature on 
ZN staining indicates that the specificity is compromised by bacteria like Rodococcus that 
have the same acid fast characteristics thus giving some false positives (Coetzer, 2004). 
Definitive diagnosis on the other hand requires that a physician knows exactly which type 
of Mycobacterium is causing the clinical signs. This can be achieved using fast clinical 










Fig. 4 & 5. Show the insertion sequences 1311 and 1245 of M. avium sub sp hominissuis 
isolated from humans with cervical lymphadenitis and cattle with disseminated tuberculosis 
respectively adapted from Oloya et al.,2007 a&b. 
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Most of these methods are available in Uganda however; they are mainly used for research 
and not routine clinical diagnostics. This is largely due to the fact that majority of people in 
Uganda cannot afford these extra costs to arrive at a definitive diagnosis. Fortunately, quick-
cheaper, specific and sensitive diagnostic tools have been developed for example the ESAT-6 
polymerase chain reaction primers which has been tailor-made to definitively diagnose M. 
avium, Serotyping  methods using serotype specific sera for Mycobacterium interacellulare 
scrofulaceum (MAIS complex) and M. avium usually associated with AIDS patients  can also 
be used in small and medium scale laboratories for definitive diagnosis (Kiehn et al., 1985; 
Singh et al., 2007; Wisselink et al 2010). NTM are generally resistant to the standard therapy 
Isoniazid, Rifampicin and Clarithromycin (Bum-Joon et al 2004). The reported resistance of 
M. tuberculosis (Asimwe et al., 2010) can be a contributing factor for the resistance in NTM 
due to constant exposure to these antibiotics as a result of lack of definitive diagnosis. There 
is optimism because of the consistent reported developments in medication which may 
improve on the treatment of NTMs for example dalfopristin, quinupristin and methoxy 
moieties of floroquinolones that are reported to have better effects (Lu et al., 2001; Braback, 
2002; Singhai et al., 2010; Griffith et al., 2010). Their affectivity is however yet to be tested by 
the self prescriptive behavior common among Ugandans 
5.2 Attitudes surrounding NTM  
Uganda is blessed with a wide range of ethnic groups some with unique attitudes and 
perceptions with regard to prevention and control of infections (Nyanzi et al., 2005). 
Beliefs, myths, values, norms, taboos language, ritual and art are some of the cultural 
aspects that influence health of a given society. These cultural aspects describe the 
interaction between people, land and activities; they are also reported to influence the 
spread, control and prevention of diseases (Ntseane, 2004; Kyagaba, 2004). Tuberculosis, 
leprosy and Buruli ulcer are well documented simply because of the priority given to 
them by the Uganda health sector; this has negatively influenced the attitudes and 
perception of people towards the rest of NTMs that are regarded to be of less public 
health importance.  
5.2.1 Socio-cultural attitudes in pastoral areas  
In Uganda, studies done in rural areas have shown that there are many beliefs, attitudes 
and practices associated with NTM and other mycobacterial infections even when it is 
largely known that farming communities lack awareness with regards to mycobacterial 
infection, their epidemiology, and prevention and control strategies. Apart from 
mycobacterial infections due to zoonotic tuberculosis and classic tuberculosis; infections 
due to NTM have rarely been reported. Farming communities in Nakasongola and 
Mubende districts of Uganda lay their emphasis on the sharing of drinking water from 
open water sources with both domestic and wild animals as one of the major transmission 
route of NTM infection to humans and animals at the human-environment- livestock 
/wildlife interface (Kankya et al., 2010). Furthermore, attitude based studies have shown 
complacency in pastoral communities which is reflected in reports from service providers  
highlighted by statements like  ‘‘we teach community members that drinking un-boiled water is 
dangerous but they are stubborn as they continue to drink un-boiled water….many times they tell 
us that they have not died yet they have been drinking un-boiled water for decades” commented; 
clinical officer Kiyuni Government Health Centre III, Mubende district Uganda (Kankya 
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et al 2011 in press). Similarly in neighbouring sub county of Madudu residents said “our 
grandparents and great grandparents used to drink un boiled water and milk and their cause of 
death was not as a result of drinking un boiled water and milk. We grew up drinking all these 
consumables raw, and that we have made it a cultural norm not to boil milk and water before 
consumption” .  Rural Africa is always punctuated with witchcraft, some communities 
have the belief that NTM infections can be caused by witchcraft (voodoo) and thus can be 
treated (Kankya et al 2011). Therefore families that have witches are believed to have the 
power to cause such diseases, and that this power can be inherited. Stigmatisation is 
probably one of the most important reason why these infections are under reported, rural 
communities are reported to say  “Some of us are sick and infected with mycobacterial 
infections such as tuberculosis, but we fear to disclose since these infections are associated with 
HIV/AIDS…’’ (Kankya et al 2011). The affected individual would quickly be associated 
with HIV/AIDS. For the same reason, therefore affected individuals tend to shy away 
from seeking health services from the qualified health professionals. This aspect greatly 
impacts the health seeking behaviour (HSB) among the pastoral communities (Ashemeire, 
2010).  
5.3 Challenges and futures trends 
The relative importance of mycobacterial diseases has been undergoing an evolution during 
the past few years, and further changes and modifications are expected to occur in the near 
future. The other concern especially in Africa has been the fact that non tuberculous 
mycobacteria diminishes the efficacy of the BCG (Brandt, 2002), the only available vaccine 
against tuberculosis. In a study done in Denmark it was shown in a mouse model that prior 
exposure to the Kalonga-Malawi environmental mycobacteria isolates resulted in reduction 
of efficacy or complete blockage of BCG activity (Brandt, 2002). This has however not yet 
been given its due attention in Uganda and therefore is anticipated to be a future challenge 
in the control of Tuberculosis especially in infants. 
6. Conclusion  
Non tuberculous mycobacterial infections have not been fully documented in Uganda 
because; 1) they are given less priority compared to TB regardless of the documented 
synergistic role they play in tuberculosis lesion development. 2) The dismissive attitude of 
communities, medical and veterinary fields as to their importance helps maintain their low 
priority status. With the wind of technological advancement in diagnostics and treatment 
blowing towards Africa, the increasing number of immune compromised individuals due to 
AIDS, it is anticipated that more infections due to NTM are likely to be discovered. 
Therefore the threat of NTM infections in Uganda is as real as the pandemic that precedes 
them. 
7. Recommendations 
1. NTMs are a force to reckon in the world today and therefore should be given priority 
by government, public, medical and veterinary fields. 
2. The Ministry of Health and the available health marketing groups should put more 
emphasis on the campaigns geared towards a stigma free environment with regards to 
HIV/AIDS so as to improve the health reporting behavior among Ugandans 
  
Global View of HIV Infection 
 
32
Most of these methods are available in Uganda however; they are mainly used for research 
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/wildlife interface (Kankya et al., 2010). Furthermore, attitude based studies have shown 
complacency in pastoral communities which is reflected in reports from service providers  
highlighted by statements like  ‘‘we teach community members that drinking un-boiled water is 
dangerous but they are stubborn as they continue to drink un-boiled water….many times they tell 
us that they have not died yet they have been drinking un-boiled water for decades” commented; 
clinical officer Kiyuni Government Health Centre III, Mubende district Uganda (Kankya 
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et al 2011 in press). Similarly in neighbouring sub county of Madudu residents said “our 
grandparents and great grandparents used to drink un boiled water and milk and their cause of 
death was not as a result of drinking un boiled water and milk. We grew up drinking all these 
consumables raw, and that we have made it a cultural norm not to boil milk and water before 
consumption” .  Rural Africa is always punctuated with witchcraft, some communities 
have the belief that NTM infections can be caused by witchcraft (voodoo) and thus can be 
treated (Kankya et al 2011). Therefore families that have witches are believed to have the 
power to cause such diseases, and that this power can be inherited. Stigmatisation is 
probably one of the most important reason why these infections are under reported, rural 
communities are reported to say  “Some of us are sick and infected with mycobacterial 
infections such as tuberculosis, but we fear to disclose since these infections are associated with 
HIV/AIDS…’’ (Kankya et al 2011). The affected individual would quickly be associated 
with HIV/AIDS. For the same reason, therefore affected individuals tend to shy away 
from seeking health services from the qualified health professionals. This aspect greatly 
impacts the health seeking behaviour (HSB) among the pastoral communities (Ashemeire, 
2010).  
5.3 Challenges and futures trends 
The relative importance of mycobacterial diseases has been undergoing an evolution during 
the past few years, and further changes and modifications are expected to occur in the near 
future. The other concern especially in Africa has been the fact that non tuberculous 
mycobacteria diminishes the efficacy of the BCG (Brandt, 2002), the only available vaccine 
against tuberculosis. In a study done in Denmark it was shown in a mouse model that prior 
exposure to the Kalonga-Malawi environmental mycobacteria isolates resulted in reduction 
of efficacy or complete blockage of BCG activity (Brandt, 2002). This has however not yet 
been given its due attention in Uganda and therefore is anticipated to be a future challenge 
in the control of Tuberculosis especially in infants. 
6. Conclusion  
Non tuberculous mycobacterial infections have not been fully documented in Uganda 
because; 1) they are given less priority compared to TB regardless of the documented 
synergistic role they play in tuberculosis lesion development. 2) The dismissive attitude of 
communities, medical and veterinary fields as to their importance helps maintain their low 
priority status. With the wind of technological advancement in diagnostics and treatment 
blowing towards Africa, the increasing number of immune compromised individuals due to 
AIDS, it is anticipated that more infections due to NTM are likely to be discovered. 
Therefore the threat of NTM infections in Uganda is as real as the pandemic that precedes 
them. 
7. Recommendations 
1. NTMs are a force to reckon in the world today and therefore should be given priority 
by government, public, medical and veterinary fields. 
2. The Ministry of Health and the available health marketing groups should put more 
emphasis on the campaigns geared towards a stigma free environment with regards to 
HIV/AIDS so as to improve the health reporting behavior among Ugandans 
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2a. The government should invest in disseminating free clean water sources like bore holes 
and piped spring water in rural areas to replace the valley dams which are reported to 
be the source of highly contaminated water. 
2b. The government should improve the current waters sources for livestock and sensitize 
pastoral communities on the need to maintain them at reasonably high standards in a 
bid to reduce exposure to livestock. 
3. The government should invest in research and innovation so that Ugandans develop 
tailor made diagnostic and therapeutic for Uganda and the great lakes region. 
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Human Immunodeficiency Virus (HIV) is the causative organism of AIDS which has 
become one of the greatest public health challenges faced by mankind. AIDS was first 
identified in 1981 in Los Angeles, USA. Two types of HIV exist presently- HIV-1 and HIV-2 
(Alizon et al., 2010; Adoga et al., 2010). HIV-1 was first isolated in the early 1980s (Barre-
Sinoussi et al., 1983) and linked as causative agent of AIDS (Gallo et al., 1984). HIV-2 which 
is similar to HIV-1 was later identified in the developing world (Clavel, 1987, Clavel et al., 
1986), but found to be less virulent and can differ in its response to antiretroviral agents. 
HIV-1 is classified into three groups [M, N and O] based on the genetic diversity. Group M 
(major) has 10 subtypes (A-J), and Group O (outlier) represents a number of highly 
divergent strains (Carr et al., 1998; Jassens et al., 1997 Chen et al., 2010). Francois Simon and 
his group reported a group N of HIV-1. Despite the phenotypic classification of HIV-1 into 
subtypes, the number of sequenced isolates remains limited (Sharp et al., 1994). Both strains 
are spread in the same way and have the same AIDS causing consequences. While HIV-1 
has been reported to have a shorter incubation period of 7-10years, HIV-2 is considerably 
longer and often less severe (Barre-Sinoussi, 1996; WHO, 1989). 
HIV infection is usually followed by a chronic progressive destruction of the immune and 
neurologic system (Price, 1996), which if not managed leads to the possible invasion and 
establishment of multiple opportunistic infections.( Lindo et al., 1998; Pozio et al., 1997) and 
malignancy (Schulz et al., 1996). Although on average, an infected individual spends several 
years without manifesting the disease, AIDS has always been certain. The time from infection 
to AIDS varies widely between individuals, from a few months to as many as 20 years with 
existing evidences accepting  that 50% of individuals progress to AIDS in 7-10years and this 
has been accepted as the incubation period of the virus (Del Amo et al., 1998; WHO, 1994). 
2. Portals of HIV transmission 
The concentration of virus in a body fluid and the extent of exposure to body fluids 
determine to a great extent the transmission of a virus. Jaffe and McMahon-Pratt  (1983) first 
indicated in their Epidemiological studies conducted in 1981 and 1982 that the major 
channel of transmission of AIDS were intimate sexual contact and contaminated blood. 
Gottlieb et al (1981); Masur et al (1981); Siegal et al (1981); Callazos et al (2010); van 
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Griensven and de Lin van Wijngaarden (2010) all described the syndrome in homosexual 
and bisexual men and, intravenous drug users, while Harris et al (1983); Padian et al (1991); 
Cameron et al (1989); Quinn et al (2000) and Decker et al (2010) recognised their mode of 
transmission through heterosexual activity. Evidences later showed that transmission 
recipients and haemophiliacs could contract the illness from blood or blood products (CDC, 
1982; Peterson, 1992; CDC, 2010) and newborn infants get infected from their mothers’ 
(Ammann et al., 1983; Scarlatti, 1996; Brookmeyer, 1991; Landesman, et al., 1996; Goedert et 
al., 1989; Mackelprang et al., 2010). Brookmeyer (1991); Stoneburner et al (1990) all agreed 
that the three principal means of transmission – blood, sexual contact and mother-to-child 
have not changed  which could be attributed to a greater degree to the relative amount of 
the virus in various body fluids. 
 
 
Fig. 1. Diagrammatic representation of HIV-1 and HIV-2 showing their dependent and 
independence on CD4+ [Courtesy-] 
HIV is present in semen (including pre-seminal fluid), vaginal/cervical secretions and blood, 
breast milk expressed through feeding; organ donations; sharing infected objects (needles, 
tattoos and piercing) which are the main vehicles through which the virus is transmitted (Kim 
et al., 2010; Yu et al., 2010; Suligoi et al., 2010; Pruss et al., 2010 and Baggaley et al., 2010). The 
virus may also be present in saliva, tears, urine, cerebrospinal fluid and infected discharges, 
but these are not vehicles of which HIV is spread.  Epidemiological survey do not support 
transmission through water or food, sharing eating utensils, coughing or sneezing,  vomiting, 
toilets, swimming pools, insect bites, shaking of hands or other casual contacts, hence there is 
no public health reason for discrimination and or restrictions.  
A study of French hospital patients by Grabar  et al (2009) found that approximately 0.5% of 
HIV-1 infected individuals retain high levels of CD4+ T-cells and a low or clinically 
undetectable viral load without anti-retroviral treatment. These individuals are classified as 
HIV controllers or long-term non-progressors. 
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For conveniences, we will share the mode of infections into: Sexual and Non-sexual. 
 
 
Fig. 2. Routes of Transmission of Human Immuno-deficiency Virus. [HIV] 
 
 
Low HIV plasma load,




Fig. 3. Levels of HIV load in semen [Courtesy:…] 
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3. Vertical or Mother To Child Tranmission (MTCT) 
The major source of paediatric infection of Human immunodeficiency virus one (HIV-1) is 
from mother to child. Since the first reported case of HIV-1 transmission in children in 1983, 
the global pandemic has had a serious impact on the health and survival of children. 
Transmission rates have been reported to be about 14% in industrialised countries and 
about 35-45% in developing countries especially in Africa (Bryson, 1996; Reinhardt et al., 
1995). 
It was estimated that MTCT accounts for over 1.5million HIV infection in children (Burton, 
1996) with the WHO projecting between 5-10million child infections through MTCT during 
the next decade. HIV-2 though is related to HIV-1 is less readily transmitted from mother to 
child, this could be attributed to their differences which influences pathogenecity, natural 
history and therapy so that their susceptibility to antiretroviral therapy (ART) follows 
different mutation pathways to develop drug resistance (Mamata and Merchant, 2010). 
According to Wollinsky et al (1992) as quoted by Pasquier et al (1998), the transmission of 
HIV-1 from mother to child occur utero, intrapartum, or postnatally by breastfeeding and a 
fourth dimension as reported by Pasquier et al (1998) which involves the transmission of 
multiple maternal variants to the infant and a rapid, fatal outcome in the child and the 
development of an HIV-based clinical disease in children seems to be correlated with the 
timing of the vertical transmission. 
Infection in about two-thirds of children are thought to have occurred at the terminal end of 
pregnancy or at delivery with the disease progressing slowly; while in one-thirds, it is 
thought to progress rapidly to AIDS with increased indices of viral replication (De Rossi et 
al., 1998), these children appear to have been infected during pregnancy. 
Infected children with slow progression to AIDS have a higher viral diversity than children 
who progress rapidly as evidenced in molecular variability studies (Halapi et al., 1996; 
Strunnikora et al., 1995) as reported in Adults (Delwart et al., 1997; Pasquier et al., 1998). 
Although progress has been made in recent years in the curbing of MTCT, the mechanisms 
and timing of transmission remains uncertain and the relative contributions of each of the 
three modes of transmission is still not well defined. Bryson et al (1992) proposed that in 
most non-breastfeeding population; the lack of detection of virus in the child at birth might 
indicate that contamination took place at or shortly before delivery while detection of virus 
at birth indicates utero contamination. Evidences for both early and late utero transmission 
have been documented (Peckham and Gibb, 1995; Kuhn and Stein, 1995). Most prior 
estimates and hypothesis seem to agree that transmission usually occur during the 
intrapartum HIV exposure just as premature infants. 
Perinatal or Antepartum HIV transmission has been documented as a route of infection 
estimated to occur in 13-30% of infants delivered to HIV-1 infected mothers (Andiman et al., 
1990). 
High proviral DNA/ or RNA concentration of virus is a risk factor for the transmission of 
HIV-1 from an untreated mother to infant. The reduction in such transmission after 
zidovudine is only partly explained by the reduction in plasma levels of viral RNA. To 
prevent HIV-1 transmission initiating maternal treatment with zidovudine is recommended 
regardless of the plasma level of HIV-1 RNA or the CD4+ Count (Sperling et al., 1996). 
Because of the different mutation pathways to develop drug resistance, pregnant women 
with detectable HIV-2 should be ideally managed using a Highly Active antiretroviral 
therapy (HAART) regimen to which the virus is sensitive. Non-nucleoside Reverse 
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Transcriptase Inhibitor (NNRTIs) and Fusion Inhibitor Enfuvirtide have no activity against 
HIV-2 and in the light of the current albeit limited data, zidovudine mono-therapy should not 
be used. These factors make it crucial that proper selection of and adherence to the first 
antiretroviral combination regimen is in place in order to achieve a successful treatment 
response. Though of recent, a combination of Combivir and nevarapine is given to mothers to 
prevent transmission of HIV to children. The Emergency Lower Segment Caesarian Section 
(ELSCS) could be planned at 38 weeks of gestation with regards to the mode of delivery if the 
viral load is undetectable or the mother is either symptomatic or has low CD4 cell count. HIV 
is present in breast milk and postnatal transmission via breastfeeding is an important 
component of MTCT in Sub-Saharan Africa (Kreiss, 1997). World-wide, an estimated one in 
three of vertical transmission may be due to breastfeeding with above 12months of age 
carrying higher risk (Bulterys et al., 1995). Kuhn and Stein (1997) demonstrated that under 
certain conditions prevailing in specific settings in developing countries, breast feeding for six 
months would be preferable to breast feeding beyond this age. Breastfeeding has been 
reported to account for 5-15% of infants becoming infected with HIV-1 after delivery (ECS 
1991; Ryder et al., 1989; Mok et al., 1989). Although the placental entry of some infections is a 
critical aspect of these infections, the role of placental cells and the mechanism by which 
pathogens pass from the maternal to the foetal circulation varies. The placenta provides a 
barrier that prevents transmission of some viruses, but allows others to reach the foetal 
circulation. Mother to foetus placental transmission of some viruses occurs through 
transcytosis across placental cells. The placenta may also act as a reservoir in which virus 
replicates before reaching the foetus. Placental transmission of HIV-1 is a complex 
incompletely understood process which requires advanced studies (Al-husaini, 2009). The 
antiretroviral therapy, zidovudine (ZDV) is metabolized into its active form in the placenta 
(Qian et al., 1994). ZDV inhibits HIV replication within placental cells. To reach the foetal 
circulation, HIV-1 should cross the trophoblastic placental barrier (cytotrophoblasts and 
syncitiotrophoblasts). Blood borne maternal pathogens that arrive at the uteroplacental 
circulation and intervillous space may reach the foetus through the villous capillaries. HIV-1 
has been detected on both the maternal and the foetal parts of the placenta. HIV-1 experiences 
replication in the placenta. The virus may cross the trophoblastic barrier by endocytosis, or by 
an injured villous surface. However, superficial breaks in syncytiotrophoblast cells do not 
radically affect the vertical transmission of viruses (Burton et al., 1996). The reverse 
transcriptase enzyme of HIV-1 is important in the life cycle of the virus by converting the 
single-stranded RNA genome into double-stranded DNA that integrates into the host 
chromosome. There is a lower degree of viral heterogeneity in transmitting mothers compared 
with nontransmitting mothers (Sundaravaradan et al., 2005). 
Human chorionic gonadotropin (hCG) has been shown in vitro to inhibit reverse 
transcriptase and to block viral transmission between virus-carrying lymphocytes and 
placental trophoblasts (Bourinbaiar and Lee-Huang, 1995). However, role of hCG in 
protecting the foetus from vertical transmission HIV-1 needs to be studied. In summary, the 
restricted heterogeneity of HIV-1 in the infected mothers is more likely associated with lack 
of vertical transmission (Al-husaini, 2009). 
As access to services for preventing the mother-to-child transmission of HIV has increased, 
the total number of children being born with HIV has also decreased. An estimated 370 000 
[230 000–510 000] children were newly infected with HIV in 2009 (a drop of 24% from five 
years earlier)[UNAIDS, 2010]. 
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3. Vertical or Mother To Child Tranmission (MTCT) 
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estimates and hypothesis seem to agree that transmission usually occur during the 
intrapartum HIV exposure just as premature infants. 
Perinatal or Antepartum HIV transmission has been documented as a route of infection 
estimated to occur in 13-30% of infants delivered to HIV-1 infected mothers (Andiman et al., 
1990). 
High proviral DNA/ or RNA concentration of virus is a risk factor for the transmission of 
HIV-1 from an untreated mother to infant. The reduction in such transmission after 
zidovudine is only partly explained by the reduction in plasma levels of viral RNA. To 
prevent HIV-1 transmission initiating maternal treatment with zidovudine is recommended 
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Human Immunodeficiency Virus Transmission   
 
47 
Transcriptase Inhibitor (NNRTIs) and Fusion Inhibitor Enfuvirtide have no activity against 
HIV-2 and in the light of the current albeit limited data, zidovudine mono-therapy should not 
be used. These factors make it crucial that proper selection of and adherence to the first 
antiretroviral combination regimen is in place in order to achieve a successful treatment 
response. Though of recent, a combination of Combivir and nevarapine is given to mothers to 
prevent transmission of HIV to children. The Emergency Lower Segment Caesarian Section 
(ELSCS) could be planned at 38 weeks of gestation with regards to the mode of delivery if the 
viral load is undetectable or the mother is either symptomatic or has low CD4 cell count. HIV 
is present in breast milk and postnatal transmission via breastfeeding is an important 
component of MTCT in Sub-Saharan Africa (Kreiss, 1997). World-wide, an estimated one in 
three of vertical transmission may be due to breastfeeding with above 12months of age 
carrying higher risk (Bulterys et al., 1995). Kuhn and Stein (1997) demonstrated that under 
certain conditions prevailing in specific settings in developing countries, breast feeding for six 
months would be preferable to breast feeding beyond this age. Breastfeeding has been 
reported to account for 5-15% of infants becoming infected with HIV-1 after delivery (ECS 
1991; Ryder et al., 1989; Mok et al., 1989). Although the placental entry of some infections is a 
critical aspect of these infections, the role of placental cells and the mechanism by which 
pathogens pass from the maternal to the foetal circulation varies. The placenta provides a 
barrier that prevents transmission of some viruses, but allows others to reach the foetal 
circulation. Mother to foetus placental transmission of some viruses occurs through 
transcytosis across placental cells. The placenta may also act as a reservoir in which virus 
replicates before reaching the foetus. Placental transmission of HIV-1 is a complex 
incompletely understood process which requires advanced studies (Al-husaini, 2009). The 
antiretroviral therapy, zidovudine (ZDV) is metabolized into its active form in the placenta 
(Qian et al., 1994). ZDV inhibits HIV replication within placental cells. To reach the foetal 
circulation, HIV-1 should cross the trophoblastic placental barrier (cytotrophoblasts and 
syncitiotrophoblasts). Blood borne maternal pathogens that arrive at the uteroplacental 
circulation and intervillous space may reach the foetus through the villous capillaries. HIV-1 
has been detected on both the maternal and the foetal parts of the placenta. HIV-1 experiences 
replication in the placenta. The virus may cross the trophoblastic barrier by endocytosis, or by 
an injured villous surface. However, superficial breaks in syncytiotrophoblast cells do not 
radically affect the vertical transmission of viruses (Burton et al., 1996). The reverse 
transcriptase enzyme of HIV-1 is important in the life cycle of the virus by converting the 
single-stranded RNA genome into double-stranded DNA that integrates into the host 
chromosome. There is a lower degree of viral heterogeneity in transmitting mothers compared 
with nontransmitting mothers (Sundaravaradan et al., 2005). 
Human chorionic gonadotropin (hCG) has been shown in vitro to inhibit reverse 
transcriptase and to block viral transmission between virus-carrying lymphocytes and 
placental trophoblasts (Bourinbaiar and Lee-Huang, 1995). However, role of hCG in 
protecting the foetus from vertical transmission HIV-1 needs to be studied. In summary, the 
restricted heterogeneity of HIV-1 in the infected mothers is more likely associated with lack 
of vertical transmission (Al-husaini, 2009). 
As access to services for preventing the mother-to-child transmission of HIV has increased, 
the total number of children being born with HIV has also decreased. An estimated 370 000 
[230 000–510 000] children were newly infected with HIV in 2009 (a drop of 24% from five 
years earlier)[UNAIDS, 2010]. 
  
Global View of HIV Infection 
 
48
4. Risk factors for vertical transmission of HIV 
Documented evidence primarily based on PCR and virus culture studies or co-culture 
studies but short of serology which revealed maternal antibodies present in infants at birth 
showed that transmission of HIV from mother to child appears to occur in 11-60% of 
children delivered by HIV-positive mothers but reasons for  the wide variations in virus 
transmission and sources of virus in newborn which could have provided approach to 
prevention are not known (Ades et. al., 1991; Courgnaud et. al., 1991; Lindgren et. al., 1991; 
Newell et. al., 1992; Scarlatti et. al., 1991; Tovo and Martino, 1988; Oxtoby, 1990; Rogers et. 
al., 1991). 
Maternal, viral, obstetric, foetal, infant factors all affect transmission making it essentially 
multifactorial. Frequency of sexual activity, ‘hard’ drug ingestion during pregnancy, 
unprotected sexual intercourse, cigarette smoking during pregnancy, lack of adherence to 
drugs, HIV disease, degraded maternal immunocompetence or prolonged rupture of the 
amniotic membranes before delivery (Havens et al., 1997; Turner et al., 1996; Bryson, 1996; 
John and Kreiss, 1996; Lambert, 1996; Glenn and Dietrich, 1993). 
The maternal factors involve transmission through the placenta to the unborn child, at the 
time of labour and delivery, or through breast-feeding.  (CDC HIV/AIDS surveillance, 
October, 1989), seroconversion during pregnancy, advanced stage of the disease with high 
viral load and low immunity, concomitant malnutrition, micronutrient deficiencies, 
sexually transmitted diseases, no or suboptimal therapy; in the intranatal period, risk 
factors for increased transmission are mode of delivery, prolonged contact with maternal 
blood or cervicovaginal secretions, prolonged rupture of membranes, chorioamnionitis, 
invasive procedures like episiotomy, foetal scalp electrode, instrumental delivery; thin 
skin, susceptible mucous membranes, immature immune functions and low levels of 
maternal antibodies make prematurity a risk factor for increased transmission. In the 
postnatal period, risk factors are breast feeding, feeding with cracked nipples/mastitis, 
mixed feeding, new seroconversion of the mother, high viral load, low CD4 cell count; In 
the absence of any intervention, rates of MTCT of HIV-1 can vary from 15 to 30% in 
developed countries and increase to 30 to 45% in developing countries, the difference 
mainly attributable to infant feeding practices that comprise almost universally of 
breastfeeds for prolonged duration (De Cock et al., 2000 as quoted by Mamata and 
Merchant, 2001). 
The foetus and mother circulatory systems though different, there still exists tiny mixing of 
blood that could serve as portal for the flow of infected maternal white blood cells or the 
AIDS virus in the maternal serum to be transmitted to the foetus with a confirmation found 
in the foetal tissues affirming such spread (CDC HIV/AIDS surveillance, October 1989; 
Glenn and Dietrich, 1993). 
Bruising, abrasions and local swelling could occur to the baby and mother during labour 
owing to a great deal of trauma which produces visible and microscopic openings that could 
allow the virus to penetrate blood stream of infant. Another means of infection could be 
experienced or seen when the mother’s perineum tears or if she receives an episiotomy 
which might lead to a large amounts of blood ingested by the baby or might get into the 
baby’s mouth, eyes, rectum or vagina. 
Glenn et al (1993) reported that breastfeeding is another means of risks exposure and it has 
been confirmed in the spread of hepatitis B from mother to infant and hepatitis B and AIDS 
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as well which are thought to occur when the infant ingests the mothers blood through a 
cracked and bleeding nipples. 
Other known correlates include high maternal plasma viremia, advanced clinical HIV 
disease, degraded maternal immunocompetence or prolonged rupture of the amniotic 
membranes before delivery. Others include vaginal delivery process and prematurity of low 
birth weight of the neonate (Bryson, 1996; John and Kreiss, 1996; Lambert, 1996). 
High frequency of sexual activity and ‘’hard’’ drug injection during pregnancy had 
previously been identified, along with unprotected sexual intercourse during pregnancy as 
certain behavioural risk factors for mother-to-child-transmission (Bulterys et al., 1997; 
Bulterys and Goedert, 1996). Firstly, unprotected intercourse might increase the 
concentration of strain diversity of HIV-1, particularly in the birth canal where ejaculated 
virus could be partially sequestered. Secondly, frequent intercourse might increase 
inflammation of the cervix or vagina either micro abrasion or if unprotected, by STDs. Third, 
frequent intercourse might increase the risk of chorioamnionitis or otherwise alter the 
integrity of the placenta (Bulterys and Goedert, 1996). Matheson et al (1997) found that 
continued drug users had significantly higher mother-to-child-transmission rates in 
maternal drug use during pregnancy. However, this was confounded by other variables 
such as premature delivery, prolonged membrane rupture, zidovudine non-use and 
unprotected sexual intercourse. 
In the USA, cigarettes’ smoking during pregnancy has been identified as independent risk 
factor for mother-to-child-transmission. The effect was greatest among women with critical 
evidence of more advanced HIV disease (Turner et al., 1996). Intensive nurse care 
management in supporting zidovudine use in women with HIV infection and their infants is 
a proven effective method in decreasing mother-to-child-transmission (Havens et al., 1997). 
MTCT of HIV is influenced by multiple factors. Known correlates include high maternal 
plasma viremia, advanced clinical HIV disease, degraded maternal immunocompetence or 
prolonged rupture of the amniotic membranes before delivery. Others include vaginal 
delivery process and prematurity of low birth weight of the neonate (Bryson 1996; John and 
Kreiss, 1996; Lambert, 1996). 
Results from zidovudine therapy to bridge MTCT have improved understanding of the 
pathophysiology of MTCT. First, the reduction in plasma viremia and MTCT (from 25.5% to 
8.3%) by treating the mother and neonates suggests that relatively small changes in maternal 
viral load might have substantial effects on MTCT (Bulterys and Godert 1996; CDC, 1994). 
Secondly, cleaning of birth canal with chlorhexidine had no overall effect yet apparently did 
reduce MTCT for one subgroups of high-risk deliveries; those after 4hrs of membrane 
rupture (Scarlatti, 1996). 
Maternal immunologic and virologic factors such as quantitative HIV-1 RNA (though 
insufficient) are strongly correlated with Mother-to-child-transmission. When stratified by 
the stage of HIV disease, the only group with significant association between viral load and 
mother-to-child-transmission were AIDS-free women with high CD4+ Counts. The 
interactions of virus burden and maternal immune status has also demonstrated that CD4+, 
CD8+ cell subsets are percentages of CD8+ cell subsets (e.g. activation markers CD8/CD38 
and CD8/DR) were all associated with vertical transmission. Women in the highest CD4+ 
cell percentage quartile or the lowest CD8+ cell percentage quartile had only less than or 
equal to 4 percent of mother-to-child-transmission (Njoku, 2004). 
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5. Parental, saliva and other body fluids 
Prior to Groopman and Greenspan (1996) report of oral manifestation of AIDS which 
increases the potentials of HIV transmission through several lesions which form exists for 
virus into the saliva, it was assumed that about 10% of both free virus and infected cells 
report in saliva were not very important in the spread of HIV (Groopman et al., 1984). 
Dean et al (1988) and Mundy et al (1987) reported none or low level of pathogens in urine, 
sweat, breast milk, branchoalvolar lavage fluid, amniotic fluid, synovial fluid, faeces and 
tears which were not thought to be important source in virus transmission (Fujikawa et al., 
1985), but this assumption has also changed with the report of Groopman and Greenspan 
(1996); Amory et al. (1992); Scarlatti (1996); van da Perre et al. (1991). Though not a natural 
source of HIV transmission, cerebrospinal fluid (CSF) in neurologic patients have been 
shown to contain large amount of virus when compared to other body fluids (Hollander and 
Levy, 1987; Ho et al., 1989). 
6. Organs, blood, tissue donors and occupational health workers 
Prior to 1985 (PPHS/MMWR, 1985; MMWR, 1985), when screening of blood, organ and 
tissue donors for HIV-1 antibody became available, several reports have documented the 
transmission of HIV-1 by transplantation of kidney (MMWR, 1987; Kumar et al., 1987; Erice 
et al., 1991; Schwartz et al., 1987; Prompt et al., 1985; L’age-Stehr et al., 1985; Neumayer et 
al., 1987; Quarto et al., 1989; Carbone et al., 1988), liver (MMWR, 1987; Kumar et al., 1987; 
Erice et al., 1991; Schwartz et al., 1987; Prompt et al., 1985; L’age-Stehr et al., 1985; Neumayer 
et al., 1987; Quarto et al., 1989; Carbone et al., 1988; Samuel et al., 1988), heart (Erice et al., 
1991; Dummer et al., 1989), pancreas (Erice et al., 1991), bone (MMWR, 1988a) and possibly 
skin(Clarke, 1987) and In most cases involving donors whose serum had not been tested for 
HIV-1 antibody (MMWR, 1987; Kumar et al., 1987; Erice et al., 1991; Schwartz et al., 1987; 
Prompt et al., 1985; L’age-Stehr et al., 1985; Neumayer et al., 1987; Quarto et al., 1989; 
Carbone et al., 1988; Samuel et al., 1988; Dummer et al., 1989; MMWR, 1988a; Clarke, 1987). 
As proposed by Simonds et al (1992), approaches to prevention could include: the screening 
of prospective donors and laboratory markers for HIV1 infection (MMWR, 1985); the 
inactivation of HIV-1 in allograft through processing techniques (Hilfenhaus et al., 1990; 
Kitchen et al., 1989; Wells et al., 1986) and the quarantining of tissues from living donors 
until repeated antibody testing more definitely excludes the possibility of subsequent 
seroconversion in the donor (MMWR, 1988a ; MMWR, 1988b). 
The U.S. Centers for Disease Control and Prevention (2002) reported that in the health care 
industry there have been 57 confirmed cases and an additional 139 possible cases of health 
care workers in the U.S. who have become HIV positive from exposure to HIV in the work 
place.  The Canadian HIV/AIDS Legal Network (2001) has also reported two of such cases 
in the laboratory workers and one health-care provider in Canada. 
7. Horizontal (heterosexual) transmission 
These could be through unprotected and protected sexual process. Ma et al (2010) reported 
that the probability of unprotected heterosexual transmission may vary with population and 
be influenced by many factors, these could include: the type of sex (Mastro et al., 1994: De 
Vincenzi, 1994; Varghese et al., 2002); bleeding during intercourse (Royce  et al., 1997), 
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semen viral load (Gupta et al., 1997; Tachet et al., 1999; Kalichman et al., 2008; Butler et al., 
2008), stage of HIV infection (Mastro et al., 1994; Fauci et al., 1996; Wawer et al., 2005), co-
morbid sexually transmitted diseases (Royce et al., 1997), vaginal or anal canal, co-occurring 
psychosocial risk factors (Safren et al., 2010). 
Sexual forms of transmission are seen as a major portal of entry of HIV as 10-30% of 
seminal/vaginal fluids have transmissible virus (Royce et al., 1997; Henin et al., 1993). 
In semen viral load, the males HIV-1 infected cells forms about 104 of the 106 leucocytes per 
ejaculation (Winkelstein et al., 1987), which confirms AIDS first association with sexual 
route, with the high prevalence in homosexual men. The virus subsequently became 
synonymous with heterosexual activity and is now attributed to the AIDS pandemic 
(UNAIDS 1986; Nkowane 1991; Stoneburner et al., 1990). Bouvier et al (1997) believes that 
vaginal pH neutralization by semen is a co-factor of HIV transmission. 
The chances of transmission also depends on the type of sexually transmitted infections 
(STI), as co-infection with genital ulcers have been reported to increase the chances of 
transmission by increasing the susceptibility to HIV infection which also depends on HIV 
subtypes efficient (Gray et al., 2001; Mahiane et al., 2009; Limpakarnianarat et al., 1993; 
Wang, 2009; Xu, 2009). 
Male circumcision have been documented to decrease the chances of HIV transmission 
(Mahiane et al., 2009; Lavreys et al., 1999; Gray et al., 2000; Reynolds et al., 2004; Gray et al., 
2007; Donoval et al., 2006), but this also depends on the country (Ben et al., 2008; Sullivan et 
al., 2009; Ruan et al., 2009; Wawer et al., 2009).   
The high level of heterosexual spread of HIV in Sub-Saharan Africa and developing 
countries where genital ulcers from existing venereal diseases (e.g. Chanchroid Chlamydia, 
Syphilis or Herpes virus infections) are aligned with increased HIV seroprevalence 
(UNAIDS, 1998, Hook et al., 1992; Plummer et al., 1991) could be tight to abrasions at the site 
of entry in the vagina or anal canal. Heise et al (1991) however reported that HIV could 
directly infect the bowel mucosa and perhaps cervical epithelium without the need for 
ulcerations which gave clue to the relatively low risk of the mucosal lining of the foreskin, 
urethral canal and oral genital contact (through minimal) to be implicated (Winkelstein et 
al., 1987). 
Men having Sex with Men (MSM) have been reported as one of the first way of transmission 
of HIV. Various authors have showed evidence that the involvement of MSM could be 
traced to psychosocial behaviour (PB). These PB are said to be depression, violent 
victimisation, substance abuse, alcohol, psychiatric disorders, psychological distress, lower 
perceived social support (Berlan et al., 2010; King et al., 2008; Meyer , 2003; Cochran et al., 
2003; Cochran and Mays, 2000; Gilman et al., 2001., Marshal et al., 2008; Mimiaga et al., 
2009a; b; Safren and Heimberg, 1999; Stall et al., 2001; Chesney et al., 2003; The EXPLORE 
Study Team, 2004; Herbst et al., 2005). Although some studies have shown how substance 
use and high risk of HIV transmission are correlated (Stall et al., 2001; Hirshfield et al., 
2004), most recent studies are now focussing on how ‘syndemic’- a situation where these 
diverse psychosocial issues could interact to enhance HIV risky behaviour among MSM 
(Mustanski et al., 2007; 2010; Stall et al., 2008; Centers for Disease Control and Prevention, 
2010). However, varieties of cognitive behavioural interventions have been studied and 
validated for the treatment of mood and anxiety disorders (Barlow, 2008) behavioural 
activation therapy and HIV risk reduction counselling in MSM who abuse crystal 
methamphetamine (Mimiaga et al., 2010). 
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5. Parental, saliva and other body fluids 
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tears which were not thought to be important source in virus transmission (Fujikawa et al., 
1985), but this assumption has also changed with the report of Groopman and Greenspan 
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The U.S. Centers for Disease Control and Prevention (2002) reported that in the health care 
industry there have been 57 confirmed cases and an additional 139 possible cases of health 
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semen viral load (Gupta et al., 1997; Tachet et al., 1999; Kalichman et al., 2008; Butler et al., 
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morbid sexually transmitted diseases (Royce et al., 1997), vaginal or anal canal, co-occurring 
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route, with the high prevalence in homosexual men. The virus subsequently became 
synonymous with heterosexual activity and is now attributed to the AIDS pandemic 
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transmission by increasing the susceptibility to HIV infection which also depends on HIV 
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Wang, 2009; Xu, 2009). 
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(Mahiane et al., 2009; Lavreys et al., 1999; Gray et al., 2000; Reynolds et al., 2004; Gray et al., 
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al., 2009; Ruan et al., 2009; Wawer et al., 2009).   
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urethral canal and oral genital contact (through minimal) to be implicated (Winkelstein et 
al., 1987). 
Men having Sex with Men (MSM) have been reported as one of the first way of transmission 
of HIV. Various authors have showed evidence that the involvement of MSM could be 
traced to psychosocial behaviour (PB). These PB are said to be depression, violent 
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2009a; b; Safren and Heimberg, 1999; Stall et al., 2001; Chesney et al., 2003; The EXPLORE 
Study Team, 2004; Herbst et al., 2005). Although some studies have shown how substance 
use and high risk of HIV transmission are correlated (Stall et al., 2001; Hirshfield et al., 
2004), most recent studies are now focussing on how ‘syndemic’- a situation where these 
diverse psychosocial issues could interact to enhance HIV risky behaviour among MSM 
(Mustanski et al., 2007; 2010; Stall et al., 2008; Centers for Disease Control and Prevention, 
2010). However, varieties of cognitive behavioural interventions have been studied and 
validated for the treatment of mood and anxiety disorders (Barlow, 2008) behavioural 
activation therapy and HIV risk reduction counselling in MSM who abuse crystal 
methamphetamine (Mimiaga et al., 2010). 
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Addressing co-occurring psychosocial behaviour is a means to increase the effective size of 
current HIV prevention intervention and allow for more effective uptake by MSM, since 
they have been reported to be more than 44 times more likely to be newly diagnosed with 
HIV than other men (Purcell et al., 2010) and the focus on ameliorating disparities in HIV 
infection is essential for enhancing the health of MSM at the population level (Sanfren et al., 
2010). 
The Centers for Diseases Control and Prevention (CDC, 2007) reported the prevalence rate 
among heterosexual African American (AA) women and men with data indicating that 
more heterosexual AA women having a 74% HIV/AIDS prevalence as compared to the 27% 
in their male counterpart. 
Myths and misperceptions of HIV/AIDS such as HIV being a genocide, suspicion of 
government information, belief that it is possible to identify risky partners by odour and 
appearance, belief that partners reported histories are accurate, misperceptions about the 
meaning of safe sex and the believe that specific classes of people (not one self) are at risk of 
HIV that resulted from sexual risk contributes to the risky behaviours of HIV transmission 
(Essien et al.,2002; Catania et al.,1994; Smith et al., 2000; Coleman et al., 2010;  Coleman and 
Ball, 2007; Coleman, 2007). 
The increase in the number of sexual partners also increases HIV transmission (Stranford, 
1999; Coleman, 2007; Catania et al., 1994; Smith et al., 2000; Coleman et al., 2010; Coleman 
and Ball, 2007) with most under the influence of alcohol or drugs. 
Unprotected oral and vaginal sex have been reported as a risk factor in the transmission of 
HIV especially where it is carried out in high risk settings, having sex more often under the 
influence of alcohol and/or drugs (Milam et al., 2006; Catania et al., 1994; Smith et al., 2000). 
Even under protection for example the use of condoms, many cases has been reported 
where the barrier has failed especially where risky behaviours are undertaken. A case in 
study which made the People Living With HIV/AIDS (PLWHA) in Nigeria to sue the 
Federal Government of Nigeria to Court for promotion of condoms (Ogundele, 2010). 
Though Tenofovir gel has been advocated for women to prevent HIV transmission (Karim 
et al., 2010). 
The nature of HIV transmission from anecdotal records has not changed neither is a new 
means of transmission of the virus recorded. In view of this development, it is the earnest 
desire of this write up to bring to fore genealogical reports of the transmission of HIV and to 
also continue to write on the various modes of transmission as a way of curtailing the 
spread of the dreaded virus. 
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1. Introduction
The imprisonment of large numbers of drug addicts has the potential to create environments
within which social networks that enhances the transmission of infectious diseases form
(7–11; 14). About 668,000 men and women are incarcerated in sub-Saharan Africa with South
Africa having the highest prison population with 157,402 people behind bars in the region and
335 prisoners per 100,000 of the national population; it has the ninth largest prison population
in the world (21). International data show that HIV prevalence among prisoners is between
six to fifty times higher than that of the general adult population. For example, in the USA
the ratio is 6:1, in France it is 10:1; in Switzerland 27:1 and in Mauritius 50:1 (17). On a
global scale, the prison population is growing rapidly, with high incarceration rates leading
to overcrowding, which largely stems from national law and criminal justice policies. In most
countries, overcrowding and poor physical conditions prevail (20). This phenomenon poses
significant health concerns with regard to control of infectious diseases-and HIV prevention
and care most of all (21). Prisons are high risk settings for HIV transmission. However, HIV
prevention, treatment are not adequately developed and implemented to respond to HIV in
prisons (13). There is evidence to show that health programmes for the particular needs of
imprisoned drug users are not enough in USA and Canada (15; 22). In Russia, a study of
intravenous drug users demonstrated the critical role of prisons in the transmission of HIV
through high levels of needle (syringes) sharing among the imprisoned (23).
Prison populations are predominantly male and most prisons are male-only institutions,
including the prison staff. In such a gender exclusive environment, male-to-male sexual
activity (prisoner-to-prisoner and guard-to-prisoner) is frequent (18). While much of the
sex among men in prisons is consensual, rape and sexual abuse are often used to exercise
dominance in the culture of violence that is typical of prison life (19). Inmate rape, including
male rape, is considered one of the most ignored crimes. Sexual and physical abuse in
custody remains a tremendous human rights problem (1). Intravenous drug use, tattooing
and the following aspects of man-to-man sexual activity in prison make it a high risk for
HIV transmission: anal intercourse, rape and the presence of sexually transmitted infections
(STIs). Related problems in prisons across Southern Africa include overcrowding, shortages,
corruption, and the presence of juveniles alongside adult prisoners. The potential for the
spread of HIV is also increased by a lack of information and education, and a lack of proper
medical care. STIs, if left untreated, can greatly increase a person’s vulnerability to HIV
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through sexual contact, UNAIDS noted (26). Men get tattooed in prison (12). In the absence of
proper precautions and access to safe equipment tattooing can be a high-risk activity for the
transmission of HIV (24; 25).
The literature and development of mathematical epidemiology is well documented (2; 3; 6).
This paper seeks to use mathematical models to gain insights on transimission of HIV among
male prisoners while in prison in the context of homosexuality and intravenous drug use. The
rest of this paper is organized as follows. In the next section, the model and its basic properties
are presented. In Section 3, we determine stability analysis of the equilibria states. Numerical
simualtions are presented in Section 4 and finally the last section concludes the paper.
2. Model description
The model sub-divides the total male prisoner population into the following sub-populations
of susceptible intravenous drug users Sd(t), susceptible non-drug users Sn(t), intravenous
drug using HIV-only infected people not yet showing AIDS symptoms In(t), non-drug using
HIV-only infected people not yet showing AIDS symptoms Id(t), intravenous drug using
AIDS cases Ad(t) and non-drug using AIDS cases Ad(t). There is sexual interaction between
intravenous drug users and non-drug users making HIV transmission across different these
two distinct distinct groups possible. The population is patterns is heterogeneous mixing with
regard to sexual behaviour. The total population is given by;
N(t) = Nd(t) + Nn(t), Nd(t) = Sd(t) + Id(t) + Ad(t), Nn(t) = Sn(t) + In(t) + An(t), (1)
with Nn(t) and Nd(t) being the total number of non-drug using and intravenous drug using
male prisoners (intravenous drug users-IDU), respectively. The group j members make cj, j =
(d, n) sexual contacts per unit time, and that a fraction of the contacts made by a member of
group j is with a member of group i is pji , i = (d, n). Then pnn + pnd = pdd + pdn = 1. The
total number of sexual contacts per unit time by members of group ‘n’ (non-drug users) with
members of group ‘d’ (intravenous drug users) is cn pnd Nn and because this must be equal to








In this case the sexual contact rates (partner acquistion rates) cd and cn are saturating terms for
the total population and the mixing proportions may change with time. It is worth mentioning
here that intravenous drug users are more likely to have more sexual partners than the general
population. Therefore, cd = Bcn , B ≥ 1. We assume that male prisoners in AIDS stage of the
disease are nolonger sexually active as they are nolonger capable of attracting sexual mates
among prisoners. Also drug using AIDS patients nolonger share their needles with others as
other prisoners do not like sharing needles with someone whose AIDS symptoms are visible.
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with βi, i = (n, d) is probabbility on individual being infected with HIV by an individual
from the n- or d-class per sexual contact; cj, j = (n, d) are the number of sexual partners an
individual acquires per year (partner acquistion rates); βd2 is the probability an intravenous
drug user getting HIV infection through sharing non-sterile needles during drug injections
and cd2 are the number drug sharing partners an individual acquires.
It is assumed people are recruited into prison at rate Λ through committing various
crimes and the following proportions π1, π2, π3 and π4 recruited enter the classes
Sn(t), Sd(t), In(t) and Id(t), respectively. We further assume that AIDS cases are too sick to
commit a crime, so there are no recruitment of prisoners already in the AIDS stage of disease.
Furthermore, it is assumed that intravenous drug using prisoners showing AIDS symptoms
are nolonger able to exert peer pressure strong enough to make one become a drug user.
Individuals in Sn(t) and In(t) acquire drug misusing habits at rate λd(t) due to peer pressure
and move into Sd(t) and Id(t, respectively with
λdd =
βd1 cd1 (Sd + Id)
Nd
, (4)
where βd1 is the probability of becoming an intravenous drug user (IDU) following contact
with an IDU and cd1 are the number of contacts necessary for one to become an IDU (partner
acquistion rate). Individuals in Sn(t) class acquire HIV infection at a rate λnh (t) to move into
In(t). Individuals in Sd(t) class acquire HIV infection at a rate λdh (t) to move Id(t) class.
Individuals infected with HIV-only not yet displaying symptoms (In(t), Id(t)) progress to the
AIDS stage ((An(t), Ad(t)) at a rate γ. Individuals in Ad(t) leave the intravenous drug using
habits at a rate α to get into An(t) class. Individuals in all classes experience natural death
at a rate μ and those in AIDS stage of the disease experience an additional disease induced
death at a rate ν. Individuals in all classes leave the prison at rate ω upon completion of
their sentences. Individuals in the AIDS stage of the disease (final terminal stages) are further
released from prison due to sickness at rate φ. The model flow diagram is shown in Figure 1.
Based on these assumptions the following system of differential equations describe the model.
S�n(t) = π1Λ − (λd + λnh )Sn − (μ + ω)Sn,
I �n(t) = π3Λ + λnh Sn − λd In − (μ + ω + γ)In,
A�n(t) = γIn + αAd − (μ + ω + φ + ν)An,
S�d(t) = π2Λ + λdSn − λdh Sd − (μ + ω)Sd,
I �d(t) = π4Λ + λdh Sd + λd In − (μ + ω + γ)Id,
A�d(t) = γId − (μ + α + ω + φ + ν)An.
(5)
2.1 Model basic properties
In this section, we study the basic results of solutions of model system (5), which are essential
in the proofs of stability results.
69IV/AIDS Transmis ion Dynamics in Male Prisons
2 Will-be-set-by-IN-TECH
through sexual contact, UNAIDS noted (26). Men get tattooed in prison (12). In the absence of
proper precautions and access to safe equipment tattooing can be a high-risk activity for the
transmission of HIV (24; 25).
The literature and development of mathematical epidemiology is well documented (2; 3; 6).
This paper seeks to use mathematical models to gain insights on transimission of HIV among
male prisoners while in prison in the context of homosexuality and intravenous drug use. The
rest of this paper is organized as follows. In the next section, the model and its basic properties
are presented. In Section 3, we determine stability analysis of the equilibria states. Numerical
simualtions are presented in Section 4 and finally the last section concludes the paper.
2. Model description
The model sub-divides the total male prisoner population into the following sub-populations
of susceptible intravenous drug users Sd(t), susceptible non-drug users Sn(t), intravenous
drug using HIV-only infected people not yet showing AIDS symptoms In(t), non-drug using
HIV-only infected people not yet showing AIDS symptoms Id(t), intravenous drug using
AIDS cases Ad(t) and non-drug using AIDS cases Ad(t). There is sexual interaction between
intravenous drug users and non-drug users making HIV transmission across different these
two distinct distinct groups possible. The population is patterns is heterogeneous mixing with
regard to sexual behaviour. The total population is given by;
N(t) = Nd(t) + Nn(t), Nd(t) = Sd(t) + Id(t) + Ad(t), Nn(t) = Sn(t) + In(t) + An(t), (1)
with Nn(t) and Nd(t) being the total number of non-drug using and intravenous drug using
male prisoners (intravenous drug users-IDU), respectively. The group j members make cj, j =
(d, n) sexual contacts per unit time, and that a fraction of the contacts made by a member of
group j is with a member of group i is pji , i = (d, n). Then pnn + pnd = pdd + pdn = 1. The
total number of sexual contacts per unit time by members of group ‘n’ (non-drug users) with
members of group ‘d’ (intravenous drug users) is cn pnd Nn and because this must be equal to








In this case the sexual contact rates (partner acquistion rates) cd and cn are saturating terms for
the total population and the mixing proportions may change with time. It is worth mentioning
here that intravenous drug users are more likely to have more sexual partners than the general
population. Therefore, cd = Bcn , B ≥ 1. We assume that male prisoners in AIDS stage of the
disease are nolonger sexually active as they are nolonger capable of attracting sexual mates
among prisoners. Also drug using AIDS patients nolonger share their needles with others as
other prisoners do not like sharing needles with someone whose AIDS symptoms are visible.




















68 Global View of HIV Infection HIV/AIDS Transmission Dynamics in Male Prisons 3
with βi, i = (n, d) is probabbility on individual being infected with HIV by an individual
from the n- or d-class per sexual contact; cj, j = (n, d) are the number of sexual partners an
individual acquires per year (partner acquistion rates); βd2 is the probability an intravenous
drug user getting HIV infection through sharing non-sterile needles during drug injections
and cd2 are the number drug sharing partners an individual acquires.
It is assumed people are recruited into prison at rate Λ through committing various
crimes and the following proportions π1, π2, π3 and π4 recruited enter the classes
Sn(t), Sd(t), In(t) and Id(t), respectively. We further assume that AIDS cases are too sick to
commit a crime, so there are no recruitment of prisoners already in the AIDS stage of disease.
Furthermore, it is assumed that intravenous drug using prisoners showing AIDS symptoms
are nolonger able to exert peer pressure strong enough to make one become a drug user.
Individuals in Sn(t) and In(t) acquire drug misusing habits at rate λd(t) due to peer pressure
and move into Sd(t) and Id(t, respectively with
λdd =
βd1 cd1 (Sd + Id)
Nd
, (4)
where βd1 is the probability of becoming an intravenous drug user (IDU) following contact
with an IDU and cd1 are the number of contacts necessary for one to become an IDU (partner
acquistion rate). Individuals in Sn(t) class acquire HIV infection at a rate λnh (t) to move into
In(t). Individuals in Sd(t) class acquire HIV infection at a rate λdh (t) to move Id(t) class.
Individuals infected with HIV-only not yet displaying symptoms (In(t), Id(t)) progress to the
AIDS stage ((An(t), Ad(t)) at a rate γ. Individuals in Ad(t) leave the intravenous drug using
habits at a rate α to get into An(t) class. Individuals in all classes experience natural death
at a rate μ and those in AIDS stage of the disease experience an additional disease induced
death at a rate ν. Individuals in all classes leave the prison at rate ω upon completion of
their sentences. Individuals in the AIDS stage of the disease (final terminal stages) are further
released from prison due to sickness at rate φ. The model flow diagram is shown in Figure 1.
Based on these assumptions the following system of differential equations describe the model.
S�n(t) = π1Λ − (λd + λnh )Sn − (μ + ω)Sn,
I �n(t) = π3Λ + λnh Sn − λd In − (μ + ω + γ)In,
A�n(t) = γIn + αAd − (μ + ω + φ + ν)An,
S�d(t) = π2Λ + λdSn − λdh Sd − (μ + ω)Sd,
I �d(t) = π4Λ + λdh Sd + λd In − (μ + ω + γ)Id,
A�d(t) = γId − (μ + α + ω + φ + ν)An.
(5)
2.1 Model basic properties
In this section, we study the basic results of solutions of model system (5), which are essential
in the proofs of stability results.
69IV/AIDS Transmis ion Dynamics in Male Prisons
4 Will-be-set-by-IN-TECH
Fig. 1. Structure of the model.
Lemma 1. The equations preserve positivity of solutions.
Proof. The vector field given by the right hand side of (5) points inward on the boundary of
R6+ \ {0}. For example, if Sn = 0 then S�n = π1Λ ≥ 0. All the other components are similar.
Lemma 2. Each non-negative solution is bounded in L1-norm by max {N(0), Λ/μ}.
Proof. The norm L1 norm of each non-negative solution is N and it satisfies the inequality
N� ≤ Λ− μN. Solutions to the equation M� = Λ− μM are monotone increasing and bounded
by Λ/μ if M(0) < Λ/μ. They are monotone decreasing and bounded above if M(0) ≥ Λ/μ.
Since N� ≤ M� the claim follows.
Corollary 1. The region
Φ =
{





is invariant and attracting for system (5).
Theorem 1. For every non-zero, non-negative initial value, solutions of model system (5) exist for all
times
Proof. Local existence of solutions follow from standard arguments since the right hand side
of (5) is locally Lipschitz. Global existence follows from the a-priori bounds.
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Following van den Driessche and Watmough (27), the effective reproduction number of model
system (5) is given as
RSD = cd2 βd2+cd pdd βd2a3 + cn
(






√( cd2 βd2+cd pdd βd
2a3 + cn
(





− cnβn(cd2 pnn βd2+cdβd(pnn pdd−pnd pdn ))a3a4
(8)
with a1 = μ + ω, a2 = μ + ω + φ + ν, a3 = μ + ω + γ, a4 = μ + ω + γ + cd1 βd1 ,
a5 = μ + ω + φ + ν, a6 = π2(μ + ω) + cd1 βd1 throughout the manuscript. The reproduction
number RSD is defined as the number of secondary HIV infections produced by one HIV
infected individual during his/ her entire infectious period in a mixed population of non-drug
users and intravenous drug male prisoners. Theorem 2 follows from van den Driessche and
Watmough (27).
Theorem 2. The disease free equilibrium E0 of model system (5) is locally asymptotically stable if
RSD < 1 and unstable otherwise.
Analysis of the effective reproduction number, RSD
The reproduction number is differentiated into categories:
Case 1: No intravenous drug users in the community






which is the number of secondary HIV infections produced by one HIV infected individual
through homosexual tendencies in a male prison. It is important to note R0S is a decreasing
function of ω, suggesting that increasing the number of prisoners leaving the prison reduces
the concentration of HIV cases in prison. Theoretically this is feasible, in reality this begs
more questions than answers as sentences communicated cannot be reversed because of HIV.
Perhaps, it may be necessary to consider the use of open prison systems where prisoners with
less serious crimes can serve their sentences while staying at their homes. This has a further
advantage of reducing the high levels of raping of man by man in prisons and the homosexual
tendencies which male prisoners resort to in enclosed prisons which is one of the major forces
driving HIV/AIDS in male prisons.
Increase in intravenous drug users
In this case (ppp , βd1 cd1 ) → (1, ∞) so that RSD becomes R0D which is given by
R0D =
βdcd + βd1 cd1
a3
. (10)
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R0D just like is R0S is a decreasing function of ω, meaning that use of open prison systems
will be beneficial in the control of HIV among male prisoners. It is important to note that
levels of sexual contact are higher among intravenous drug users than non-drug users, with it
increased risk of contracting HIV, so cnβn < cdβd and this translates R0S < R0D . This suggest
that intravenous drug use enhances HIV transmission in male prisons. Drug using prisoners
are at an increased risk of HIV infection than their non-drug using counterparts. May
be introducing drug substitution treatment together with introducing needle free exchange
programmes will reduce the epidemic in prisons. A reduction in needle in sharing among
prisoners result in HIV/AIDS prevalence as the sharing of unsterile needles in a major source
of HIV transmission among male prisoners.
4. Numerical simulations
In this section, we carry out detailed numerical simulations using MatLab programming
language to assess the effects of HIV transmission among male prisoners in the absence any
interventional strategy which is more common in developing countries in Africa for different
initial conditions. The parameter values that we use for numerical simulations are in Table
1. In Table 1, NPA denotes National Prison Administration (Zimbabwe). For influence of
Parameter Symbol Value Source
Recruitment rate Λ 0.00163yr−1 ∗ 3000000 NPA
Natural mortality rate μ 0.02yr−1 (5)
Natural rate of progression to AIDS γ 0.1yr−1 (5)
Rate of leaving prison due to AIDS related sickness φ 0.25 Assumed
AIDS related death rate ν 0.4yr−1 (5)
Product of effective contact rate for HIV
infection and probability of HIV transmission
per drug injection cd2 βd2 0.562yr
−1 (16)
Probability of HIV transmission per sexual contact βn, βd 0.125 (0.01-0.95)yr−1 (5)
Sexual acquistion rate cn, cd 3yr−1 (5)
Product of effective contact rate for becoming
a drug user and probability of becoming a
drug misuser per contact with a misuser cd1 βd1 0.4yr
−1 (4)
Rate of quitting drug misuse of sickness α 0.3yr−1 (4)
Rate of release from prison ω 0.25yr−1 Assumed
Proportion recruited into Sn, Sd, In, Id classes π1, π2, π3, π4 0.375,0.375,0.125,0.125 Assumed
Table 1. Model parameters and their interpretations.
peer pressure forces influencing one to become an IDU, we used values adapted from Bhunu
et al. (4) which are peer pressure forces necessary for one to start smoking, for the sake of
illustration. For influence of peer pressure forces influencing one to become an IDU, we used
values adapted from Bhunu et al. (2010) (4) which are peer pressure forces necessary for one
to start smoking.
Figure 2 is a graphical representation showing the effect of varying initial conditions when
RSD > 1. In Figures 2(a) and 2(b) show the effects of varying the HIV-infected not yet
showing sysmptoms on HIV-infected only and AIDS, respectively. Both graphs show a higher
number of HIV-only and AIDS among intravenous drug using male prisoners than non-drug
users. This tends to show intravenous drug using male prisoners are at increased risk of HIV
infection due to sharing of unsterile needles and increased rates of homosexual sex habits.
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Fig. 2. Effects of varying the HIV infected-only initial conditions when RSD > 1. Parameter values used
are in Table 1.
(a)































































Fig. 3. Simulations showing the effects of varying the rate at which non-drug using prisoners become
intravenous drug users on the population on drug using HIV-infected prisoners. Parameter values used
are in Table 1.
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language to assess the effects of HIV transmission among male prisoners in the absence any
interventional strategy which is more common in developing countries in Africa for different
initial conditions. The parameter values that we use for numerical simulations are in Table
1. In Table 1, NPA denotes National Prison Administration (Zimbabwe). For influence of
Parameter Symbol Value Source
Recruitment rate Λ 0.00163yr−1 ∗ 3000000 NPA
Natural mortality rate μ 0.02yr−1 (5)
Natural rate of progression to AIDS γ 0.1yr−1 (5)
Rate of leaving prison due to AIDS related sickness φ 0.25 Assumed
AIDS related death rate ν 0.4yr−1 (5)
Product of effective contact rate for HIV
infection and probability of HIV transmission
per drug injection cd2 βd2 0.562yr
−1 (16)
Probability of HIV transmission per sexual contact βn, βd 0.125 (0.01-0.95)yr−1 (5)
Sexual acquistion rate cn, cd 3yr−1 (5)
Product of effective contact rate for becoming
a drug user and probability of becoming a
drug misuser per contact with a misuser cd1 βd1 0.4yr
−1 (4)
Rate of quitting drug misuse of sickness α 0.3yr−1 (4)
Rate of release from prison ω 0.25yr−1 Assumed
Proportion recruited into Sn, Sd, In, Id classes π1, π2, π3, π4 0.375,0.375,0.125,0.125 Assumed
Table 1. Model parameters and their interpretations.
peer pressure forces influencing one to become an IDU, we used values adapted from Bhunu
et al. (4) which are peer pressure forces necessary for one to start smoking, for the sake of
illustration. For influence of peer pressure forces influencing one to become an IDU, we used
values adapted from Bhunu et al. (2010) (4) which are peer pressure forces necessary for one
to start smoking.
Figure 2 is a graphical representation showing the effect of varying initial conditions when
RSD > 1. In Figures 2(a) and 2(b) show the effects of varying the HIV-infected not yet
showing sysmptoms on HIV-infected only and AIDS, respectively. Both graphs show a higher
number of HIV-only and AIDS among intravenous drug using male prisoners than non-drug
users. This tends to show intravenous drug using male prisoners are at increased risk of HIV
infection due to sharing of unsterile needles and increased rates of homosexual sex habits.
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Fig. 2. Effects of varying the HIV infected-only initial conditions when RSD > 1. Parameter values used
are in Table 1.
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Fig. 3. Simulations showing the effects of varying the rate at which non-drug using prisoners become
intravenous drug users on the population on drug using HIV-infected prisoners. Parameter values used
are in Table 1.
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Figure 3 shows the effects of intravenous drug use on HIV/AIDS transmission dynamics
among male prisoners is illustrated by varying the rate a male prisoner becoming an
intravenous drug user while in prison. It shows an increase in the number of HIV/AIDS
cases among drug users cases with increase in drug use while the opposite will be happening
among non-drug users. This suggest that effective control of HIV among male prisoners to
some extent on the control of intravenous drug use.
5. Discussion
A mathematical model have been presented in attempt to understand the transmission
dynamics of HIV/AIDS among male prisoners. Male prisoners are infected with HIV while
in prison through intravenous drug use using unsterile needles (syringes) and homosexual
tendencies. Intravenous drug use in male prisons act in two way: (i) sharing of unsterile
needles/ syringes enhance the transmission of HIV; (ii) flashing blood that drawing is blood
from someone who would have injected himself with a drug and inject it into one self which
on its own exposes the injector to the HIV infection. Also intravenous drug using prisoners
are more likely to engage in homosexual relations with other male prisoners and with it
increased risky of HIV transmission. Analysis of the reproduction number have shown
that (i) a reduction in drug use results in a decrease of HIV/ AIDS prevalence among male
prisoners, (ii) release of prisoners may also act in reducing the concentration HIV/AIDS
cases in prisons. The later fact is not feasible, but perhaps implementing opening prison
systems where prisoners of less serious crimes are allowed to save their crimes while staying
with their families enables male prisoners to cope up with stressful prison conditions. Open
prison systems will reduce the influence of peer pressure among prisoners as they will have
moral and pyschological support from the family which does not exist in enclosed prison
systems. Numerical simulations carried also support the analytic results that increase in
drug use and tattooing increases HIV/ AIDS prevalence among male prisoners. The result
of this study have a public health implication considering high rates of syringe lending and
borrowing in prisons. This might explain why there are more HIV cases in prisons than the
general population in the case of the USA (8) and this might be the case world wide. HIV
infected men in prison pose a risk to their communities upon release from prison, especially
in Africa where partners in marriage rarely discuss safe sex so in the absence open prison
systems, it may be best to have mandatory HIV/ AIDS screening and specific educational
programmes for prisoners. This will reduce the prevalence of high-risk behaviours and lower
HIV transmission in male prisons, thus reducing post-release public health threat. Given
the high levels of HIV in prisons about three and half times higher among prisoners than
the general population, it may be best to consider the introduction of needle/ syringe free
exchange programme and drug substitution treatment as a way of keeping in check HIV
transmission in men prisons. Additionally provision of condoms might also help given the
high levels of homosexuality in male prisons.
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Individuals with HIV/AIDS: Clinical 
Manifestations in the Oral Cavity  
in the Post-HAART Era 
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1. Introduction 
Oral lesions are very common in individuals with HIV (human immunodeficiency virus) 
infection and AIDS (acquired immune deficiency syndrome). They are reported to occur in 
50% of people infected with HIV and in about 80% of  people diagnosed  with AIDS 
(Palmer, et al., 1996).  Introduction of HAART (highly active anti-retroviral therapy)  in 1996 
has reduced the mortality and morbidity in people affected with HIV and AIDS as well as 
improved their quality of life. It has also resulted in a decrease, to a certain extent, in the 
incidence and prevalence of oral lesions.  
Since HIV infection was first diagnosed in 1981, a variety of oral lesions has been associated 
with infected individuals, and they can be good indicators of the disease in otherwise 
healthy people. Oral lesions can also help determine the progression of the disease. In 
developed countries, CD4 lymphocyte counts and HIV viral load are the two main 
laboratory markers that are used to determine disease progression. However, in certain 
developing countries, people do not always have access to these tests, and severity of the 
oral lesions can serve as good indicators of disease progression.  
Table 1 highlights the importance of diagnosing and treating oral lesions in individuals with 
HIV (Coogan, et al., 2005) 
 
1. Can help diagnose the presence of HIV infection in otherwise healthy individuals 
2. Develop early in an infection 
3. Help determine the progression of HIV infection to AIDS 
4. Entry and end-points in vaccine trials 
5. Used in staging and classification of HIV diseases as determinants of opportunistic 
infection and anti-HIV therapy 
Table 1. Importance of oral manifestations of HIV disease 
1.1 Classification of oral lesions associated with HIV 
The EC-Clearinghouse on oral problems related to HIV infection and WHO Collaborating 
Centre on Oral manifestations of the immunodeficiency virus proposed the classification of 
oral manifestations of HIV infection in September of 1992 based on their strength of 
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association with the presence of HIV infection: ("Classification and Diagnostic Criteria for 
Oral Lesions in HIV Infection. EC-Clearinghouse on Oral Problems Related to HIV Infection 
and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus," 
1993). More recently in 2002,  an international workshop was convened to discuss the 
classification of oral lesions associated with HIV/AIDS almost 2 decades after the virus was 
first identified (Patton, et al., 2002) and it was agreed that the original EC-Clearinghouse 
classification could still be used in current times.  Table 2 summarizes the classification of 
oral lesions associated with HIV.  
 
Group 1: Lesions strongly 
associated with HIV 
infection 
Group 2: Lesions less 
commonly associated with 
HIV infection 
Group 3: Lesions seen in 
HIV infection 
Candidiasis  
Hairy leukoplakia  
Kaposi’s sarcoma 
Non-Hodgkin’s lymphoma 













Salivary gland disease 
Dry mouth due to 
decreased salivary flow 
Unilateral/bilateral 




Herpes simplex virus 
Human papillomavirus  
Condyloma acuminatum 

























Table 2. Classification of oral lesions associated with HIV 
In this chapter, we will discuss only those lesions that are commonly seen in persons 
infected with HIV.  
2. Candidiasis 
2.1 Background 
Candidiasis is a common opportunistic infection caused by an overgrowth of the Candida 
microorganisms already present in the oral cavity.  Incidence of oral candidiasis has been 
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high in developing countries (Tukutuku, et al., 1990). Since the discovery of HIV in 1981, 
candidiasis has been shown to be associated with HIV-infected individuals (Gottlieb, et al., 
1981). Previous reports show that oral candidiasis occurs in 54-93% of individuals with 
AIDS (Schmidt-Westhausen, et al., 1991). In recent reports, due to the introduction of anti-
retroviral therapy only 20% of individuals infected with HIV showed oral candidiasis 
(Davies, et al., 2006).  
2.2 Pathogenesis 
Oral candidiasis is primarily caused by a dimorphic ubiquitous Candida albicans. The cell 
wall of Candida is primarily made up of three polysaccharides, mannan, glucan and chitin. 
Candida attaches to oral tissues and dentures with the help of adhesins such as Als1p, Als5p, 
Int1p and Hwp1p (Chaffin, et al., 1998, Hostetter, 1994). These glycoproteins bind to the 
extracellular matrix of mammalian cells such as fibrinogen, laminin and collagen (Chaffin, et 
al., 1998). Candidal adhesion to endothelial surfaces is achieved by the cell surface 
polysaccharide mannan, which binds to complement receptor 3 (CR3), an integrin found on 
human cells (Calderone and Braun, 1991). There is increased association of integrin analogs 
(iC3B and CR3d receptor) and fibronectin receptor with most of the virulent forms of 
Candida (Ollert, et al., 1990). Thus, CR3-like proteins promote adherence of Candida albicans 
to host cells.  
2.3 Clinical features 
There are three clinical forms of candidiasis: pseudo-membranous (thrush), 
erythematous (atrophic) and perioral angular chelitis. Proliferation of pseudo-
membranous fungi forms a gray-white structure composed of inflammatory substrate 
and matted organisms resting on an erythematous base. These lesions are most 
commonly evident on the tongue, buccal mucosa, hard and soft palate and pharyngeal 
tissues. The erythematous form  shows mucosal hyperemia and inflammation with a 
reddened erythematous patches (Calderone and Fonzi, 2001). The mucous membrane 
appears dry, red and glazed.  Affected individuals show burning sensitivity and pain 
sensation of dry mouth, odynophagia, dysgeusia and smell of yeast infection. Angular 
chelitis shows commissural involvement as erythematous/hyperkeratotic with fissuring 
and sensitivity. Individuals receiving HAART show low occurrence of these clinical 
features. Before the emergence of HAART, the incidence of oral candidiasis was 
relatively high in persons with AIDS.  
2.4 Treatment 
An early study for treatment of Candida infections was carried out by Williams in 1977, where 
nystatin was compared to no treatment in 56 patients (Williams, et al., 1977). Since then 
ketoconazole, fluconazole, clotrimazole, itraconazole, neomycin sulphate, colistin, trimethoprin 
and sulphamethoxazole have been tried in combination and at different concentrations for 
treatment of oral candidiasis (Hann, et al., 1982, Owens, et al., 1984, Palmblad, et al., 1992, 
Philpott-Howard, et al., 1993, Rozenberg-Arska, et al., 1991, Vogler, et al., 1987). Most recently 
ketoconazole and clotrimazole were found most effective in treatment of oral candidiasis 
(Worthington, et al., 2002). Initial local treatments are first line of therapy (Bensadoun, et al., 
2008). Mucosal contact for 2 minutes is recommended either by rinsing, gargling or swallowing. 
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Systemic treatments are considered in high-risk patients only when local therapy fails (Charlier, 
et al., 2006). When topical and systemic therapy fails, intravenously administered amphotericin 
B and echinocandins are considered in high-risk patients. Intermittent use of antifungal agents 
has been advocated to prevent development of resistant fungal infections (Samaranayake, et al., 
2002). Recently, gel formulation of fluconazole has proven to be a better alternative treatment 
form than tablet formulation (Nairy, et al.).  
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Fig. 5. Angular Chelitis 
3. Hairy leukoplakia 
3.1 Background 
OHL (Oral hairy leukoplakia) is caused by Epstein-Barr virus and was first described in 
1984. 50% of individuals with HIV present with this condition and it is a very good indicator 
of immunosuppression. The lesion usually presents itself when the CD4 cell counts fall 
below 0.3*109/L (Bravo, et al., 2006). According to the CDC (Centers for Disease Control and 
Prevention), this condition has a clear prognostic value in predicting the future 
development of AIDS ("1993 Revised Classification System for HIV Infection and Expanded 
Surveillance Case Definition for AIDS among Adolescents and Adults," 1992). 
3.2 Pathogenesis 
The pathogenesis of OHL is due to the replication of Epstein-Barr virus and increased 
virulence in conjunction with a decrease in local and systemic host immunity.  
3.3 Clinical features 
OHL present themselves as white, corrugated lesions on the lateral surface of the tongue 
and are not painful. There has been a decrease in the incidence of OHL due to the potent 
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anti-retroviral drugs. However, if OHL is seen in an HIV-infected person, it may indicate 
failure of current therapy. Differential diagnosis of this condition includes oral candidiasis, 
lichen planus, other forms of leukoplakia, HPV (human papilloma virus) associated 
intraepithelial neoplasia, and oral squamous cell carcinoma. 
 
 
Fig. 6. Oral Hairy Leukoplakia 
3.4 Treatment 
OHL is a relatively benign condition with low morbidity and does not require any specific 
treatment. Most of the time, these lesions resolve spontaneously. However, several 
treatment options are available for those who feel uncomfortable or have cosmetic concerns 
due to the lesion. Since the lesion is caused by multiplication of the Epstein-Barr virus 
topical and systemic anti-viral agents work effectively in resolving the lesion. High doses of 
Acyclovir (800 mg 5 times a day) (Resnick, et al., 1988), Valacyclovir (1000 mg 3 times a day), 
and Famciclovir (500 mg 3 times a day) have all been shown to  resolve  the lesions in 1-2 
weeks (Schofer, et al., 1987). However, once the effect of the anti-viral agent wears off, the 
lesions can recur several weeks later.  
Topical application of Podophyllin resin in 25% solution has  produced resolution of the 
lesion in 1-2 weeks (Gowdey, et al., 1995). Topical therapy with retinoic acid has also 
been shown to cause resolve the lesions due to inhibition of Epstein-Barr virus 
replication. Ablative and cryotherapy have also had success in treatment of the lesions. 
Although the above treatment options are effective in resolving the lesion, OHL can 
recur several weeks after treatment since none of these agents eliminate the latent state 
of infection.  
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4. Kaposi’s sarcoma 
4.1 Background 
KS (Kaposi’s sarcoma) is an angioproliferative tumor described by the Hungarian 
pathologist Moritz Kaposi in 1872. It is caused by  KSHV (Kaposi’s sarcoma-associated 
herpes virus) or γ2-herpes virus. KSHV belongs to the genus Rhadinovirus and has a DNA 
sequence similar to other rhadinoviruses (Albrecht, et al., 1992). With the introduction of 
HAART in 1996, the incidence of AIDS-related cancers such as KS and NHL (non -
Hodgkin’s lymphoma) has decreased (Shiels, et al., 2008). During the 1980s and early 1990s, 
US population rates of KS increased 30 fold (Eltom, et al., 2002). There were no KS cases 
during 1975-1979, before the advent of AIDS. In an HIV cancer match study, 81% of KS cases 
matched to HIV registries during 1980-2007 (Shiels, et al., 2011). AIDS occurred in a higher 
proportion of patients with Kaposi’s sarcoma in age groups of 0-29 and 30-59 years (Shiels, 
et al., 2011). 
4.2 Pathogenesis 
KS lesions show varying cell diversity. Lesions are flat, comprising of inflammatory cells (T, 
B cells and monocytes). Neovascularization develops prior to development of these lesions 
and contain spindle-shaped cells. This dermal stage progresses to the plaque stage, in which 
the lesions are more indurated, edematous, and red or violet in color.  The lesion eventually 
reaches the nodular stage and is characterized by visible masses with dominant spindle cells 
and inflammatory cells. These spindle cells express lymphatic-specific markers (e.g., 
Podoplanin and lymphatic vessel hyaluronan receptor LYVE-1) as well as participate in the 
signaling process during lymphangiogenesis (Skobe, et al., 1999, Weninger, et al., 1999).  
4.3 Clinical features 
There are four types of KS: classic type, endemic African KS, KS in organ transplant 
recipients, and HIV-infection/AIDS associated KS (Trattner, et al., 1993). KS is the most 
common neoplasm (20-50%) found in HIV-infected individuals (mostly homosexual and 
bisexual men) (Scully, et al., 1991).Oral lesions are evident in 40% of KS (Greenspan and 
Greenspan, 1990).Red or purplish macules, papules or nodules appear most frequently on 
the hard palate (Greenspan and Greenspan, 1990). Unless infected or ulcerated, these lesions 
do not blanch on pressure (Greenspan and Greenspan, 1990). Laryngeal involvement is also 
evident in individuals with KS (Pantanowitz and Dezube, 2006). Primary symptoms are 
hoarseness, throat discomfort, urge to cough, aphonia, dysphagia, stridor, and complete 
airway obstruction. 
4.4 Treatment 
The extent and bulk of the disease determines the therapeutic alternative that needs to be 
considered. Individuals with fewer than five cutaneous lesions are kept on watch until 
rapid proliferation, widespread dissemination or KS-related symptoms become more 
apparent. Treatment with HAART or other anti-retroviral therapies are beneficial and 
have shown histologic regression of existing lesions (Eng and Cockerell, 2004). HAART 
therapy causes inhibition of HIV replication, diminishes the HIV-1 transactivating protein 
Tat, ameliorates the immune response against KSHV, and shows direct anti-angiogenic 
activity (Cattelan, et al., 1999, Pati, et al., 2002, Sgadari, et al., 2002).  Radiotherapy is 
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indicated for lesions on the face, hands and upper extremities, obstructive 
lymphadenopathy, periorbital edema, lesions on soles of the feet, anorectal or genital 
lesions, oral lesions and ulcerating cutaneous lesions. Radiotherapy shows merits in 
symptomatic disease where systemic treatment is not necessary and expensive 
chemotherapy can be avoided (Swift, 1996). If an active opportunistic infection is 
observed, chemotherapeutic agents should be considered. Systemic chemotherapeutic 
treatment is indicated in extensive KS of oral cavity, widespread skin involvement, pedal 
or scrotal edema, symptomatic visceral involvement and flare induced by immune 
reconstitution inflammatory syndrome (Osoba, et al., 2001). Individuals may suffer from 
neutropenia and thrombocytopenia and hence controlled therapy should be the choice of 
treatment. Only nodular and symptomatic lesions of oropharynx should be treated with 
radiation. Recombinant and non-recombinant alpha interferons can be used for treatment 
of epidemic KS (De Wit, et al., 1988).  
 
 
Fig. 7. Kaposi’s Sarcoma 
5. Human Papilloma Virus (HPV) infections 
5.1 Background 
HPV is the leading cause of orpharyngeal carcinomas (D'Souza, et al., Rosenquist, 2005). 
HPV16 is a common cause for the majority of oropharyngeal carcinomas (Kreimer, et al., 
2005) . HPV-positive individuals are most frequently Caucasian and belong to high 
socioeconomic status (Gillison, et al., 2008).  HIV-infected individuals have two to four-fold 
increase in risk for developing HPV-related oral cancers (Gilbert, et al.). HPV has also been 
considered as one of the etiologic factors for OHL (oral hairy leukoplakia) (Fejerskov, et al., 
1977), as shown by identification of HPV antigens and HPV DNA (Loning, et al., 1985). 
HPV-induced OL shows prevalence ranged from 17% to 68.6% (Shroyer, et al., 1993, 
Sugiyama, et al., 2003). 
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HPV is mainly infectious through expression of oncogenes such as E6/E7 (Al-Bakkal, et al., 
1999),  which cause phosphorylation of CHK2, leading to caspase activation (Al-Bakkal, et 
al., 1999, Moody and Laimins, 2009, Tominaga, et al., 1999). The intrinsic apoptotic pathway 
of caspase activation plays an important role in HPV replication (Moody, et al., 2007). HPV 
proteins flourish and regulate amplification primarily by caspase activation, leading to 
immortalization of the suprabasal layer of epithelium, specifically the keratinocytes (Sakai, 
et al., 1996). 
5.3 Clinical features 
HPV induced oral and pharyngeal cancers are most evident in younger females (<40 years). 
OSCC (oral squamous cell carcinoma) normally occur on the buccal mucosa (2-10%), lip (4-
40%), alveolar ridge (2-18%) retromolar trigonous (2-6%), hard palate (3-6%), floor of mouth 
(25%), ventral two third of tongue (50%), alveolar ridge (2-18%), floor of mouth (25%) and 
oropharynx (25%). Squamous cell carcinoma of the oropharynx most commonly originates 







Fig. 8. Human Papilloma Virus Lesions 
 




Treatment of HPV infection can be achieved either by use of targeted therapy against the 
virus or immune-stimulating therapy. Most dysplastic tissue can be treated by ablative and 
excisional therapy. Use of radiochemotherapy in the form of radiation ± cisplatin or 
cetuximal has shown beneficial results in treatment of oropharyngeal carcinoma. The overall 
survival rate was 60 % in HPV-positive individuals and 73 % in HPV-negative individuals 
(Lill, et al.). 
6. Periodontal lesions associated with HIV 
6.1 Linear Gingival Erythema (LGE) 
6.1.1 Background 
This lesion is also known as ‘red-band gingivitis’ or ‘HIV-associated gingivitis’. LGE is 
commonly seen in immune-compromised individuals and is considered to be a potential 
precursor for necrotizing ulcerative gingivitis (NUG)/ necrotizing ulcerative periodontitis 
(NUP). According to the recent classification of periodontal diseases (Armitage, 1999), LGE 
is classified under ‘Gingival diseases of fungal origin.’ 
6.1.2 Pathogenesis 
There is an increased number of bacteria and Candida species in the gingival sulcus 
associated with LGE. The bacteria seen include those commonly observed in periodontal 
disease such as Bacteriodes gingivalis, Bacteriodes intermedius, Actinomyces viscosus, 
Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans.  
6.1.3 Clinical features 
The lesions present themselves as 2-3 mm wide red band around the marginal gingival of 
the teeth. These lesions are not typically painful, but bleed readily.  
6.1.4 Treatmen 
Typically, no treatment is needed for this condition.  Although LGE is listed under ‘Lesions 
of fungal origin’, it is not typically treated with anti-fungal medications. Mechanical 
removal of plaque and calculus helps reduce inflammation and excessive bleeding. 
Chlorhexidine gluconate (0.12%) mouth rinses can be used twice daily. If the lesion persists, 
systemic antibiotics (metronidazole) may be prescribed to reduce the bacterial load.  
6.2 Necrotizing Ulcerative Gingivitis and Periodontitis (NUG and NUP) 
6.2.1 Background 
NUG is a painful condition of the gingiva characterized by ulcerations, bleeding, and foul 
breath. It is also called Vincent’s infection, Vincent’s angina, or trench mouth. When the 
infection spreads to the alveolar bone, it is called NUP.  Prevalence of NUP in HIV-infected 
individuals has been reported by various researchers. Its prevalence with HIV was reported 
in 1994 as 6% (Glick, et al., 1994). Over a period of a decade, the incidence of HIV in NUP 
patients increased to 69.6% (Shangase, et al., 2004). Recent reports suggest 43% of patients 
with NUP were HIV-seropositive (Phiri, et al.). Studies have shown that HIV-infected 
individuals with NUP are 20.8% more likely to have a CD4+ count lower than 200 (Glick, et 
al., 1994). 
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Fig. 9. Linear Gingival Erythema 
6.2.2 Pathogenesis 
NUP is commonly a progression of NUG  that demonstrates bone loss and clinical 
attachment levels (MacCarthy and Claffey, 1991). Both are primarily caused by bacterial 
infection with microflora consisting of Treponema and Selenomonas species, Prevotella 
intermedia, Fusobacterium nucleatum and Porphyromonas gingivalis (Falkler, et al., 1987, 
Loesche, et al., 1982). Malnutrition, smoking, stress, trauma and preexisting gingivitis are 
other etiologic factors (Peruzzo, et al., 2007, Taiwo, 1993). Most persons with NUG have 
alterations in the immune system making them more prone to microbial infections (Cogen, 
et al., 1983). This immunosuppression is also evident in infection by HIV (Goedert, et al., 
1984). Treponema denticola (T. denticola) is the principal oral helical-shaped anaerobic 
spirochete that plays an essential role in immunosuppression. The disease process is 
mediated through adherence to mucosal surfaces, specific cleavage of cell surface receptors, 
inhibition of host defense mechanisms, penetration in epithelial cells, and induction of 
gingival inflammation and bone resorption. Proteases such as chymotrypsin, phospholipase 
C, oligopeptidase and cystalysin play an important role in pathogenicity (Chi, et al., 2003, 
Ellen and Galimanas, 2005, Fenno and McBride, 1998) and is induced by a range of pro-
inflammatory cytokines such as IL-1α, IL-1β, tumor necrosis factor-α, IL-6 and IL-8 
(Gemmell and Seymour, 1998, Nixon, et al., 2000). These cytokines affect connective tissue 
destruction and alveolar bone desorption (Gemmell and Seymour, 1998). Phosphorylation of 
intracellular receptors such as Fos-c, MKK1, MAP kinase and nuclear factor κB molecules by 
T. denticola affect these changes (Tanabe, et al., 2008).  
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6.2.3 Clinical features 
The clinical characteristics of NUG includes ulcerated and necrotic papillary and marginal 
gingival covered by a yellowish-white or grayish slough or “pseudomembrane”, blunting 
and cratering of papillae, spontaneous bleeding or bleeding on probing, pain and fetid 
breath (Barnes, et al., 1973, Falkler, et al., 1987, Horning and Cohen, 1995).  It may be 
accompanied by fever, lymphadenopathy, and malaise. Progression of gingivitis to NUP is 
commonly associated with clinical attachment loss and alveolar bone destruction.  
 
 
Fig. 10. Necrotizing Ulcerative Periodontitis 
6.2.4 Treatment 
The first treatment for NUG was devised by Dr. S. Schluger in 1949 (Schluger, 
1949).Bacterial pathogens were controlled or  eliminated by mechanical debridement or use 
of antibiotics in earlier days (Johnson and Engel, 1986). Aureomycin and penicillin were the 
first antibiotics considered for treatment of NUG in 1950 (Goldman and Bloom, 1950, 
Montis, 1950). Mechanical treatment consists of scaling and root planing. In addition to 
mechanical debridement, antibiotic and antimicrobial therapies are essential for 
management of NUP. Oxidizing mouthwash such as 3% hydrogen peroxide has also shown 
to have beneficial effects in management of NUG and NUP. 
7. Non-Hodgkin lymphoma 
7.1 Background 
There are three subtypes of on-Hodgkin’s lymphoma (NHL): diffuse large B cell lymphoma 
(DLBCL), Burkitt’s lymphoma (BL) and central nervous system lymphoma (CNSL)(Engels, 
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commonly associated with clinical attachment loss and alveolar bone destruction.  
 
 
Fig. 10. Necrotizing Ulcerative Periodontitis 
6.2.4 Treatment 
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of antibiotics in earlier days (Johnson and Engel, 1986). Aureomycin and penicillin were the 
first antibiotics considered for treatment of NUG in 1950 (Goldman and Bloom, 1950, 
Montis, 1950). Mechanical treatment consists of scaling and root planing. In addition to 
mechanical debridement, antibiotic and antimicrobial therapies are essential for 
management of NUP. Oxidizing mouthwash such as 3% hydrogen peroxide has also shown 
to have beneficial effects in management of NUG and NUP. 
7. Non-Hodgkin lymphoma 
7.1 Background 
There are three subtypes of on-Hodgkin’s lymphoma (NHL): diffuse large B cell lymphoma 
(DLBCL), Burkitt’s lymphoma (BL) and central nervous system lymphoma (CNSL)(Engels, 
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et al., 2006).  An increase in occurrence of DLBCL (10.2%), BL (27.8%) and CNSL (48.3%) was 
seen in individuals with AIDS during 1990-1995 (Shiels, et al., 2011). The 5-year survival rate 
improved from 1960 to the mid 1970s, but not much after that in the USA (Shiels, et al., 
2011). NHL relates to congenital and acquired immunodeficiency diseases (Filipovich, et al., 
1992). The relative risk of NHL in individuals with AIDS is about 150-250 in Western 
countries and over 1000 in children (Goedert, 2000).  
7.2 Pathogenesis 
The head and neck regions are the most common sites for NHL, showing in 30-40% of cases 
(Economopoulos, et al., 1996). The neoplastic cells express CD20, CD79, BCL-2 and BCL-6, 
most of which are B-cell antigens (Hoefnagel, et al., 2003). The hallmark of B-cell 
malignancies is chromosomal translocation involving the immunoglobulin heavy chain 
(IGH) gene at band 14q32.33 with specific oncogene loci, referred to as the 14q32 
translocation. Among these specific 14q32 translocations, de novo acute leukemia/lymphoma 
with c-MYC and/or BCL6 abnormalities in addition to t(14;18) was characterized by an 
extremely aggressive clinical course with nodal and/or extranodal involvement, and 
massive bone marrow infiltration(Kramer, et al., 1991). Incidence of IGH translocation on B-
cell NHL  has been reported in previous studies (Kramer, et al., 1998). Thus multiple 
involvement of the IGH gene in chromosomal rearrangements is associated with the 





Fig. 11. Histology of NUP lesion- Infiltration of Spirochetes into the Connective Tissue 
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Stage I Involvement of a single lymph node region (I) or a single extralymphatic organ or site (IE) 
Stage II 
Involvement of two or more lymph node regions on the same side 
of the diaphragm (II) alone or with localized involvement of an 
extralymphatic organ or site (IIE) 
Stage III 
Involvement of lymph node regions on both sides of the 
diaphragm (III) alone or with localized involvement of an 
extralymphatic organ or site (IIIE) or spleen (IIIS) or both (IIISE) 
Stage IV 
Diffuse or disseminated involvement of one or more 
extralymphatic organs with or without associated lymph node 
involvement 
Table 3. Ann Arbor Classification of Non-Hodgkin’s Lymphomas (Rupniewska, 1979) 
7.3 Clinical features 
Oral NHL lesions are often in disseminated disease states. The most common oral sites of 
involvement are the palate, tonsil, buccal mucosa, floor of the mouth, and the retromolar 
region. These lesions are non-tender, diffuse swellings usually involving the gingiva, buccal 
vestibule and posterior hard palate. Gnathic lesions arise from soft tissue invading the bony 
skeleton. One third of patients show fever, weight loss, adenopathy, night sweats, or 
hepatosplenomegaly. Oral lesions are fluctuant swellings showing ulceration, pain, tooth 
mobility and paresthesia when peripheral nerves are involved (Vega, et al., 2005). Salivary 
gland lymphomas account for approximately 3% of all salivary gland tumors (Barnes, et al., 
1998). About 80% of the cases are reported in parotid gland, 16% in submandibular, 2% in 
sublingual and 2% in minor salivary glands. Affected bony areas show a “punched out” 
pattern that is due to multiple areas of destruction with ill defined radiolucent lesion. 
Involvement of the maxillary sinus will cause opacification with eroded cortical walls and 
associated sinus mass (Fukuda, et al., 1987). The Ann Arbor staging system, originally 
designed for Hodgkin’s disease, is used for NHL as evident above. 
7.4 Treatment 
A prognostic index has been developed by the International NHL prognostic factors project 
based on data from 2,031 patients with aggressive lymphomas treated with regimens 
containing doxorubicin ("A Predictive Model for Aggressive Non-Hodgkin's Lymphoma," 
1993). Analysis of 1274 patients younger than 60 years showed three clinical features 
independently associated with survival: serum LDL (lactate dehydrogenase) levels, tumor 
stage, and their performance status ("A Predictive Model for Aggressive Non-Hodgkin's 
Lymphoma," 1993). Past studies showed the importance of gallium-67 uptake in lymphomas 
as a useful prognostic indicator (Janicek, et al., 1997). The importance of prognostic index is 
that good-risk patients can be identified for standard therapy and poor-risk patients can be 
identified for new research protocols to improve the rate of therapy. With conventional 
therapy only 25% of patients who were gallium-positive midway through therapy  had 
durable responses , while 70% of those who were gallium-negative remained free of disease 
(Janicek, et al., 1997). In patients with stage I or II disease, regional therapy leads to long-
term control, with relapse rate of 44%-47% at 10 years and survival rates of 75% for patients 
younger than 60 years (Vaughan Hudson, et al., 1994). Stage III and IV patients can be 
treated by alkylating agents, combination chemotherapy regimens with 2-4 drugs, and high 
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treated by alkylating agents, combination chemotherapy regimens with 2-4 drugs, and high 
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dose therapy with bone marrow transplant reinfusion(Freedman, et al., 1996, Govindan, et 
al., 2009). 
8. Conclusions 
Thorough examination of the oral cavity should be part of the physical examination for 
everybody, but especially in HIV-positive individuals and those who are at a high risk for 
acquiring HIV infection. Oral lesions can not only compromise the quality of life and 
increase morbidity in patients with HIV/AIDS, but can also serve as indicators for the 
presence of the disease and disease progression. It is also very important for health care 
providers and medical practitioners from different specialties to collaborate in providing the 
overall care for these immune-compromised patients.  
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1. Introduction 
Kaposi’s sarcoma was first described in 1872 by Moritz Kaposi, a Vienna-based Hungarian 
dermatologist, as a rare multifocal angioproliferative tumour involving blood and lymphatic 
vessels in elderly men of Jewish origin (Kaposi, 1872). Before the AIDS epidemic three 
clinico-epidemiological forms with similar histological features have been described. The 
classic Kaposi’s sarcoma (KS) originally described by Kaposi is primarily a skin disease with 
a chronic indolent course that can sometimes regress spontaneously (Kaposi, 1872). Most of 
the cases occurred in elderly men of Mediterranean and Jewish origin. The African-endemic 
KS is seen in the indigenous population of sub-Saharan Africa (Franceschi & Geddes, 1995). 
It is also seen more commonly among male patients, but differs from the classic form in that 
it may affect a younger population and is more likely to spread to visceral organs and 
lymphatics. In addition, it has a variable clinical presentation ranging from a benign disease 
with few skin lesions to a widely disseminated disease associated with high morbidity and 
mortality (Franceschi & Geddes, 1995; Taylor et al 1971). Kaposi’s sarcoma seen in patients 
as a result of immunosuppression complicating organ transplantation may have chronic or 
progressive course and spontaneous remission after discontinuation of immunosuppressive 
therapy is observed in the majority of patients (Penn, 1979). 
The first description of AIDS-associated Kaposi’s sarcoma (AAKS) was in 1981, when 
Friedman-Kien et al (1981) reported some previously healthy young homosexual men with 
Kaposi's sarcoma involving lymph nodes, viscera, and mucosa as well as skin. This was 
associated with life-threatening opportunistic infections and a profound defect in cell-
mediated immunity. This aggressive and frequently fatal form of Kaposi's sarcoma is the 
most common cancer in patients with HIV infection (Schwartz, 2004). Before the discovery 
and widespread use of highly active antiretroviral therapy (HAART) KS was over 20,000 
times more common in AIDS patients than the general population (Engels et al 2006). 
However, several studies showed that HAART reduced the incidence of KS in high income 
countries (.Franceschi et al, 2008; Pipkin et al, 2011; Simard et al, 2011). The cumulative 
incidence of Kaposi sarcoma declined from 14.3% during 1980 to 1989, to 6.7% during 1990 
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to 1995, and to 1.8% during 1996 to 2006 (Simard et al, 2011). In a Swiss HIV cohort study, 
the overall KS incidence was 33.3 per 1000 person year (py) in 1984–1986 and did not change 
significantly in the subsequent periods until 1996–1998, when it fell to 5.1 (95% CI, 3.9–6.5) . 
The incidence further decreased to 1.4 per 1000 py in 1999–2001 and remained constant 
thereafter (Franceschi et al, 2008). In another recent pan-European multi-centre study, there 
was a decrease in the incidence rate of KS from 24.7 cases (95% CI 17.2–32.2) per 1000 py in 
1994 to 4.7 (95% CI 2.7–6.7) per 1000 py in 1997 and 1.7 (95% CI 0.7–3.4) per 1000 in recent 
years among HIV-infected individuals (Pipkin et al, 2011). In a report from Sao Paulo Brazil, 
a low income country, 17% of a cohort of patients on HAART was seropositive for human 
herpesvirus-8 of which only 2% developed AAKS in 5 years compared to 20% prevalence of 
AAKS detected in the same region before the HAART era (Yoshioka et al, 2004). In contrast, 
the incidence of KS has been steadily increasing in parallel with the AIDS epidemic in sub-
Saharan Africa (Bassett et al, 1995; Parkin et al, 2008; Sasco et al, 2010). In 2002, of 66,200 
estimated KS cases worldwide, 58,800 ware estimated to be in Africa (Parkin et al, 2008). Of 
these, about 39,500 cases in males and 17,100 cases in females occurred in sub-Saharan 
Africa compared to 102 males and 17 females in Northern Africa (Parkin et al, 2008). In areas 
such as Malawi, Uganda and Zimbabwe where Kaposi’s sarcoma was common before the 
AIDS epidemic, the incidence of this cancer has increased by about 20-times and it is now 
the most common cancer in males and second most common cancer in females (Sasco et al, 
2010). In Zimbabwe, the age-adjusted incidence of KS per 100,000 population was 2.3 in men 
and 0.3 in women before the AIDS epidemic, compared to 48 and 18, respectively, during 
the AIDS epidemic (Bassett et al, 1995). Recent studies conducted in South Africa and 
Rwanda found a clear association between HIV infection and KS with odd ratio ranging 
from 21.9 (95% CI 12.5–38.6) to 47.1 (95% CI 31.9–69.8) (Newton et al, 1995; Stein et al, 2008). 
Similarly, Newton et al (2001)in a study carried out in Kampala, Uganda found a higher risk 
of KS among HIV- infected compared to HIV-negative children with an odd ratio of 94.9 
(95% CI 28.5–315.3). 
Although the course of AAKS is variable most patients would eventually develop progressive 
and disseminated disease requiring active therapy. The choice of treatment is determined by 
the stage of KS, its rate of progression, the degree of immune competence and HIV associated 
diseases. Several therapeutic options are available for AAKS but the optimal therapy is still 
unclear. Highly active antiretroviral therapy including protease inhibitors may be the first 
treatment step for indolent slowly progressive disease (Martellotta et al, 2009). Following 
treatment with HAART, there may be complete remission   in patients with good 
immunological response and limited disease (Martellotta et al, 2009). However, recent studies 
indicate that there is no significant regression when patients with advanced, symptomatic 
AAKS are treated with HAART without simultaneous chemotherapy (Krown, 2004; Martin-
Carbonero 2004). A wide variety of chemotherapeutic agents, individually and in combination, 
have been evaluated for the treatment of AAKS. In high income countries, combination of 
vincristine, doxorubicin and bleomycin (VAB) that was considered the standard 
chemotherapy regimen for AAKS has been supplanted by liposomal anthracylines due to their 
higher efficacy and reduced toxicity (Ashish et al 2007; Cooley, 2007). In addition, the 
angiogenic nature of KS makes it particularly suitable for therapies based on targeted agents 
such as metalloproteinase inhibitors, angiogenesis inhibitors and tyrosine kinase inhibitors 
(Koon et al, 2011; Sullivan et al, 2009). In low income countries, the choice of therapeutic agents 
is limited to the combination of VAB or even more toxic drugs such as therlidomide because 
liposomal anthracyclines are not available or affordable (Makombe et al, 2009).   
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1.1 Aetiology and pathogenesis 
For a long time, the aetiology and pathogenesis of KS remained unclear. The discovery in 
1994 of KS-associated herpes virus (KSHV), also known as human herpes virus-8 (HHV-8), 
in cells isolated from an AAKS lesion was followed by molecular and epidemiological data 
confirming an aetiological link between this virus and all clinical forms of KS (Chang et al, 
1994; Hengge et al, 2002). Though infection with HHV-8 is not sufficient for tumour 
development, the virus has developed various mechanisms to manipulate host cell signal 
transduction, and thereby lead to the activation of numerous pro-growth and anti-apoptotic 
pathways. HIV-1 transactivation (Tat) protein is a short-term growth factor for KS 
(Guadalupe et al, 2011; Hassman et al, 2011). Tat protein through the mediation of IFN-γ,   
b-FGF and other cytokines has the capacity to induce endothelial cell proliferation and 
facilitate invasion of extracellular matrix (Hassman et al, 2011). In addition, it enhances 
HHV-8 infectivity for endothelial cells and increases its viral load by reactivating it from 
latent state (Guadalupe et al, 2011). On the other hand, HHV-8 activates nuclear receptors 
NF-kappa and NF-AT and this level of activation is synergistically increased by HIV-1 Tat 
protein (Guadalupe et al, 2011). Thus, infection with HHV-8 is associated with KS the risk 
for which correlates with HHV-8 viral load. However, for a given HHV-8 titre, the risk is 
greater in HIV-seropositive, as compared to HIV-seronegative individuals (Casper, 2011). 
Exceptions have been found in some parts of West Africa, South America and Australia 
where although the incidence of HHV-8 infection is high only few cases of KS are found 
(Ablashi et al 1999; Rezza et al, 2001). This indicates that other factors are important in the 
pathogenesis of KS. 
In Nigeria, the incidence of HIV/AIDS was estimated at 4.1 million and is on the downward 
trend (National Action Committee on AIDS (NACA) 2010). KS has become the most 
common malignant skin tumour with the disease appearing in areas where it did not exit in 
the past (Asuquo & Ebughe, 2009; Iregbu & Elegba, 2006). A report from Calabar South 
Eastern Nigeria showed that KS is the most common malignant skin tumour accounting for 
38.0% cases (Asuquo & Ebughe, 2009). Reports from Abuja and Benin both in Nigeria 
showed KS in 0.8% of newly diagnosed HIV infected patients compared to a prevalence of 
0.5% a decade earlier (Akinsete et al, 1998; Iregbu & Elegba, 2006; Onunu et al, 2007). Most 
of our patients present with extensive and advanced disease that usually required a 
combination of HAART and chemotherapy. This together with limited therapeutic facilities 
resulted in poor outcome of treatment (Ahmed et al, 2001; Asuquo & Ebughe, 2009). With 
improved AIDS awareness and access to HAART more patients are likely to present earlier. 
Our institution is one of the Federal Government HIV/AIDS designated treatment centre 
and we see patients from various parts of Nigeria. There is little information on the 
treatment and outcome of KS in HIV-1infected patients who have been treated with HAART 
in Africa. The objective of this study was to review the clinical features, treatment and 
outcome of AIDS –associated Kaposi’s sarcoma patients in our institution particularly in the 
context of increasing use of highly active antiretroviral therapy. We shall also highlight the 
difficulties in the evaluation and treatment of these patients. 
2. Patients and method 
This prospective study was carried out at Ahmadu Bello University Teaching Hospital 
Zaria, the premier referral and teaching hospital in Northern Nigeria. Patients with 
concurrent diagnosis of HIV infection and Kaposi’s sarcoma seen between January 2007 and 
  
Global View of HIV Infection 
 
104 
to 1995, and to 1.8% during 1996 to 2006 (Simard et al, 2011). In a Swiss HIV cohort study, 
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The incidence further decreased to 1.4 per 1000 py in 1999–2001 and remained constant 
thereafter (Franceschi et al, 2008). In another recent pan-European multi-centre study, there 
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have been evaluated for the treatment of AAKS. In high income countries, combination of 
vincristine, doxorubicin and bleomycin (VAB) that was considered the standard 
chemotherapy regimen for AAKS has been supplanted by liposomal anthracylines due to their 
higher efficacy and reduced toxicity (Ashish et al 2007; Cooley, 2007). In addition, the 
angiogenic nature of KS makes it particularly suitable for therapies based on targeted agents 
such as metalloproteinase inhibitors, angiogenesis inhibitors and tyrosine kinase inhibitors 
(Koon et al, 2011; Sullivan et al, 2009). In low income countries, the choice of therapeutic agents 
is limited to the combination of VAB or even more toxic drugs such as therlidomide because 
liposomal anthracyclines are not available or affordable (Makombe et al, 2009).   
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December 2010 were included. Only patients 18 years or more were included. Consent was 
obtained from each patient after counselling and at the time of taking blood sample, tissue 
specimen or taking photographs of accessible lesions. Permission for the study was also 
obtained from the hospital ethical committee.    
2.1 Patient’s evaluation and treatment 
Patients were assessed at the time of diagnosis of AAKS and at four to eight weekly 
intervals during follow-up. At each visit, weight, vital signs and Kaposi’s sarcoma 
symptoms were recorded, and a physical examination was performed. During evaluation 
efforts were made to discover the probable mode of HIV transmission to the patient. The 
dimension, number, appearance and sites of involvement of KS lesions were recorded. 
Lesions causing disfigurement were photographed. Tumour size was defined as the sum of 
the greatest diameters of each measurable tumour. The Karnofsky score status of the 
patients was also recorded. The tumour was staged according to AIDS Clinical Trials Group 
(ACTG) classification using the tumour (T), immune system (I) and systemic illness (S) 
(Krown et al, 1997). Tumour was defined as T0 if disease was confined to the skin and 
lymph nodes or oral involvement was confined to the hard palate, or T1 if there was 
pulmonary or gastrointestinal involvement, tumour associated oedema or ulceration, or 
extensive oral involvement. Cutaneous KS lesions confined to one anatomical area were 
classified as local while lesions involving two or more sites as disseminated. 
Morphologically the lesions were classified as macular, nodular and ulcerative. Tumour 
response was assessed by comparing lesion characteristics to the baseline tumour 
evaluations. Treatment responses were assessed according to ACTG criteria. A complete 
response (CR) was defined as the absence of any detectable residual disease, including 
tumour-associated oedema, persisting for at least four weeks. Partial response (PR) was 
defined as ≥50% decrease in the number or size of previously existing evaluable lesions 
lasting for at least four weeks without the appearance of new lesions or tumour-associated 
oedema. Stable disease (SD) was defined as any response that did not meet the criteria for 
progression or PR. Overall response rate was defined as both complete and partial response 
rates. Progressive disease (PD) was defined as ≥25% increase in the size of previously 
existing lesions or the appearance of new ones or the development of new or increasing 
tumour-associated oedema or effusion. Relapse was defined as the development of 
progressive disease in the presence of a documented CR, or PR.  
Screening test for HIV antibodies were performed by parallel testing using Enzyme-linked 
immunoabsorvent assay (ELISA) with Immunocomb II, HIV-1 and HIV-2 (M/S Orgenics, 
Israel) and Stat Pak (Trinity Biotech, Wicklow, Ireland). Positive test results from the two 
different kits were taken as confirmatory evidence of HIV antibodies.  The CD4 cell counts 
were performed using the Dynabeads method (Dynal Biotech LLC, Milwaukee, WI, USA). 
Patients that presented from 2008 to 2010 were screened with Stat Pak (Trinity Biotech, 
Wicklow, Ireland) and Bundi HIV-1 and HIV-2 (Bundi International Diagnostics, Abia, 
Nigeria) and confirmed with Western blot method. Their CD4 count was performed with 
Partec flow cytometre (Partec GmbH, Munster, Germany). Plasma HIV-1 RNA levels were 
measured with Roche-Ampiclor HIV-1 monitor test, (version 1.5 (Roche-Ampiclor-Roche 
Diagnostics, Branchburg, USA). Viral load less than 400 copies/mL was considered 
undetectable. Diagnosis of Kaposi’s sarcoma was based on histological examination of tissue 
specimens fixed in 10% formalin embedded in paraffin wax and stained with haematoxylin 
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and eosin. Special stains were employed in selected cases. Serum urea and electrolytes, liver 
function test and complete blood count with differential and platelet count were done at the 
time of diagnosis of AAKS and before administration of chemotherapy. Chest radiographs, 
ECG, abdominal ultrasound, faecal occult blood and gastrointestinal endoscopic 
examination were performed in appropriate cases. 
Our protocol for the treatment of AAKS has been presented previously (Ahmed et al, 2001). 
Following evaluation, patients were resuscitated and started on HAART which we defined 
as therapy consisting of at least three antiretroviral drugs in accordance with national 
guidelines (NACA, 2007). Our protocol recommends that patients with AAKS are started on 
HAART irrespective of CD4 count. Stable patients that have KPS of ≥40 and adequate bone 
marrow, renal and hepatic functions were then commenced on specific anti-KS 
chemotherapy. This consisted of six courses of three weekly cycles of vincristine 1.5mg/m2, 
doxorubicin 10mg/m2 and bleomycin 15mg/m2 by bolus intravenously. Treatments were 
delayed for up to two weeks for recovery from grade ≥3 neutropenia, thrombocytopenia or 
severe diarrhoea. Patients with relapse were treated with same course. Radiotherapy and 
surgical excision of localised lesions were performed in appropriate cases. Treatment 
complications and outcome were monitored. Patients were followed-up at four to eight 
weekly intervals until death or lost to follow-up.  
2.2 Statistical analysis 
We analysed data using SPSS statistical software (version 17.0, SPSS, Chicago IL). Data were 
reported as proportions, mean ± standard deviation (SD) or median (range). Categorical 
variables and proportions were compared by Fisher’s exact test while continuous variables 
were compared by Wilcoxon two-sample test. In patients that responded to treatment, the 
duration of response was summarised using Kaplan Meier method. Fisher’s exact test was 
used to test for agreement between the occurrence of clinical benefit and the presence of 
clinical response. Survival was calculated from the day of KS diagnosis until death or the 
date of last follow-up. Overall survival duration curves and duration of tumour response 
were plotted according to Kaplan-Meier method. Logistic regression modeling performed to 
identify independent determinants of survival and tumour response was done using the 
following clinicopathologic variables: age, sex, presence of comorbid condition, presence of 
systemic symptoms, KPS, stage of tumour, viral load and CD4 count at presentation. Risk 
factors were first analysed univariately, and the statistically significant variables were used 
to construct a multivariate model. Interactions were also analysed to confirm independence.  
We considered p ≤ 0.05 to be statistically significant. 
3. Results  
3.1 Patient’s characteristics 
During the period of study 7,155 patients with HIV infection were seen of which 98 (1.4%) 
had associated Kaposi’s sarcoma. The number of patients with AAKS increased steadily 
from 2007 to 2010 (table 1). Their ages ranged from 18 to 54 years (Figure 1), mean of 33.6 ± 
3.8 SD. Nine (9.2%) patients were less than 21 years old while 44 (44.9%) were in the third 
decade. There were 56 males and 42 females, male to female ration of 1.3:1. The male to 
female ratio decreased from 1.5:1 in 2007 to 1:1 in 2010. Females were younger than males 
(mean age of 27years vs. males 34; p< 0.04). Comorbid conditions were seen in 43 (43.9%) 
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patients including 20 (20.4%) pulmonary tuberculosis, 17 (17.3%) oral candidiasis, 15(15.3%) 
hypertension and 2 diabetes mellitus. Duration of symptoms of AAKS ranged from 1 to 13 
months, mean 5.7 ±1.2SD. Symptoms were present in 91 (92.9%) patients and included pain 
(62.2%), swelling of the limbs (figure 2) (52.6%) and cosmetic disability (31.6%). Seven (7.1%) 
patients had no symptoms of Kaposi’s sarcoma and the diagnosis was made during routine 
clinical evaluation (figure 3) at antiretroviral therapy (ART) clinic. Kaposi’s sarcoma was the 
AIDS defining disease in 64 (65.3%) patients while in the remaining 34 (34.7%) it was 
diagnosed between 1 and 15 months after the initial diagnosis of AIDS. Sixteen patients had 
used HAART for 1- 13 months at the time of diagnosis of AAKS. The KPS ranged from 20% 
to 100%, median of 60%. All the patients were heterosexual although 11 were men having 
sex with men (MSM). Patients on anti-retroviral therapy at the time of diagnosis had a mean 
CD4 count of 267± 65SD cell/mm3. Overall, the mean CD4 count at presentation was 165 
cells/mm3 (range: 26 – 875; 95% CI: 97 - 425). The mean HIV-1 viral load (VL) assessed in 71 
patients was 48,593 copies/mL (range: 200- 989,571; 95% CI: 28,593- 76,225).  
3.2 Tumour characteristics 
The anatomic distribution of AAKS lesions is shown in table 2. All patients had multiple 
lesions the lower limbs being most frequently involved (45.9%). In 20 (20.4%) patients, 
tumour was limited to extremities, with fungating and exophytic growth invading and 
destroying the subcutaneous and surrounding tissues including the underlying bones 
(Figure 4). Unusual sites including 7 conjunctiva, 9 penile and 12 vulva were also involved. 
Perineal involvement was more common in females. Visceral lesions included 3 rectal, 5 
intestinal and 2 gastric tumours. Tumour size ranged from 2.0 to 58.0cm, mean 29± 15.7SD. 
The histological type was mixed cellularity in 63 (64.3%) patients and anaplastic in 9 (9.2%). 
KS stage at presentation was T1, I1, S1 in 47 (48.0%); T1, I1, S0 in 22 (22.4%); T0, I0, S1, in 8 
(8.2%) and T0, I0, S0 in 21 (21.4%). Overall, 77 (78.6%) patients had poor prognosis stage 
comprising 38 (90.5%) females and 39 (69.6%) males (OR= 3.5, 95% CI 1.7–5.6, P < 0.01). 
Women also had more disseminated cutaneous AAKS lesions involving an increased 
number of lesions at multiple anatomical sites, compared to more localised lesions in males 
(OR =3.4, 95% CI = 1.7–5.5, P = 0.001). Despite the differences in age and disease severity 
between males and females, no gender-specific differences were observed in CD4 counts or 
plasma HIV-1 viral load. However, when males and females were analysed separately, there 
were significant correlations between the severity of KS and the degree of immune 
suppression as measured by CD4 count (χ2 test, P= 0.001) and between poor disease 
prognosis and immune suppression (P= 0.001) 
 
Year 
HIV infected patients AIDS associated Kaposi’s sarcoma patients 
No % No. % of HIV patients 
Male: 
Female 
2007 1667 23.3 20 1.2 1.5:1 
2008 1755 24.5 23 1.3 1.3:1 
2009 1837 25.7 25 1.4 1.2:1 
2010 1896 26.5 30 1.6 1:1 
Total 7155 100 98 1.4 1.3:1 
Table 1. Prevalence of HIV infection and AIDS-associated Kaposi’s sarcoma 
 












Fig. 2. Nodular Kaposi’s sarcoma with swelling of the lower limb 
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Year 
HIV infected patients AIDS associated Kaposi’s sarcoma patients 
No % No. % of HIV patients 
Male: 
Female 
2007 1667 23.3 20 1.2 1.5:1 
2008 1755 24.5 23 1.3 1.3:1 
2009 1837 25.7 25 1.4 1.2:1 
2010 1896 26.5 30 1.6 1:1 
Total 7155 100 98 1.4 1.3:1 
Table 1. Prevalence of HIV infection and AIDS-associated Kaposi’s sarcoma 
 












Fig. 2. Nodular Kaposi’s sarcoma with swelling of the lower limb 
  

















Site No. % 
Lower limb 45 45.9 
Trunk 37 37.8 
Lymph node 33 33.7 
Perineum 19 19.4 
Oropharynx 15 15.3 
Upper limb 13 13.3 
Visceral 9 9.2 
Other 6 6.1 
Table 2. Anatomical distribution of AIDS-associated Kaposi’s sarcoma lesions 
 




Fig. 4. Fungating Kaposi’s sarcoma lesions of upper and lower limbs 
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19 3.5 (1.7) 0.84 67 3.9 (1.3) 1.25 0.14 
Viral load (x103 
copies/mL) 10 503 (128.8) 17.50 41 512 (125.0) 15.9 0.15 
CD4 count 
(cell/uL) 19 162 (56.4) 2.37 67 168 (55.8) 1.45 0.07 
Sex         0.75 
Male 12    42     
Female 7    25     
ACTG Stage          
Good 
prognosis 4 (21.1%)   16 (23.9%)    
Poor 
prognosis 15 (78.9%)   51 (76.1%)    
Time of 
diagnosis of KS         0.18 
At diagnosis 




7 (36.8%)   24 (35.8%)    
SD= standard deviation; ACTG = AIDS clinical trials group; KS= Kaposi’s sarcoma 
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and 
Bleomycin 
Table 3. Characteristics of patients that were treated with HAART alone or HAART and 
VAB 
3.3 Treatment and outcome 
Overall, 67 (68.4%) patients were treated with both HAART and VAB of which 53 had 
completed six cycles. Of the 14 patients that did not complete anti-KS therapy, eight died in 
the course of treatment after two to five courses, treatment was stopped in two because of 
severe side effects and four were lost to follow-up (LTF). The median time to start 
chemotherapy after diagnosis of AAKS was three months (range 1 to 5months). Because of 
financial constraints, 19 (19.4%) patients had only antiretroviral therapy. The patients that 
had both HAART and VAB and those that had HAART alone had similar ACTG clinical 
stage, KPS and CD4 counts (table3). The remaining 12(12.2%) patients had only supportive 
care because of poor KPS (7) and refusal of consent (5). Two patients had limb amputation, 
five had excision of localised ulcerated lesions while 17(17.4%) had radiotherapy. Overall, 69 
(70.4%) patients had improvement of AAKS symptoms that lasted a median duration of ten 
months (range 3 months to 4 years). The cumulative tumour response is shown in figure 5. 
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Fifty four (80.6%) patients treated with HAART and VAB had tumour response compared to 
8 (42.1%) of those treated with HAART alone (p< 0.005). Patients treated with both HAART 
and VAB were more likely to have tumour response or stable disease (OR 2.7; CI: 1.8- 3.6) 
compared to those that had HAART alone (table 4). There was a positive correlation 
between symptoms control and tumour response (Pearson correlation coefficient, r = 0.35 
and r = 0.28; p < 0.05 by two tailed Fisher exact test). While haematotoxicity was the most 
frequent toxicity in both treatment groups, neutropenia grades three and four was higher in 
patients treated with both HAART and VAB (22.4%) compared to HAART alone (10.5%)(P < 
0.001). Digestive toxicity was frequently observed in both groups, with a higher rate of 
diarrhea in the HAART and VAB group. Five patients had peripheral neuropathy while two 
others had asymptomatic cardiomyopathy. These toxicities delayed chemotherapy by 1-2 
weeks in 15 patients.  
 
Patient’s response HAART alone (n=19) 
HAART +VAB 
(n=67) P -value 
Symptom control   0.003 
No.  (%) 10 (52.6) 59 (88.1)  
Median duration of symptoms 
control, months (range) 5 (1- 13) 12 (5- 54) 0.001 
Overall tumour response 8 (42.1) 54 (80.6) 0.005 
Complete response 2 (10.5) 31 (46.3) 0.001 
Partial response 6 (31.6) 23 (34.3) 0.075 
Median duration of tumour  
response, months (range) 5 (1-17) 11 (2- 54) 0.001 
Median time to relapse, months 
(range) 3 (2.5-15) 9 (5-26) 0.001 
Treatment related complications    
No. (%) 7 (36.8) 38 (56.7) 0.015 
Median KPS (range)    
At diagnosis of KS 60 (30-90) 60 (30-90)  
3 months after diagnosis of KS 60 (20-90) 60 (40-90) 0.017 
Mortality at 6 months    
No. (%) 6 (31.5) 7 (10.4) 0.005 
KS= Kaposi’s sarcoma; KPS= Kernofsky performance score 
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and 
Bleomycin 
Table 4. Response of patients to treatment with HAART alone or HAART and VAB. 
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Fig. 5. Cumulative tumour response following treatment of AIDS-associated Kaposi’s 
sarcoma 
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Overall, median survival was 14 months from the time of diagnosis of AAKS. The median 
survival was 12 months for patients treated with HAART compared to 18 months for those 
treated with both HAART and VAB (figure 6). Overall 56 (57.1%) patients had significant 
improvement in quality of life. Seven (7.1%) patients died during their first admission in the 
hospital while additional 7 were lost to follow-up. At one year 34 (34.7%) patients had died, 
comprising of 12 (100%) patients that had only supportive treatment, 9(47.4.0%) of those 
treated with HAART and 13 (19.4%) treated with HAART and VAB (figure 6). Univariate 
analysis showed that females, poor ACTG stage, CD4 count <200 cells/mm3, viral load > 
21,000 copies/mL, and not using antiretroviral therapy were significantly associated with 
poorer survival (table 5). When these factors were subjected to multiple regression analysis, 
poor ACTG stage (p=0.015), viral load > 21,000 copies/mL (p=0.001), not using 
antiretroviral (p=0.005) and not using anticancer chemotherapy (p=0.003) were the 
significant independent factors associated with poorer survival.  Patient’s follow-up ranged 
from one month to four years. Fifty two (53.1%) patients were followed-up for one year. 
 
Variable Number of patients 
Death 
OR 95% CI P -value No % 
Sex  
Male 56 21 37.5 1  
Female 42 20 47.6 1.4 1.2 – 2.9 0.049 
Age (years)  
1-20 9 4 44.4 1  
21-40 76 32 42.1 1.5 1.4 – 3.5  
41-60 13 5 38.5 1.3 1.1  –2.7 0.175 
Time of diagnosis of KS  
After diagnosis of AIDS 34 13 38.2 1  
As AIDS defining 
disease 64 27 42.2 1.7 1.5 – 4.9 0.075 
ACTG stage  
Good prognosis 21 5 23.8 1  
Poor prognosis 77 35 45.5 4.8 3.7 – 12.4 0.005 
CD4 count (cells/mm3)  
>200 40 15 37.5 1  
≤200 58 25 43.1 2.4 1.6 – 3.9 0.016 
Viral load (copies/mL)  
0-20,000 11 2 18.2 1  
≥ 21,000 40 19 47.5 2.9 2.7 – 6.5 0.003 
Use of HAART  
Yes 86 28 32.5 1  
No 12 12 100.0 5.5 3.9 – 14.6 0.001 
Use of VAB  
Yes 67 18 26.8 1  
No 31 22 71.0 3.2 2.1 – 5.7 0.001 
OR= odd ratio; CI = confidence interval; ACTG = AIDS clinical trials group; KS= Kaposi’s sarcoma 
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and Bleomycin 
Table 5. Univariate analysis of factors related to mortality in patients with AIDS-associated 
Kaposi’s sarcoma 
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Fig. 6. Cumulative survival following treatment of patients with AIDS-associated Kaposi’s 
sarcoma 
4. Discussion  
To our knowledge, this is the largest study to date on the treatment and outcome of patients 
with AIDS-associated Kaposi’s sarcoma from Nigeria. The present study identified KS in 
1.4% of HIV-1 infected patients. The patients are young with female patients being relatively 
younger than males. The male to female ratio decreased from 1.5:1 in 2007 to 1:1 four years 
later. Majority of the patients (78.6%) presented with high tumour burden that was 
categorised as poor prognosis disease, while 20 (20.4%) had pulmonary tuberculosis. 
Simultaneous treatment with HAART and combination chemotherapy was carried out on 
67(68.4%) patients. This treatment was associated with significant morbidity but was the 
only chance for control of symptoms and prolonged survival. 
In high income countries the incidence of AAKS has decreased significantly from mid 1990s 
(Franceschi et al, 2008; Pipkin et al, 2011). This reduced AAKS incidence is due to wide 
spread use of HAART which has the effect of immune reconstitution and direct inhibitory 
effects on angiogenesis. In addition, there are safer sex practices and other preventive and 
therapeutic measures against HIV infection. Recently, Phatak et al (2010) from India 
identified no case of KS among 46 AIDS-associated cancers reviewed over 5 years. In 
another report from Thailand, the incidence was 0.026 per 100,000 despite high incidence of 
HIV infection because HHV-8 infection is low at 4.0% (Sriplung & Parkin, 2004). In the 
present study, there was progressive increase in prevalence of AAKS over the study period 
(table 1). In a previous report from our institution, 15 AAKS patients were seen from 1991 to 
1995 compared to 98 patients seen from 2007 to 2010 in the present study (Ahmed et al, 
2001). Overall, the prevalence of AAKS in this study was 1.4% which is lower than 1.6% 
reported from Jos, Nigeria and 3.4% from South Africa, but higher than 0.8% reported from 
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other centres in Nigeria (Agaba et al, 2009; Iregbu & Elegba, 2006; Chu et al 2010).  The high 
incidence of HHV-8 infection and limited access to HAART and other preventive measures 
explain in part the reason for increasing incidence of AAKS in sub-Saharan Africa. 
Prior to the HIV epidemic KS was a disease of middle-aged men (Penn, 1979; Taylor et al, 
1971). The mean age of 33.6 years in the present study is similar to that reported in other 
studies in our sub-region (Chu et al, 2010; Phipps et al, 2010). The lower age of these patients 
is probably due to the high risk behaviour and incidence of HIV infection is highest in the 
age group 20-40 years in sub-Saharan Africa. In addition, our female patients were younger 
than males. The finding that AAKS occurs at an earlier age in women when compared with 
men has been reported previously (Mosam et al, 2008; Phipps et al, 2010). In the present 
study, the proportion of KS patients was highest among women in their mid-20s who 
heterosexually acquired HIV-1 infection. This indicates that females acquire HIV-1 infection 
at an earlier age than males. Alternatively, immunosuppression from HIV infection and KS 
pathogenesis might progress more rapidly in females compared to males. Previous studies 
have shown that the age-specific distribution pattern for female KS was essentially similar to 
that previously reported for HIV-1 infection (Jombo et al, 2006). Therefore, the risk of 
developing AAKS is closely related to the epidemiology of HIV-1 infection in females.  
 
Variable Category OR 95% CI P-value 





5.3 2.2- 17.3 0.015 
CD4 count (cells/mm3) ≤ 200 vs.  > 200 1.6 1.3- 3.8 0.075 
Viral load (copies/mL) ≥ 21,000 vs. < 21,000 3.1 2.6- 9.5 0.001 
Use of HAART No vs. Yes 2.8 2.3- 6.9 0.005 
Use of VAB No vs. Yes 1.9 1.5- 3.8 0.003 
OR= odd ratio; CI = confidence interval; ACTG = AIDS clinical trials group;  
HAART= highly active antiretroviral therapy; VAB= combination of Vincristine, Doxorubicin and 
Bleomycin 
Table 6. Multiple regression analysis of factors related to mortality in patients with AIDS-
associated Kaposi’s sarcoma 
In Western countries all forms of KS are more common among men than women (Simard et 
al, 2011; Martellotta et al 2009). This is similar to the findings in Africa before the advent of 
HIV infection (Sasco et al, 2010; Taylor et al, 1971). Among HIV-infected individuals other 
than MSM, reported incidence rates of KS are still higher in men in other studies (Kagu et al, 
2006; Sissolak & Mayaud, 2005). In a recent study from Brazil 94.4% of 107 AAKS patients 
were men, giving a male to female ratio of 18:1 (Yoshioka et al, 2004). The observations that 
a tumorigenic KS cell line could not be established in pregnant immunodeficient mice and 
that human chorionic gonadotropin (hCG) inhibited KS growth in-vitro suggested a possible 
biologic basis for the lower KS incidence among women (Lunardi-Iskandar et al, 1995; 
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Rabkin et al, 1995).  However, therapeutic trials with hCG have been inconclusive while 
studies in women with HIV infection revealed that pregnancy afforded no protection from 
KS development or dissemination (Rabkin et al, 1995). In our patients, the male to female 
ratio was 1.3:1 which decreased progressively from 1.5:1 in 2007 to 1:1 four years later. This 
is similar to 1.4:1 recently reported from South Africa (Chu et al, 2010). A report from Jos 
Nigeria revealed a reversal of the gender ratio from a male to female ratio of 10:1 about four 
decades ago to 1:1.4 (Agaba et al, 2009). The reason for the near equivalent distribution of 
AAKS cases among men and women in recent studies may be a reflection of the high 
proportion of HIV infected females with >60% of person living with the virus in Africa 
being women. Additionally, women are more frequently subjected to HIV testing as routine 
counselling and testing has been applied to perinatal settings, and this may lead to higher 
number of AAKS cases being identified among women. Finally, unlike in Western countries 
where MSM constitute a high proportion of AAKS cases, the heterosexual mode of HIV 
transmission in our patients mean that HHV-8 would be equally distributed among men 
and women. Therefore, the trend in increasing proportion of female patients with AAKS 
may continue until when females predominate.  
Patients in this study presented with extensive and disseminated disease with 78.6% having 
poor prognosis stage, a much higher proportion than reported from resource rich countries 
(Ashish et al, 2007; Krown 2004). Other reports from poor resource countries revealed that 
poor prognosis disease constitute 60-82% of cases (Agaba et al, 2009; Bassett et al, 1995; Phipps 
et al 2010). Cutaneous lesions were present in 64.7% of patients in this series followed in order 
of frequency by lymphadenopathy and visceral lesions. Moderate enlargement of peripheral 
lymph nodes is not uncommon in HIV infected patients. A biopsy of such nodes would often 
reveal a focus of KS, a finding that appears to have little clinical consequence (Krown 2004). 
However, 11 of our patients had massive generalised lympadenopathy in the absence of 
evidence of KS elsewhere.  In sub-Saharan Africa lymphadenopathy is comparatively common 
and has various causes including tuberculosis, lymphoma, KS and HIV infection.  There is a 
significant overlap in the clinical presentation of these diseases although each requires 
distinctly different treatment. Histology provides a reliable and cost effective definitive 
diagnosis since each disease can be distinctively diagnosed under the microscope. However, it 
has been suggested that co-existing lesions can be missed even in biopsy material if special 
stains for demonstration of microorganisms are not performed (Pantanowitz et al 2010). 
Involvement of the gastrointestinal tract (GIT) was seen in only nine of our patients. However, 
most patients with GIT KS are asymptomatic, and because the lesions are submucosal they are 
not visualized on contrast-enhanced radiographs (Kibria et al 2010). Previous studies showed 
that asymptomatic GIT lesions have little clinical consequences hence, endoscopy should be 
carried out only on symptomatic patients (Kibria et al, 2010; Sissolak & Mayaud, 2005). In our 
patients, KS involved multiple anatomical regions. The lower limbs were most frequently 
affected with an associated lymphoedema which may be extensive and disproportionate to the 
extent of cutaneous disease. This lymphoedema may result from tumour involvement of 
dermal lymphatics or from the production by KS cells of growth factors that increase vascular 
permeability (Feller et al, 2008). Additionally, HHV-8-induced exuberant proliferation of 
endothelial cells may lead to the occlusion of lymphatic vascular lumens leading to 
lymphoedema (Feller et al, 2008).  
In this as in other reports, at the time of diagnosis women had more widespread and 
advanced AAKS compared to men (Chu et al 2010; Meditz et al, 2007). It is probable that the 
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reason for the increased severity of AAKS in women is not related to virological or 
immunological differences since both men and women in our study had similar mean VL 
and mean CD4 counts. This is in agreement with studies from Zimbabwe and South Africa 
(Meditz et al, 2007; Mosam et al, 2008). Of special interest is a small cohort of 14 patients 
who were on HAART for 6-13 months at the time of diagnosis of KS. These patients had a 
median CD4 count of 375 cells/mm3 and undetectable HIV viral load. They required 
systemic therapy to control their KS but were more likely to have complete resolution of 
their tumours and demonstrated a trend towards better survival than patients having KS 
with lesser CD4 counts and detectable HIV viral loads. In the past, AAKS has been reported 
in African patients with CD4 counts of >350 cells /mm3 indicating that severe 
immunosuppression is not necessary for development of KS (Morgan et al, 2000). Similarly, 
recent reports from high income countries have identified a group of patients that 
developed AAKS despite effective and sustained HIV suppression and good immune 
system function (Crum-Cianflone et al, 2010; Mani et al, 2009; Maurer et al, 2007). This raises 
questions about the integrity of the immune system and its ability to control certain viruses 
in patients with long-standing HIV infection. It has been suggested that with the ageing of 
HIV infected patients those who are co-infected with HHV-8 may develop KS despite good 
control of HIV infection (Crum-Cianflone et al, 2010).  The impacts of AAKS on quality of 
life are varied. In our patients, extensive oedema of the lower limbs was associated with 
stiffness and pain that may interfere with walking while ulcerated tumours were infected 
and foul smelling. Lesions of the face and genitalia also have social and emotional 
consequences, including isolation because of obvious disfiguring lesions, and depression 
and anxiety from the constant visible reminder of illness. 
The disability and suffering associated with AAKS means that treatment to reduce 
symptoms and improve quality of life should be carried out promptly and efficiently. 
HAART is an essential treatment for all AAKS patients (Krown, 2004; Tirelli & Bernardi, 
2001). In patients with low tumour burden and slowly progressing disease, histological 
regression of existing KS lesions has been shown in response to HAART (Martellotta et al, 
2009). However, HAART alone can not effectively control all cases of KS and there may be 
initial tumour progression as part of the immunoreconstitution syndrome (Bower et al, 
2005). In addition, it is not possible to state with certainty what proportion of patients with 
AAKS will benefit from HAART alone, or what are the precise characteristics that can be use 
to identify such patients. In our patients as in others, HAART is an effective post-
chemotherapy maintenance treatment in patients with advanced and extensive disease that 
has been reduced significantly as a result of conventional chemotherapy (Cooley et al, 2007; 
Martin-Carbonero, 2004). The effects of HAART on Kaposi’s sarcoma are multifactorial and 
include inhibition of HIV replication, diminished production of HIV-1 transactivating 
protein Tat, reconstitution of immune response against HHV-8 and possibly direct 
antiangiogenic activity by inclusion of protease inhibitors (Tirelli & Bernardi, 2001). In the 
present study, decision to initiate systemic chemotherapy was based on the extent of 
Kaposi’s sarcoma in addition to other considerations such as patient KPS, end organ 
function, degree of immunosuppression, and other HIV comorbidities.  
Our patients were treated with a combination of vincristine, doxorubicin and bleomycin, 
similar to reports from other low income countries (Chu et al, 2010; Dedicoat et al, 2003).  In 
high income countries liposomal anthracyclines and taxanes are being used for treatment of 
AAKS due to higher efficacy and reduced toxicity (Ashish et al, 2007; Cooley et al, 2007). In 
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(Meditz et al, 2007; Mosam et al, 2008). Of special interest is a small cohort of 14 patients 
who were on HAART for 6-13 months at the time of diagnosis of KS. These patients had a 
median CD4 count of 375 cells/mm3 and undetectable HIV viral load. They required 
systemic therapy to control their KS but were more likely to have complete resolution of 
their tumours and demonstrated a trend towards better survival than patients having KS 
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HIV infected patients those who are co-infected with HHV-8 may develop KS despite good 
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regression of existing KS lesions has been shown in response to HAART (Martellotta et al, 
2009). However, HAART alone can not effectively control all cases of KS and there may be 
initial tumour progression as part of the immunoreconstitution syndrome (Bower et al, 
2005). In addition, it is not possible to state with certainty what proportion of patients with 
AAKS will benefit from HAART alone, or what are the precise characteristics that can be use 
to identify such patients. In our patients as in others, HAART is an effective post-
chemotherapy maintenance treatment in patients with advanced and extensive disease that 
has been reduced significantly as a result of conventional chemotherapy (Cooley et al, 2007; 
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Kaposi’s sarcoma in addition to other considerations such as patient KPS, end organ 
function, degree of immunosuppression, and other HIV comorbidities.  
Our patients were treated with a combination of vincristine, doxorubicin and bleomycin, 
similar to reports from other low income countries (Chu et al, 2010; Dedicoat et al, 2003).  In 
high income countries liposomal anthracyclines and taxanes are being used for treatment of 
AAKS due to higher efficacy and reduced toxicity (Ashish et al, 2007; Cooley et al, 2007). In 
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a meta- analysis comparing pegylated doxorubicin (PLD) and VAB among 499 patients, 
Dedicoat et al (2003) found a better response among the PLD group although there was no 
survival advantage by either group. However, liposomal anthracyclines are unlikely to be 
available or affordable in low income countries where the majority of AAKS patients live. In 
a recent analysis from Brazil, PLD was found to be associated with improved efficacy and 
less toxicity but in terms of cost effectiveness, the VAB regimen is the most rational 
treatment option for AAKS patients in poor resource settings (Vanni et al, 2006). Our results 
showed that six cycles of this regimen could produce a significant and quick response in 
symptomatic patients with advanced AAKS. Overall response rate of 80.6% in our patients 
compares favourably to 50% to 88% reported in other studies (Dedicoat et al, 2003; 
Makombe et al, 2008; Phipps et al, 2010). Differences in response rates are largely 
attributable to differences in the patient populations evaluated, the lack of strictly defined 
response criteria and variations in the dosing schedules used.  Of the 67 patients that had 
chemotherapy in this study, 52% had complete resolution of their disease within 36 months 
of diagnosis. This is similar to observed resolution rates of 44%-60% reported using similar 
regimen (Bihl et al, 2007; Nasti et al, 2000; Nguyen et al, 2008). However, we found the 
median time to complete resolution to be 9 months which is considerably longer than 5 
months previously reported (Bihl et al, 2007). This is provably because chemotherapy was 
not immediately started in many of our patients due to financial constraints. In the present 
study, both HAART and VAB were independently associated with complete resolution of 
tumour suggesting that even in the HAART era, chemotherapy plays a significant role in the 
treatment of advanced AAKS patients. In addition, HIV viral load was significantly 
associated with resolution of KS. This finding is consistent with other reports of AAKS 
improvement or resolution associated with significant decrease or undetectable HIV viral 
load (Nguyen et al, 2008). Indeed, it seems that controlling HIV viral load is essential for 
clinical improvement, disease resolution of KS, and perhaps decreased risk of relapse. In this 
as in other studies there was no association between CD4 T-cell count and KS response, 
suggesting that suppression of HIV replication plays a more vital role in the resolution of KS 
than immune reconstitution (Mosam et al, 2008; Iregbu & Elegba, 2006). In our patients, 
there was positive correlation between tumour response and clinical response, and the 
response was maintained for a significant period of time after discontinuation of 
chemotherapy. Clinical response was associated with improved quality of life as evidenced 
by control of fungating and foul smelling ulcers and improvement of pain, cosmetic 
appearance and KPS. In the present study, median survival was 18 months following 
chemotherapy compared to 12 months following HAART alone. Both VAB and HAART are 
independently associated with improved survival, similar to the Multicenter AIDS Cohort 
Study which demonstrated an 81% reduced risk of death for KS patients treated with 
HAART (Tam et al, 2002). Whilst CD4 count <200 cells/mm3 was associated with mortality 
on univariate analysis, it was not on multivariate analysis. This may be due to the effects of 
advanced KS disease (T1 and S1 stages) whose effects were stronger than CD4 count. 
The toxicities observed following chemotherapy in our patients are similar to those reported 
in other studies using same regimen and are well tolerated (Dedicoat et al, 2003; Guadalupe 
et al, 2011). In the absence of haemopoetic growth factors, cytotoxic chemotherapy was used 
cautiously in our patients to minimise the risk of bone marrow suppression that may lead to 
infectious complications. Bacterial infections which resulted from severe neutropenia 
secondary to chemotherapy were observed in three of our patients. Doxorubicin causes 
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significant bone marrow suppression which is at its nadir on day 14 after administration. 
This bone marrow suppression recovers slowly over 7-10 days but in an HIV infected 
individual the magnitude and duration of the bone marrow suppression may be longer, 
hence the need to wait for three weeks to allow the bone marrow to recover before the next 
cycle of chemotherapy is given. The selection of therapy for KS must take into account the 
potential benefit and adverse effects of treatment, interactions with other medications, and 
potential impact on underlying immunosuppression.  
When dealing with localised bulky or cosmetically disturbing lesions, radiotherapy is the 
most effective local therapy. In this as in other reports, irradiated lesions regress with 
treatment, but regrowth, after 6 months is common (Bih et al, 2007; Nguyen et al, 2008). In 
addition to providing effective palliation, radiotherapy is associated with minimal side 
effects. Although surgery is effective in excision of localised isolated lesions, heroic surgery 
is unjustified. Our study has several limitations. Among the patients that died, other risk 
factors for mortality such as tuberculosis were not independently considered hence the 
actual death due to KS were not isolated. In addition, some of our patients were lost to 
follow-up and a previous study indicates that about 40% of these patients were actually 
dead (Brinkhof et al, 2009). Similarly, because many patients lost to follow-up were treated 
with VAB, the beneficial effects of chemotherapy may be underestimated. Finally, follow-up 
of patients was difficult and inconsistent hence, it was not possible to monitor the timing of 
treatment outcome accurately. 
5. Conclusion   
In conclusion KS is not uncommon in patients with HIV-1 infection. The patients present 
with extensive and advanced disease that requires systemic treatment. All AAKS patients 
should receive HAART. In low income countries like ours, chemotherapy consisting of a 
combination of vincristine, doxorubicin and bleomycin should be given simultaneously with 
HAART to patients that can physiologically withstand such therapy. The usual number of 
cycles for effective therapy is six cycles. However, chemotherapy may continue for 1-2 
cycles beyond complete remission to maximise the chance of attacking all microscopic KS 
cells. Following successful treatment chemotherapy can be restarted for recurrent tumour. If 
KS continues to grow in the presence of effective HAART regimen, chemotherapy with VAB 
should be stopped and alternative treatment modalities should be instituted if possible, or 
else palliative KS management should be started. Palliative care for KS may include 
adequate pain relief, reduction of the size of tumours with radiotherapy and reduction of 
the offensive smell of ulcerated lesions with appropriate dressing argent. Prevention and 
treatment of other opportunistic infections is necessary as uncontrolled infections may 
stimulate KS progression probably due to production of angiogenic cytokines. Using this 
approach we achieved quick and prolonged tumour response in addition to improved 
quality of life as evidenced by symptoms control and improved cosmetic appearance and 
KPS. High satisfaction and reduced toxicities as well as availability, affordability and ease of 
administration of the drugs led to good patient’s compliance. This approach is 
recommended for treating AAKS patients in a poor resource setting. It is necessary to 
identify KS patients early in the disease when treatment is likely to provide significant 
benefits in terms of reducing the bulk of disease and improving long-term survival. 
However, early access to highly active antiretroviral therapy constitutes the best hope for 
the control of this stigmatizing and lethal disease in sub-Saharan Africa. With improvement 
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combination of vincristine, doxorubicin and bleomycin should be given simultaneously with 
HAART to patients that can physiologically withstand such therapy. The usual number of 
cycles for effective therapy is six cycles. However, chemotherapy may continue for 1-2 
cycles beyond complete remission to maximise the chance of attacking all microscopic KS 
cells. Following successful treatment chemotherapy can be restarted for recurrent tumour. If 
KS continues to grow in the presence of effective HAART regimen, chemotherapy with VAB 
should be stopped and alternative treatment modalities should be instituted if possible, or 
else palliative KS management should be started. Palliative care for KS may include 
adequate pain relief, reduction of the size of tumours with radiotherapy and reduction of 
the offensive smell of ulcerated lesions with appropriate dressing argent. Prevention and 
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stimulate KS progression probably due to production of angiogenic cytokines. Using this 
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quality of life as evidenced by symptoms control and improved cosmetic appearance and 
KPS. High satisfaction and reduced toxicities as well as availability, affordability and ease of 
administration of the drugs led to good patient’s compliance. This approach is 
recommended for treating AAKS patients in a poor resource setting. It is necessary to 
identify KS patients early in the disease when treatment is likely to provide significant 
benefits in terms of reducing the bulk of disease and improving long-term survival. 
However, early access to highly active antiretroviral therapy constitutes the best hope for 
the control of this stigmatizing and lethal disease in sub-Saharan Africa. With improvement 
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in the access to antiretroviral therapy in sub-Saharan Africa, it is necessary to designed 
studies that investigate the effects of cheaper and more widely available chemotherapeutic 
argents for the treatment of AIDS-associated Kaposi’s sarcoma among patients on highly 
active antiretroviral therapy. 
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in the access to antiretroviral therapy in sub-Saharan Africa, it is necessary to designed 
studies that investigate the effects of cheaper and more widely available chemotherapeutic 
argents for the treatment of AIDS-associated Kaposi’s sarcoma among patients on highly 
active antiretroviral therapy. 
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1. Introduction 
Nowadays, the Human Immunodeficiency Virus (HIV), which is the causative agent of  
Acquired Immune Deficiency Syndrome (AIDS),  represents a serious public health 
problem. According to the World Health Organization (WHO), in 2009 there were 33.3 
million  people living  with HIV worldwide, and more particularly in sub-Saharan Africa, 
where the overwhelming majority  (67%) of cases appear.  Furthermore, 2.6 million people 
have been  recently infected with the virus in 2009,  when HIV/AIDS was estimated to have 
caused  1.8 million deaths  (United Nations Program on HIV/AIDS [UNAIDS], 2010).  
Due to the  impairment of their  immune system,  HIV bearers  are more susceptible to 
opportunistic infections, such as Tuberculosis (TB), which is a leading cause of HIV-related 
deaths worldwide. The risk for TB is 20-37-fold  greater among HIV-infected individuals, 
depending on the  status of the HIV epidemic. According to WHO, one-third of people 
living with  HIV are infected with TB, and there was an estimate of  1.4 million new TB cases 
per year  among said population.  Moreover, one in four TB deaths occurs in HIV-positive 
patients, while  TB was responsible  for 23% of AIDS-related deaths (WHO, 2010a).  
This situation becomes  especially alarming in view of the number of  challenges in  the 
control and management of TB in HIV-infected  individuals, such as the difficulties to 
conclude a TB  diagnosis, as well as  the complexity involved in the  treatment of HIV 
infection-related TB. Due to their great relevance to the subject matter of this work, the  
above factors will be emphasized  in the next section.  
2. Challenges in the management of HIV infection-related TB    
2.1 Diagnosis of TB in HIV-infected individuals  
Within the context of lung diseases,  there are some aspects that may constitute a bar to the 
diagnosis of TB (Box 1): HIV-infected patients are minimally symptomatic or asymptomatic, 
as they present few or less specific classic symptoms of TB (productive cough, chest pain, 
fever, night sweats, weight loss, hemoptysis); patients with low CD4+ T lymphocyte counts 
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1. Introduction 
Nowadays, the Human Immunodeficiency Virus (HIV), which is the causative agent of  
Acquired Immune Deficiency Syndrome (AIDS),  represents a serious public health 
problem. According to the World Health Organization (WHO), in 2009 there were 33.3 
million  people living  with HIV worldwide, and more particularly in sub-Saharan Africa, 
where the overwhelming majority  (67%) of cases appear.  Furthermore, 2.6 million people 
have been  recently infected with the virus in 2009,  when HIV/AIDS was estimated to have 
caused  1.8 million deaths  (United Nations Program on HIV/AIDS [UNAIDS], 2010).  
Due to the  impairment of their  immune system,  HIV bearers  are more susceptible to 
opportunistic infections, such as Tuberculosis (TB), which is a leading cause of HIV-related 
deaths worldwide. The risk for TB is 20-37-fold  greater among HIV-infected individuals, 
depending on the  status of the HIV epidemic. According to WHO, one-third of people 
living with  HIV are infected with TB, and there was an estimate of  1.4 million new TB cases 
per year  among said population.  Moreover, one in four TB deaths occurs in HIV-positive 
patients, while  TB was responsible  for 23% of AIDS-related deaths (WHO, 2010a).  
This situation becomes  especially alarming in view of the number of  challenges in  the 
control and management of TB in HIV-infected  individuals, such as the difficulties to 
conclude a TB  diagnosis, as well as  the complexity involved in the  treatment of HIV 
infection-related TB. Due to their great relevance to the subject matter of this work, the  
above factors will be emphasized  in the next section.  
2. Challenges in the management of HIV infection-related TB    
2.1 Diagnosis of TB in HIV-infected individuals  
Within the context of lung diseases,  there are some aspects that may constitute a bar to the 
diagnosis of TB (Box 1): HIV-infected patients are minimally symptomatic or asymptomatic, 
as they present few or less specific classic symptoms of TB (productive cough, chest pain, 
fever, night sweats, weight loss, hemoptysis); patients with low CD4+ T lymphocyte counts 
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have atypical chest radiograph findings, with lower prevalence of cavitary disease, while 
the findings could be normal in  up to 22% of HIV-infected  individuals; the main method 
used worldwide for  TB detection, namely  the microscopic examination of Ziehl-Neelsen-
stained sputum smears, has low sensitivity among HIV-infected  individuals, as they 
develop  acid-faster smear negative diseases with higher frequency than  HIV-uninfected 
people (Sterling et al., 2010).  
Furthermore, HIV-infected individuals present more often the subclinical form of  TB,  said 
factor leading to a delay in the  diagnosis  and treatment. Another  difficulty for the  TB 
diagnosis in HIV-infected individuals is the increased risk (10-20% in HIV-uninfected 
individuals, compared to 40-80% in HIV-infected  persons) to develop extrapulmonary TB, 
whose  most prevalent forms are pleural effusion, lymphadenopathy, pericardial disease, 
miliary disease, meningitis and disseminated TB (Chaisson et al., 1987).  
 
 
2.2 TB treatment in HIV bearers  
In addition to  diagnostic difficulties,  the treatment of HIV infection-related TB also 
presents several challenges, such as duration and frequency,   determining the precise 
moment to start  antiretroviral therapy (ART), management of drug interactions, as well as 
several side effects from therapy. 
As regards the  duration of TB therapy, WHO recommends a 6-month rifampicin-based 
treatment (2HRZE/4HR, Table 1), applying  to both HIV-infected and uninfected  
individuals. Nevertheless, Perriens and  collaborators showed that, after providing a  12-
month therapy with 2HRZE/4HR,   the recurrence rate at the 18th  month shall be lower 
than those observed at  the standard regime (Perriens et al., 1995). Furthermore, another 
study performed by Fitzgerald et al indicated that the administration of isoniazid for 1 year 
upon termination of the therapy under  standard regime reduces the recurrence of TB only 
among HIV-infected patients (Fitzgerald et al., 2000). It is  worthy to mention that, in both 
studies,  patients  had no access to antiretroviral therapy, which  contributes to extend the 
beneficial effects from TB treatment, without presenting the  risks that are inherent to the 
combination of TB-HIV drugs.  
 
Phase Duration (months) Dosing Frequency Drugs 
Intensive 2 Daily HRZE 
Continuous 4 Daily or three times per weeka HR 
a For the continuation phase, the optimal dosing frequency may be also daily; should the administration 
of such a dosage be impossible,  three times per week is a suitable alternative. 
H = isoniazid, R= rifampicin, Z = pyrazinamide, E= ethambutol 
Table 1. TB treatment  for HIV bearers, as recommended by WHO. 
Box 1. Usual difficulties involved in the diagnosis of TB in HIV-infected individuals  
 Minimally symptomatic or asymptomatic patients; 
 Atypical chest radiograph findings; 
 Acute prevalence of acid--fast smear negative disease ; 
 High frequency of subclinical TB form; 
 Increased risk of development of extrapulmonary TB. 
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Providing another relevant  instruction on TB treatment in HIV-infected patients, WHO also 
recommends a daily TB therapy within, at least,  the intensive phase (WHO, 2010b). Such 
orientation  is based on a recent study, which showed that the incidence of relapse and 
failure among HIV-positive TB patients who were treated with intermittent TB therapy 
throughout treatment was 2–3 times higher, in comparison with patients who received a 
daily intensive therapy (Kahn et al., 2010). Moreover, another study indicated that, among  
HIV-positive patients, the risk of acquired resistance to rifampicin  is higher when failing a 
three times weekly short-course intermittent regime (Kahn et al., 2010).  
In relation to HIV treatment (Box 2), WHO recommends that the first-line ART regime 
should comprise a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) 
and one non-nucleoside reverse transcriptase inhibitor (NNRTI), as  said drugs are effective, 
available at low costs in the market,  and present  generic and fixed-dose combinations 




AZT= zidovudine, TDF= tenofovir,  3TC= lamivudine, FTC= emtricitabine, EFV= efavirenz , NVP= 
nevirapine.  
2.3 Optimal timing to start the ART treatment 
A critical issue among HIV-infected individuals diagnosed with  TB is to determine the 
precise moment to initiate  ART. Although ART improves the survival of  HIV-positive 
patients, including those with TB, the optimal deadline from the onset of TB to start such a 
treatment is a matter that still requires further clarification. According to WHO, the  TB 
treatment should be initiated  in all HIV bearers  showing active TB disease, regardless of 
their CD4+ lymphocyte count. TB treatment should be started first, and, then, followed by 
ART as soon as possible, and preferably  within the first weeks from the beginning of the  
TB treatment (WHO, 2010b). However, the concomitant treatment of both diseases results in 
several disadvantages,  whose examples are listed  and discussed  at the Table 2. 
In spite of a number of clinical trials intended to determine the  optimal timing for ART 
administration in bearers of  HIV infection-related TB,  the question still requires further 
studies  (Piggot & Karakousis, 2011). Among the above referred works,  Abdool Karim and  
collaborators have been performing the Starting Antiviral Therapy at Three Points in TB 
(SAPIT), which is an open-label, randomized and controlled trial conducted in Durban, 
Box 2. Combined regime for  both HIV and TB treatment. 
 First-line regime: 2NRTIs + 1NNRTI  
 [AZT or TDF] and [3TC or FTC] plus [EFV or NVP]; 
 ART regime containing EFV is preferred, since interactions with anti-TB drugs 
are minimal; 
 EFV should not be administrated to  women during  the first trimester 
pregnancy, due to its teratogenic effects . 
  In cases of EFV intolerance,  of  HIV resistant to EFV, or contraindications  to an 
EFV-based regime: [AZT + 3TC + NVP] or TDF + [3TC or FTC] + NVP or the triple 
NRTI regime [AZT + 3TC + ABC] or [AZT + 3TC + TDF] 
 ART regime containing a boosted protease inhibitor (PIs) 
 If available, a rifabutin-based TB treatment should be preferable. 
 Hepatitis among healthy adults is recurrent. 
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Providing another relevant  instruction on TB treatment in HIV-infected patients, WHO also 
recommends a daily TB therapy within, at least,  the intensive phase (WHO, 2010b). Such 
orientation  is based on a recent study, which showed that the incidence of relapse and 
failure among HIV-positive TB patients who were treated with intermittent TB therapy 
throughout treatment was 2–3 times higher, in comparison with patients who received a 
daily intensive therapy (Kahn et al., 2010). Moreover, another study indicated that, among  
HIV-positive patients, the risk of acquired resistance to rifampicin  is higher when failing a 
three times weekly short-course intermittent regime (Kahn et al., 2010).  
In relation to HIV treatment (Box 2), WHO recommends that the first-line ART regime 
should comprise a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) 
and one non-nucleoside reverse transcriptase inhibitor (NNRTI), as  said drugs are effective, 
available at low costs in the market,  and present  generic and fixed-dose combinations 




AZT= zidovudine, TDF= tenofovir,  3TC= lamivudine, FTC= emtricitabine, EFV= efavirenz , NVP= 
nevirapine.  
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A critical issue among HIV-infected individuals diagnosed with  TB is to determine the 
precise moment to initiate  ART. Although ART improves the survival of  HIV-positive 
patients, including those with TB, the optimal deadline from the onset of TB to start such a 
treatment is a matter that still requires further clarification. According to WHO, the  TB 
treatment should be initiated  in all HIV bearers  showing active TB disease, regardless of 
their CD4+ lymphocyte count. TB treatment should be started first, and, then, followed by 
ART as soon as possible, and preferably  within the first weeks from the beginning of the  
TB treatment (WHO, 2010b). However, the concomitant treatment of both diseases results in 
several disadvantages,  whose examples are listed  and discussed  at the Table 2. 
In spite of a number of clinical trials intended to determine the  optimal timing for ART 
administration in bearers of  HIV infection-related TB,  the question still requires further 
studies  (Piggot & Karakousis, 2011). Among the above referred works,  Abdool Karim and  
collaborators have been performing the Starting Antiviral Therapy at Three Points in TB 
(SAPIT), which is an open-label, randomized and controlled trial conducted in Durban, 
Box 2. Combined regime for  both HIV and TB treatment. 
 First-line regime: 2NRTIs + 1NNRTI  
 [AZT or TDF] and [3TC or FTC] plus [EFV or NVP]; 
 ART regime containing EFV is preferred, since interactions with anti-TB drugs 
are minimal; 
 EFV should not be administrated to  women during  the first trimester 
pregnancy, due to its teratogenic effects . 
  In cases of EFV intolerance,  of  HIV resistant to EFV, or contraindications  to an 
EFV-based regime: [AZT + 3TC + NVP] or TDF + [3TC or FTC] + NVP or the triple 
NRTI regime [AZT + 3TC + ABC] or [AZT + 3TC + TDF] 
 ART regime containing a boosted protease inhibitor (PIs) 
 If available, a rifabutin-based TB treatment should be preferable. 
 Hepatitis among healthy adults is recurrent. 
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South Africa, with 642 HIV-positive patients with a CD4 count <500/mm3 and with smear-
positive TB (Abdool et al., 2010). The preliminary findings of SAPIT showed a decreased 
mortality rate among individuals  who had started ART during anti-TB regime, in 
comparison with those who initiated ART only upon  completion of the anti-TB therapy.  
 
Disadvantage Comments
High pill burden More than 10 pills daily; discourage treatment adherence. 
Overlapping of adverse 
effects 
Hepatotoxicity promoted by H, R and Z and also by PI and NNRTI; 
increased risk of hepatitis C virus infection (Velasco et al., 2009). 
Gastrointestinal upset and rash are common in both therapies 
Peripheral neuropathy promoted by H, didanosine and stavudine 
Immune reconstitution 
inflammatory  syndrome 
(IRIS) 
Although  ART triggers the regeneration of  immune cells,  
the immune system unexpectedly produces an overwhelming 
inflammatory response that unmasks or worsens the co-
infection symptoms  (TB is  the most common among them);  
The risk of IRIS is the main ground to initiate  TB treatment 
prior to  ART, whenever it is possible. 
Its frequent symptoms  comprise fever, swollen lymphonodes, skin 
lesions and rashes, changes in breathing, pneumonia, hepatitis, 
abscesses and eye inflammation. They often appear within 2–6 
weeks from the beginning of  HIV therapy (Antonelli et al., 2010).  
Drug-drug interactions See Table 3
Table 2. Disadvantages from the  concomitant treatment of TB and HIV. 
Following these conclusions, another study performed by Blanc and collaborators provided 
strong evidences for an early start of ART administration (Blanc et al., 2010). The Cambodian 
Early versus Late Introduction of Antiretrovirals (CAMELIA) was an open label, prospective, 
randomized controlled trial, registering HIV-positive patients with a CD4 count <200/mm3 
and smear-positive TB living in Cambodia. This study demonstrated that the group treated 
with   ART within  2 weeks from the beginning of the  TB therapy showed a relevant  decline 
of 34% at the mortality rate, when compared with patients who received  ART only 8 weeks 
after the initiation of TB treatment. In  both studies, an increased incidence of IRIS was 
observed in patients who were  early treated with  ART. Nevertheless,  the data shown by the 
SPIT trial, namely a lack of mortality or changes in antiretroviral regime attributable to IRIS,  
also   corroborate the early ART initiation in HIV infection-related TB patients. 
2.4 Management of drug-drug interactions between antiretroviral and anti-TB agents 
The most delicate kind of  interactions  involves the concomitant use of  rifamycins (among 
which the most  usual are rifampicin and rifabutin),  NNRTIs and  PIs,  given that these last 
two classes of antiretroviral drugs are essentially metabolized through cytochrome P450 
(CYP) 3A4 enzymes, whose  expression is induced by rifamycins. Consequently, the plasma 
concentration and exposure of NNRTIs and PIs are significantly reduced, when they are 
concomitantly administrated with rifamycins (Burman et al., 2001). Furthermore, rifampicin 
improves the activity of the efflux multidrug transporter P-glicoprotein, which promotes the 
elimination of  PIs (Kim et al., 1998; Schuetz et al., 1996). Due to the reduction of NNRTIs 
and PIs  at the plasma concentration, as a result from the simultaneous administration of 
rifamycins,  the HIV treatment can fail, thus giving rise to the emergence of drug resistance. 
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The Table 3 below summarizes the most relevant interactions between  rifamycins and 




Effects on pharmacokinetics parameters and comments
Rifampicin Rifabutin
NNRTIs 
EFV EFV AUC↓ by 22% 
Rifabutin AUC↓ by 38%
Increase Rifabutin dose to 450-600mg 
(daily or intermittent)
NVP NVP AUC↓ 37-58% and Cmin↓ 68% with 200mg 2x/day dose
NVP and Rifabutin AUC are not 
significantly changed
DLV 
DLV AUC↓ 95% 
Simultaneous use of such drugs 
should be avoided. 
DLV AUC↓ 95%
Rifabutin AUC↑100% 




Ritonavir AUC*↓ by 35%
Monitor for antiretroviral activity 
of ritonavir
 
Fos-Amprenavir Simultaneous use of such drugs should be avoided.
Rifabutin dose ↓ to 150mg/day or 300mg 
3x/week
Atazanavir 
Atazanavir AUC↓ by >95%
Simultaneous use of such drugs 
should be avoided.
Rifabutin AUC ↑ by 250%
Rifabutin dose ↓ to 150mg every other 
day or  3x/week
Indinavir 
Indinavir AUC↓ by 89%
Simultaneous use of such drugs 
should be avoided. 
Rifabutin AUC ↑ by 34%
Rifabutin dose ↓ to 150mg/day or 300mg 
3x/week
Nelfinavir 
Nelfinavir AUC↓ by 82%
Simultaneous use of such drugs 
should be avoided. 
Rifabutin AUC ↑ by 207% 
Rifabutin dose ↓ to 150mg/day or 300mg 
3x/week 
Saquinavir 
Saquinavir AUC↓ by 84%
Simultaneous use of such drugs 




Caution. The use of this 





Caution. The use of this 
combination could cause 
hepatitis. 
Rifabutin AUC ↑ by 303%
Rifabutin dose ↓ to 150mg every other 
day or  3x/week
Fusion Inhibitors
Enfuvritide No interaction. No dose adjustment. No interaction. No dose adjustment. 
CCR5 receptor antagonists
Maraviroc 
Maraviroc Cmin↓ by 78%
Increase Maraviroc to 600mg 
twice-daily
Change Maraviroc dose to 300mg twice 
daily and rifabutin to 300mg daily 
Integrase 
Inhibitors   
Raltegravir Raltegravir concentratios ↓ by 40-61% 
Rifabutin trough ↓ by  20% Raltegravir 
AUC is not affected 
Change Rifabutin dose to 300mg daily 
and Raltegravir to 400mg twice daily 
*AUC= area under the plasma concentration time curve; estimated  bioavailability.  
Table 3. Management of interactions among anti-TB and anti-HIV drugs. 
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South Africa, with 642 HIV-positive patients with a CD4 count <500/mm3 and with smear-
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mortality rate among individuals  who had started ART during anti-TB regime, in 
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Table 3. Management of interactions among anti-TB and anti-HIV drugs. 
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3. Thiourea derivatives: A promising class against HIV/TB co-infection  
Due to such a number of  complications that may possibly arise in the course of  treatment 
of HIV-related TB, as described above,  the development of  new drugs against HIV and TB 
should be mandatory. Said medications  should  produce relevant effects, such as the 
improvement of patient well-being   by means  of the reduction of pill burden, as well as by  
the careful management of the overlapping toxicity  resulting from the treatment of TB and 
HIV infections. Therefore, an  alternative could be  the development of drugs that might be 
able to simultaneously act  in the treatment of both diseases. In this context, thiourea 
derivatives appear as a promising class of compounds. For instance, the 
tetrahydroimidazobenzodiazepinthiones (TIBO) derivative 9-Cl-TIBO and the 
phenylethylthiazolylthiourea (PETT) derivatives LY73497 and trovirdine (TRV) play a 
significant role in the inhibition of  HIV reverse transcriptase (Fig. 1). On the other hand, the 
compound isoxyl (ISO, thiocarlide), another thiourea derivative,  is known by its  strong 
anti-TB activity (Fig. 1). By the way, although used as part of  the TB  clinical treatment since 
the 1960’s, it may be pointed out that the relevance of ISO emerged from recent researches, 
and particularly from studies in the field of  new treatments against MDR-TB. Therefore, the 
main purpose  of this chapter is to highlight the importance of thioureas  for the TB-HIV 
drug discovery, and to proceed with a review of data from recent literature, by focusing  the 






































9-Cl TIBO (R82913) 
ED50= 0.21M
 
Fig. 1. Active thioureas against HIV (9-Cl TIBO, LY73497 and trovirdine) or M. tuberculosis 
(ISO). 
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3.1 Thiourea derivatives showing a potential activity against HIV 
3.1.1 TIBO derivatives  
TIBO and HEPT [1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine] derivatives, yet 
discovered independently from each other, can be  reputed a landmark in the history of the 
antiretroviral therapy. These compounds were the first congeners from a new category of 
anti-HIV drugs, currently known as NNRTIs (De Clercq, 2004). At the beginning of the 
1990s, the only  drug that had been approved for AIDS treatment was  AZT, so that   
patients had  to live at imminent risk to develop resistant mutant virus. Therefore, it 
becomes quite clear that  the identification of a different class of antiretroviral drugs brought 
new perspectives in the  treatment of AIDS. 
The development of TIBO derivatives started from a screening program from the library of 
Janssen Research Foundation, working with 600 compounds  that were selected  due to  
their failure in producing effects on  the standard pharmacological assays, and to  their low 
toxicity in rodents as well (De Clercq, 2004). Upon evaluation of the  biological activity of 
these compounds against HIV-1/HTLVIIIB in MT-4 cells,   researchers identified the 
tetrahydro-benzodiazepine derivative R14458 (Fig. 2), which presented  a moderate anti-
HIV-1 activity (IC50= 62µM) (Pauwels et al., 1990). Using this substance as a lead compound, 
they  started a program aiming  at the improvement of its anti-HIV properties. Thereafter, 
several analogues were synthesized, thus allowing the  performance of an extensive 
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Fig. 2. Structure of TIBO derivatives R4458 and R78305.  
3.1.1.1 SAR of TIBO derivatives 
Considering that the compound R14458 is a racemic mixture, the authors initially 
investigated the role of  stereochemistry  in the biological activity of this substance. 
Although the  two optical isomers were synthesized and tested against HIV-1,  only the 
enantiomer R78305 (Fig. 2) with S configuration was found to be active, showing that this 
configuration is required for the anti-HIV-1 properties of TIBOs (Pauwels et al., 1990). The 
subsequent studies aimed  at the evaluation of systematic alterations in the structure of the 
lead compound, and its scaffold was independently modified in four different portions: the 
substituent bonded to the 6-positon nitrogen of the diazepine ring (Kukla et al., 1991a), the 
5-ring urea portion (Kukla et., 1991b), the 7-membered ring portion (Breslin et al., 1995) and 
the substituent of the aromatic ring (Ho et al., 1995). The results obtained in these studies are 
described in the next sections. 
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3. Thiourea derivatives: A promising class against HIV/TB co-infection  
Due to such a number of  complications that may possibly arise in the course of  treatment 
of HIV-related TB, as described above,  the development of  new drugs against HIV and TB 
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tetrahydroimidazobenzodiazepinthiones (TIBO) derivative 9-Cl-TIBO and the 
phenylethylthiazolylthiourea (PETT) derivatives LY73497 and trovirdine (TRV) play a 
significant role in the inhibition of  HIV reverse transcriptase (Fig. 1). On the other hand, the 
compound isoxyl (ISO, thiocarlide), another thiourea derivative,  is known by its  strong 
anti-TB activity (Fig. 1). By the way, although used as part of  the TB  clinical treatment since 
the 1960’s, it may be pointed out that the relevance of ISO emerged from recent researches, 
and particularly from studies in the field of  new treatments against MDR-TB. Therefore, the 
main purpose  of this chapter is to highlight the importance of thioureas  for the TB-HIV 
drug discovery, and to proceed with a review of data from recent literature, by focusing  the 
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3.1.1.1.1 Modifications in the substituent bonded to the 6-position nitrogen of the diazepine ring 
Initially, it was verified that the presence of bulky groups attached  to this position  was 
mandatory to trigger anti-HIV-1 activity, since compounds containing hydrogen, ethyl or a 
linear propargyl substituent were inactive. The strongest activities were  observed whenever 
an unsaturated allyl group was attached  to the 6-positon nitrogen, such as in the lead 
compound, and it was verified that the substitution at the 2-position of this group led to 
more active compounds. The improvement degree of said  activity varied in accordance 
with the following sequence: ethyl > methyl = vinyl = bromo > H. On the other hand, all 
compounds containing 2-propyl, phenyl, benzyl or fused cyclohexenyl were inactive. 
Substitutions at the 3-positon of the allyl group were also verified, and the dimethyl 
substituted compound showed the highest degree of activity found in these series. 
Introduction of bulky groups at this position usually led to completely inactive compounds. 
In view of the above results,  an optimum size to  the substituent for both 2- and 3-positions 
is required, since the substance loses its activity, as  the length of  the side chain increases or 
decreases. Moreover, the groups attached to the nitrogen which led to inactive compounds 
were the following: acetylene, alkyl groups containing heteroatom, and methylene attached 
to functional groups such as, nitrile, ketone, ester, alcohol, ether or a heteroaromatic pyrrole 
or imidazole (Kukla et al., 1991a).  
3.1.1.1.2 Modification in the 5-ring urea portion 
This portion of the tricyclic TIBO structures underwent several modifications, among which 
we can mention  the replacement of  carbonyl carbon by: nitrogen, sulfur dioxide or deletion 
of the carbonyl oxygen yielding, that are, respectively, a triazine, a sulfonamide and an 
imidazole. However, in  the most part of trials, these modifications  gave rise to inactive 
compounds. The most promising result was found  by the replacement of the urea group by 
a thiourea, yielding a compound around one hundred times more active than the original 
prototype. The ring expansion, by  insertion of a methylene or another carbonyl, led to a loss 
of  anti-HIV-1 activity, and it was also verified that methylation of 1-positon nitrogen also 
gave rise to an inactive compound, probably in view of the need of  NH to form  hydrogen 
bonding (Kukla et., 1991b). 
3.1.1.1.3 Modifications at the 7-membered ring portion 
The demethylation of carbon in 5-position or introduction of bulky groups at this position 
yielded inactive or less active compounds, thus demonstrating that the size of the methyl 
group is optimum for the biological activity. The C-4 position showed a greater tolerance for 
larger groups, and the analogues  presented a good anti-HIV-1 activity. The  7-position also 
underwent replacements, whereby high levels of activity were once more achieved.  
However, among  the modifications performed at  the 7-membered ring, none of them led to 
the discovery of compounds  showing a better HIV inhibitory activity than the simplest 5-
mono-methyl-substituted analogue (Breslin et al., 1995). 
3.1.1.1.4 Evaluation of substituent effect on the aromatic ring  
In order to evaluate the substituent effect on the aromatic ring,  researchers  used both urea 
and thiourea derivatives, and maintained the optimal conditions described by previous 
works, such as the attachment of a methyl group  to the 5-position, and bonding of a 
dimethylallyl group  to  nitrogen at the 6-positon ( except  in case of compounds presenting  
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synthetic problems, where scientists had to use  a cyclopropylmethyl, also able to lead to 
high levels of activity). The best results were found for 8-substituted analogues, which, in 
comparison to the lead compound, showed  much higher potency,  so that  halogens 
reached the highest level of activities in the substituent group.   Iodine was the only 
exception to the above conclusions, probably due to its larger volume.  Compounds 
containing a methoxy or an acetylene group bounded at 8-positon displayed similar 
activities, when compared to the parent unsubstituted compound. Although the substitution 
of 8-methoxy group by 8-thiomethyl may have led to an improvement in the biological 
activity, the replacement of methoxy  by the  ethoxy group, which is larger, resulted in a 
decrease in  anti-HIV activity. Amino, aminoacetyl, dimethylamino and nitro analogues 
remained inactive. Furthermore, the substitutions at 9-positon led to the formation of 
compounds, whose  activities are similar to those of  the parent unsubstituted compound, 
while 10-substituted compounds  were found to be less active. The replacement of the 
aromatic ring by a heteroaromatic ring was also evaluated, but the derivatives were inactive 
(Ho et al., 1995). 
3.1.1.1.5 Clinical trial with 9-Cl-TIBO (R82913) 
Extensive  SAR studies with TIBO derivatives allowed the identification of substances with 
similar or better activities than other known antiretroviral drugs, such as AZT, 
dideoxycytidine (ddC) and Dideoxyinosine (ddI). Among these substances, thiourea  
9-Cl TIBO (R82913) (Fig. 1) was selected for a phase I clinical trial. This study evaluated 22 
patients, within the age group between 27-59 years old,  who showed   HIV infection in an 
advanced stage (Pialoux et al., 1991). The drug was administrated by daily intravenous 
injection through a peripheral or a central venous catheter. R82913 had to be injected in a 
dose  of 120-200mg, in order to   reach  the  concentration observed in vitro (20-40ng/mL), 
which is required for the protection against  HIV cytopathic effects. The measured half-life 
was of 3 days, and the pharmacokinetic profile of the substance was neither influenced by 
an increase of the dose, nor by its long-term administration.  In spite of its  side effects, 
which usually comprised phlebitis, drowsiness and fatigue, a general absence  of toxicity 
could be attributed to R82913. 
3.1.2 PETT derivatives 
3.1.2.1 Discovery of PETT series and preliminary SAR studies 
Phenethylthiazolylthiourea (PETT) analogues  integrate the powerful class of NNRTIs, 
first described by researchers from Lilly laboratories in the second half of the 1990’s 
(Ahgren et al., 1995). These compounds were discovered in an attempt to indentify the 
minimal structural elements that might be necessary for the development  of the thiourea 
derivative 9-Cl TIBO biological activity (Fig. 1). The researchers disconnected some bonds 
from the rigid tricyclic nucleus of this substance, thus producing simpler structures. The 
potential pharmacophores produced after the systematically disconnections were used to  
search  similar structures in the organic compound database of Lilly Research 
Laboratories. The study disclosed approximately  250 substances, whose activity against 
HIV was duly evaluated. The N-(2-phenethyl)-N’-(2-thiazolyl)thiourea, LY73497 (Fig. 3), 
was identified as the lead compound, and used in subsequent SAR studies (Bell et al., 
1995).  
SAR studies were performed by dividing LY73497 into four portions and proceeding with 
an aleatory variation of each  of them (Fig. 3) (Bell et al., 1995). Initially, the authors 
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modified the quadrant 1  of phenyl ring, introducing different substituents,  or replacing  
it by other aromatic heterocycles. They observed that meta and ortho substitutions 
generally triggers  better activities, when compared with the para one. As regards the 
electronic nature of ortho substituents, both small electron-donating and small electron-
withdrawing groups presented good activities, and, among said elements, the preferred 
groups are the following: fluoro, chloro, azido and methoxy. A combination of alkoxy and 
halogen substitution resulted in compounds with improved activity. Although the  
introduction of an ethoxy group in meta position may have led  to a good activity, the use 
of bulky alkoxy groups, such as propoxy and isopropoxy, seems to have been responsible 
for a reduction in the  activities. Among the substances containing a heterocycle  in 
replacement of the phenyl ring, the best activity was observed for the 2-pyridyl 
compound. Changes at  the nitrogen atom for the 3- and 4-position induced a decrease in 
the activity.  
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Fig. 3. SAR studies with PETTs derivatives.  
The modifications in quadrant 2 were characterized by changes in the length of the alkyl 
linker. The main conclusion was the identification of  an ethyl linker  as optimal  to the 
activities. It was also noted that the introduction of a methyl group in the benzylic position 
of  ethylene linker enhanced the activity, while  a methyl group in the phenethyl position 
led to its reduction. 
The variations in quadrant 3 demonstrated  the crucial role played by  thiourea moiety at  
the anti-HIV activity of these compounds. In fact, the replacement of  thiourea by  urea 
resulted in an inactive compound and other isosters, such as  cyanoguanidine derivatives,  
which appeared to be less potent. The methyl substitution  at the nitrogen adjacent to the 
thiazole ring leads to a less active compound, while  methyl substitution on the nitrogen 
adjacent to the phenethyl side chain provided  compound with no activity at all. This result 
is attributed to presence of an internal hydrogen bond between the hydrogen bonded to 
nitrogen adjacent to the phenethyl side chain and the nitrogen of the thiazole nucleus in 
LY73497. 
As regards  quadrant 4, it was observed that a heterocycle in this position is  determinant to 
reach a good activity. In general, substituted thiazoles were highly active, excepting  the 4-
carboxythiazolyl compound, whose lack of activity indicated  that the allosteric site of the 
enzyme does not accept a polar group. When  thiazole nucleus was replaced by another 
heterocyle, the 2-pyridyl analog  showed the highest level of activity.  
During a second phase of  SAR studies, the authors combined the optimal substituents in 
quadrants 1-4, and  observed that these parameters are additive, able to give rise to 
compounds with optimal activity. Among them, the compound LY300046, currently known 
as trovirdine (TRV; Fig. 1), was selected for further pharmacological examinations, since the 
hydrochloride salt of this compound showed acceptable blood levels, when orally 
administrated  in rats (Ahgren et al., 1995).   
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TRV displayed a comparable or a better ED50 than other known antiretroviral drugs, such as 
9-Cl TIBO, L697661, NVP, AZT, ddI and ddC, being capable of inhibiting the replication of 
HIV-1 in MT-4 cell culture, as well as  the replication of various clinical HIV-1 isolates  in 
MT-2 cells and PBL human cells. However, this substance showed no action  against HIV-2. 
When it was tested against resistant isolates containing mutations in Ile-100, Cys-181, and 
Ile-100–H-188 reverse transcriptase (RT), the trials disclosed a cross resistance  between 
trovirdine and other non-nucleoside compounds. Nevertheless, within the group of said  
non-nucleoside derivatives, trovirdine was found to present the highest level of  activity 
against these mutants. 
In the enzymatic assay with wild-type and mutant RT enzymes, TRV was  also more active 
than the non-nucleosides 9-Cl TIBO, L697661 and nevirapine, showing a lower IC50. 
After TRV  oral administration in rats (20mg/kg), a peak concentration in plasma of 3.5µg/mL 
was observed at 0.5h. The overall half-life was of 1 h, and the area under the concentration-
time curve was 6.9µg/h/mL. The peak concentration in brain was 2.9µg/g, and the area under 
the concentration-time curve was 5.9µg/h/mL. This result shows that TRV crosses the blood-
brain barrier, which is a desirable property of anti-retroviral agents, due to the risk of HIV-
associated encephalopathy in contaminated patients (Ahgren et al., 1995).  
Despite the promising  outcomes related to the use of TRV as NNRTI, the clinical trials 
focused on this compound   were suspended. Anyway, this substance is still considered a 
standard lead compound for the development of new PETT analogues, as it  encouraged the  
course of an extensive serie of SAR studies based on modern approaches, such as 
crystallographic techniques and molecular modeling. These works will be discussed in the 
next section. 
3.1.2.2 Rational design of new PETT analogues  
This study was initiated when Vig and  collaborators (Vig et al., 1998) proposed to synthesize  
series of novel PETT derivatives based on the structure of the non-nucleoside inhibitor (NNI) 
binding pocket of HIV-1 reverse transcriptase (RT). This composite binding pocket was built by 
superimposing nine individual crystal structures of RT-NNI complexes (Sudbeck et al., 1998). 
After having conducted docking studies with TRV, they  verified the existence of  multiple 
sites, which can be used for incorporation of larger functional groups, mainly surrounding the 
pyridyl ring, the ethyl linker and near the 5-bromo position. Hence, they proposed that a better 
use of these spaces by strategically designed functional groups could lead to a high-affinity 
binding and to the discovery of more potent anti-HIV agents.   In view of the above, they 
decided to study the effects of  introduction of several substituents in different positions of the 
phenyl ring, such as methoxy group, fluorine atom or chlorine atom (Table 4).  
These results disclosed by a preliminary SAR study  attest to the potency of PETT 
derivatives  phenyl ring substitutions on various positions  (Fig. 4). After analyzing the  
composite NNI binding pocket, the authors identified three promising PETT derivatives 
with ortho-F (HI-240), ortho-Cl (HI-253) and metha-F (HI-241) substituents on the phenyl 
ring, which showed potent anti-HIV activity (IC50 [p24] values of < 1nM), selectivity indexes  
(SI) of > 100,000, and were recognized to be  more active than AZT or TRV. Among them, 
HI-240 has been chosen as the lead compound, as it presented  the  highest level of activity 
against wide-type HIV RT. This finding could be  grounded on the examination of a 
composite binding pocket model, showing that  Wing 2 region is predominantly 
hydrophobic, except at the area nearby  ortho positions on both sides of the phenyl ring, 
which would be compatible with  polar groups, such as, for instance, halogen atoms.  
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TRV displayed a comparable or a better ED50 than other known antiretroviral drugs, such as 
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trovirdine and other non-nucleoside compounds. Nevertheless, within the group of said  
non-nucleoside derivatives, trovirdine was found to present the highest level of  activity 
against these mutants. 
In the enzymatic assay with wild-type and mutant RT enzymes, TRV was  also more active 
than the non-nucleosides 9-Cl TIBO, L697661 and nevirapine, showing a lower IC50. 
After TRV  oral administration in rats (20mg/kg), a peak concentration in plasma of 3.5µg/mL 
was observed at 0.5h. The overall half-life was of 1 h, and the area under the concentration-
time curve was 6.9µg/h/mL. The peak concentration in brain was 2.9µg/g, and the area under 
the concentration-time curve was 5.9µg/h/mL. This result shows that TRV crosses the blood-
brain barrier, which is a desirable property of anti-retroviral agents, due to the risk of HIV-
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phenyl ring, such as methoxy group, fluorine atom or chlorine atom (Table 4).  
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(SI) of > 100,000, and were recognized to be  more active than AZT or TRV. Among them, 
HI-240 has been chosen as the lead compound, as it presented  the  highest level of activity 
against wide-type HIV RT. This finding could be  grounded on the examination of a 
composite binding pocket model, showing that  Wing 2 region is predominantly 
hydrophobic, except at the area nearby  ortho positions on both sides of the phenyl ring, 
which would be compatible with  polar groups, such as, for instance, halogen atoms.  
  











Compound X IC50 rRT (µM)a IC50 p24 (µM)b SIc 
HI-237 o-OMe 1.0 0.01 >1 x 104 
HI-240 o-F 0.6 <0.001 >1 x 105 
HI-253 o-Cl 0.7 <0.001 >1 x 105 
HI-239 m-OMe 0.4 0.003 >3 x 104 
HI-241 m-F 0.7 <0.001 >1 x 105 
HI-254 m-Cl 3.1 N.D. N.D. 
1 p-OMe 0.9 0.015 >6 x 103 
HI-242 p-F 6.4 N.D. N.D. 
HI-255 p-Cl 2.5 N.D. N.D. 
TRV ---- 0.8 0.007 >1 x 104 
AZT ---- >100 0.004 7 x 103 
a Purified recombinant HIV RT assay. 
b IC50 p24 values represent the inhibition of HIV-1 replication in relation to the virus control, as 
measured by p24 EIA. 
c SI (selectivity index) = IC50[MTA]/ IC50[p24]. IC50[MTA] values were >100µM. 



















Fig. 4. Preliminary SAR of PETT derivatives. 
 
Thiourea Derivatives: A Promising Class Against HIV/TB Co-Infection   
 
139 
The authors postulated that the lead compound HI-240 would be effective against HIV RT 
mutants (Mao et al., 1999). This hypothesis was confirmed, since HI-240 is three times more 
potent than TRV against the multiple-drug-resistant of HIV RT, thus  emphasizing the  
relevance of a polar ring substituent,  which could provide more favorable interactions with 
binding site residues (Table 5).  
During this SAR study, Mao and  collaborators (Mao et al., 1999) rationally designed a novel 
PETT analogue (HI-236), by using the computer model of NNI binding pocket. This 
derivative was designed through the optimization of van der Waals contact with the 
binding pocket, mainly at Wing 2 region, that  presents unrecognized spacious regions 
surrounding the phenyl ring. This strategy would improve the potency against wild-type 
RT, and also against Wing 2 mutants of RT.  In view of the above, the authors proposed the 
synthesis of HI-236,  whose 2,5-dimethoxy-substituted phenyl ring   allows favorable 
contacts with Wing 2 region, and also decreases the unoccupied volume surrounding 
phenyl ring of HI-240 by 25 Å3. Therefore, HI-236 showed a potent anti-HIV activity (IC50 < 
0.001µM), which is lower than IC50 values for AZT (0.004 µM). This substance was not 
cytotoxic, and its calculated selectivity index was > 105.  
Furthermore, HI-236  was found to be highly effective against  multidrug-resistant HIV-1 strain 
RT-MDR, whose  multiple mutations involve several RT residues (Table 5). These results are 
consistent with the prediction  according to which HI-236 would be more active than HI-240. 
 
Compounds IC50 p24 IC50 RT-MDRa IC50 A17b IC50 A17 variantb 
HI-236 <0.001 0.005 0.1 11 
HI-240 <0.001 0.005 0.2 41 
DLV 0.009 0.4 50 >100 
NVP 0.034 5 >100 >100 
TRV 0.007 0.02 N.D. N.D. 
AZT 0.004 0.15 0.006 0.004 
a V106A mutation 
b Genotypic NNRTI-resistant HIV-strains (A17 and A17 variant) carrying clinically relevant mutations 
Y181C and K103N + Y181C, respectively. 
Table 5. Inhibitory activity of HI-236 and HI-240 on p24 production in peripheral blood 
mononuclear cells infected with HIV strains HIVIIIB, RT-MDR, A17 and A17 variant. 
In another work, Mao and  collaborators (Mao et al, 1998)  proposed the synthesis of new 
PETT analogues through  replacement of the planar pyridyl ring of TVR  by a non-planar 
ring, such as a piperidinyl (HI-172) or piperazinyl ring (HI-258). This modification was 
based on the presence of unrecognized spacious regions surrounding the pyridyl ring of 
TRV (molecular volume (MV)= 160Å3), which could be better filled than the spacious Wing 
2 region of the butterfly-shaped NNI binding pocket. In comparison with the MV of TRV,  
HI-172 and HI-258 presented larger MVs  (calculated in 276 and 272Å3 respectively), being 
thus  predicted to better fit into the potentially usable space of the binding site. 
Furthermore, these heterocyclic rings are conformationally more flexible than the pyridyl ring, 
such a factor being likely  to contribute to fit an uncompromising binding pocket  in a more 
efficient way. Table 6 shows that both compounds were more potent than TRV, and that they 
inhibited HIV replication at nanomolar concentrations, without showing  cytotoxicity. These 
findings indicate that, when compared to TRV analogues, double substitutions at axial or 
equatorial positions on these heterocyclic rings could lead to PETT derivatives with a broader 
range of curvatures, and that they would also better fit to Wing 2 region. 
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Compound IC50 p24 IC50 [MTA]* SI 
HI-172 <0.001 >100 >1 x 105 
HI-258 0.002 >100 >5 x 104 
TRV 0.007 >100 >1 x 104 
AZT 0.006 50 8 x 103 
* MTA= Methyl tetrazolium assay  
Table 6. IC50 and SI values for  series of PETT derivatives. 
Following  their continuous program  aiming at the development of new potent PETTs, 
Uckun and  collaborators (Uckun et al., 1999a)  decided to replace the pyridyl ring of TRV  
by an aciclyc cyclohexenyl, adamantly or cis-myrtanyl ring. Such a proposal of  
modifications was due to the fact that these chosen groups would fit well with Wing 2 
region of the NNI binding pocket.   Given the existence of a region compatible with polar 
atoms at Wing 1, the authors  also  suggested the replacement of bromine atom by chlorine 
or trifluoromethyl group (Table 7). After a biological evaluation, they  observed that the 
replacement of the pyridyl ring of TRV by the adamantly (HI-504) or cis-myrtanyl (HI-444) 
rings resulted in a complete loss of RT inhibitory function. In another  important finding,  
bromine (HI-346) / chlorine (HI-445) atoms were found to reach the best biological result, 
thanks to their capacity of making  more hydrophobic contacts at the binding pocket, when 
compared to trifluoromethyl group (HI-347). Moreover, the lead compounds HI-346 and 
HI-445 showed a significant activity against the multidrug resistant (MDR) strain, without 









p24 RT-MDR A17 
A17 
variant 
HI-346 Cyclo-hexenyl Br >100 0.003 0.020 N.D. 18.7 
HI-445 Cyclo-hexenyl Br >100 0.003 0.001 0.068 30 
HI-347 Cyclo-hexenyl Cl >100 0.079 0.038 0.300 >100 
HI-504 Adamantyl* CF3 N.D.a N.D.a N.D.a N.D.a N.D.a 
HI-444 Myrtanyl* Br N.D.a N.D.a N.D.a N.D.a N.D.a 
TRV Pyridyl Br >100 0.007 0.020 0.500 >100 
AZT ----- ---- >100 0.004 0.2 0.006 0.004 
* methylene group, instead of ethyl linker 
a N.D.= not determined, because IC50 rRT (µM) > 100 
Table 7. CC50 and IC50 values for  series of PETT derivatives. 
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Uckun and  collaborators (Uckun et al., 1999b) carried on performing their  PETT derivatives 
SAR study, and decided to promote new replacements of the pyridyl ring of TRV with eight 
different heterocyclic substituents, including heterocyclic amines, heteroaromatic rings 
furan and thiophene, as well as  aromatic acetal piperonyl. After evaluation of HIV-RT 
inhibitory activity, the authors  concluded that these proposed modifications were critical 
for the biological activity of said  series of compounds, as  only the thiophene-substituted 









Compound Ring IC50 rRT (µM) IC90 rRT (µM) 
HI-443 Thiophene 0.8 15.0 
HI-230 Pyrrolidine 4.9 >100 
HI-436 Imidazole >100 >100 
HI-442 Indole 0.9 >100 
HI-206 1-methyl-pyrrolidine >100 >100 
HI-276 Morpholine >100 >100 
HI-257 Piperonyl* 0.7 >100 
HI-503 Furan* 1.2 >100 
TRV Pyridine 0.6 12.0 
* Methylene linker group, instead of an ethyl linker. 
Table 8. RT inhibitory activity of PETT derivatives, expressed as IC50 and IC90 values. 
After proceeding with docking studies, it was observed that the thiophene group of HI-443 
occupies the same Wing 2 region of the NNI binding pocket of RT as TRV,  although with a 
smaller molecular volume. Moreover, the geometry of  hydrogen bond between 2´-NH atom 
and the amide carbonyl or TR residue 101 deviates from the optimum geometry that  
authors had observed in relation to TRV and other PETT derivatives, such as HI-172 (Table 
6).  Said remarks could justify the lower inhibitory activity of HI-443 against HTLVIIIB RT,  in 
comparison with TRV (Table 9). Surprisingly, when HI-443 was assayed against NNI-
resistant and MDR-HIV strains, it  showed  excellent results (Table 9).  This finding  is in 
perfect accordance with the docking analysis, as this latter revealed that  thiophene group is 
located very close to  the Y181 residue. Therefore, in the Y181C mutant strains, the sulfur 
atom from its thiophene group may be more compatible with the sulfur-containing cysteine 
181 residue than the pyridyl group of TRV. 
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181 residue than the pyridyl group of TRV. 
  








p24 RT-MDR A17 A17 variant 
HI-443 >100 0.030 0.004 0.048 3.3 
HI-172 >100 <0.001 >100 >100 >100 
HI-240 >100 <0.001 0.005 0.200 41 
TRV >100 0.007 0.020 0.500 >100 
AZT >100 0.004 0.2 0.006 0.004 
Table 9. Anti-HIV activity of PETT derivatives. 
In their next work, Venkatachalam and  collaborators (Venkatachalam et al., 2001)  
designed, synthesized and evaluated 13 aromatic/heterocyclic thiazolyl thiourea 
compounds, since thiazolyl group  was expected to favorably bind to Wing 1 region of the 











Compound n Ring 
IC50 (µM) CC50 
(µM) SI HTLVIIIB A17 
A17 
variant 
2 Et 2-Thiophene <0.001 >100 N.D. 71 71,000 
3 Et 2-Cyclo-hexenyl 0.007 0.9 >100 4 571 
4 Et 1-phenoxy <0.001 4.4 >100 >100 >100,000 
5 Et 4-methyl-phenyl 0.07 3.9 >100 >100 1459 
6 Me 1-Adamantyl <0.001 0.6 1.3 40 40,000 
7 Pr 2-Furan <0.001 2.0 0.6 >100 >100,000 
8 Et 1-Imidazole <0.001 >100 >100 35 35,000 
9 Et 3-indole <0.001 2.2 3.7 28 28,000 
10 Et 1-pyperidine >100 N.D. N.D. N.D. N.D. 
11 Et 4-hydroxy-phenyl >100 N.D. N.D. N.D. N.D. 
12 Et 2-pyridine 1 N.D. N.D. 100 100 
13 Pr 1-pyrrolidinone 9 N.D. N.D. 18 2 
14 2-Bu Phenyl 0.009 2.1 1.5 10 1111 
NVP ---- ---- 0.034 >100 >100 N.D. N.D. 
DLV ---- ---- 0.009 50 >100 N.D. N.D. 
Table 10. Anti-HIV activity of thiazolyl thiourea derivatives. 
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Among 13 compounds, six lead  ones were detected (2, 4 and 6-9). They were 9-34 times 
more active than the standard NNRTI nevirapine and delavirdine. The compounds 2-9 and 
14 were also tested against NNRTI-resistant strains A17 with Y181C mutation and A17 
variant with a Y181C plus K103N mutations in RT. The most promising compounds were 6, 
7, 9 and 14, as they were effective against both NNRTI-resistant HIV-1 isolates and showed 
much greater potency against both wild-type and  NNRTI-resistant HIV-1 than nevirapine 
and delavirdine. Among these compounds, the most promising was the 7, due to its  
minimal cytotoxic effects on PBMC, as well as to its  selectivity index  > 100,000. 
 Subsequently, Venkatachalam and  collaborators (Venkatachalam et al., 2000)  proposed to 
study the influence of  stereochemistry of Halopyridyl and Thiazolidyl thiourea compounds  
on their potency as NNRTI.  For this purpose,  they  synthesized and measured  anti-HIV 
activity of  R and S stereoisomers of two cyclohexyl methyl haloperidyl thiourea compounds 
(HI-509 and HI-510), of two α-methyl benzylhalopyridyl thiourea compounds (HI-511 and 

























rRT HTLVIIIB RT-MDR A17 
A17 
variant 
HI-509(R) 1.2 0.001 0.2 0.4 10.0 
HI-509(S) >100 >1 N.D. N.D. N.D. 
HI-510(R) 1.4 0.025 0.06 0.07 8.2 
HI-510(S) >100 >1 N.D. N.D. N.D. 
HI-511(R) 1.6 0.01 0.005 0.01 2.7 
HI-511(S) >100 >1 N.D. N.D. N.D. 
HI-512(R) 1.2 0.010 0.010 0.2 10.2 
HI-512(S) >100 >1 N.D. N.D. N.D. 
HI-513(R) 13.0 0.001 5.6 0.9 5.8 
HI-513 (S) >100 >1 N.D. N.D. N.D. 
HI-542 (S) >100 >1 N.D. N.D. N.D. 
HI-543 (R) >100 >1 N.D. N.D. N.D. 
TRV 0.8 0.007 0.02 0.5 >100 
Table 11. Effects of stereochemistry on anti-HIV activity of thiourea compounds. 
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IC50 (µM) CC50 
(µM) SI HTLVIIIB A17 
A17 
variant 
2 Et 2-Thiophene <0.001 >100 N.D. 71 71,000 
3 Et 2-Cyclo-hexenyl 0.007 0.9 >100 4 571 
4 Et 1-phenoxy <0.001 4.4 >100 >100 >100,000 
5 Et 4-methyl-phenyl 0.07 3.9 >100 >100 1459 
6 Me 1-Adamantyl <0.001 0.6 1.3 40 40,000 
7 Pr 2-Furan <0.001 2.0 0.6 >100 >100,000 
8 Et 1-Imidazole <0.001 >100 >100 35 35,000 
9 Et 3-indole <0.001 2.2 3.7 28 28,000 
10 Et 1-pyperidine >100 N.D. N.D. N.D. N.D. 
11 Et 4-hydroxy-phenyl >100 N.D. N.D. N.D. N.D. 
12 Et 2-pyridine 1 N.D. N.D. 100 100 
13 Pr 1-pyrrolidinone 9 N.D. N.D. 18 2 
14 2-Bu Phenyl 0.009 2.1 1.5 10 1111 
NVP ---- ---- 0.034 >100 >100 N.D. N.D. 
DLV ---- ---- 0.009 50 >100 N.D. N.D. 
Table 10. Anti-HIV activity of thiazolyl thiourea derivatives. 
 
Thiourea Derivatives: A Promising Class Against HIV/TB Co-Infection   
 
143 
Among 13 compounds, six lead  ones were detected (2, 4 and 6-9). They were 9-34 times 
more active than the standard NNRTI nevirapine and delavirdine. The compounds 2-9 and 
14 were also tested against NNRTI-resistant strains A17 with Y181C mutation and A17 
variant with a Y181C plus K103N mutations in RT. The most promising compounds were 6, 
7, 9 and 14, as they were effective against both NNRTI-resistant HIV-1 isolates and showed 
much greater potency against both wild-type and  NNRTI-resistant HIV-1 than nevirapine 
and delavirdine. Among these compounds, the most promising was the 7, due to its  
minimal cytotoxic effects on PBMC, as well as to its  selectivity index  > 100,000. 
 Subsequently, Venkatachalam and  collaborators (Venkatachalam et al., 2000)  proposed to 
study the influence of  stereochemistry of Halopyridyl and Thiazolidyl thiourea compounds  
on their potency as NNRTI.  For this purpose,  they  synthesized and measured  anti-HIV 
activity of  R and S stereoisomers of two cyclohexyl methyl haloperidyl thiourea compounds 
(HI-509 and HI-510), of two α-methyl benzylhalopyridyl thiourea compounds (HI-511 and 

























rRT HTLVIIIB RT-MDR A17 
A17 
variant 
HI-509(R) 1.2 0.001 0.2 0.4 10.0 
HI-509(S) >100 >1 N.D. N.D. N.D. 
HI-510(R) 1.4 0.025 0.06 0.07 8.2 
HI-510(S) >100 >1 N.D. N.D. N.D. 
HI-511(R) 1.6 0.01 0.005 0.01 2.7 
HI-511(S) >100 >1 N.D. N.D. N.D. 
HI-512(R) 1.2 0.010 0.010 0.2 10.2 
HI-512(S) >100 >1 N.D. N.D. N.D. 
HI-513(R) 13.0 0.001 5.6 0.9 5.8 
HI-513 (S) >100 >1 N.D. N.D. N.D. 
HI-542 (S) >100 >1 N.D. N.D. N.D. 
HI-543 (R) >100 >1 N.D. N.D. N.D. 
TRV 0.8 0.007 0.02 0.5 >100 
Table 11. Effects of stereochemistry on anti-HIV activity of thiourea compounds. 
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The results  showed that  R stereoisomers of all five compounds inhibited the recombinant 
RT in vitro with IC50 values that were 100-fold lower. Each one of these five compounds was 
also active against NNI-resistant HIV-1 strains. Among them, HI-511(R) (see Table 11)  
presented a potent antiviral activity against NNI-resistant and multidrug resistant strains of 
HIV-1. 
Molecular modeling studies indicated that the R steroisomer [HI-509(R)] would fit the target 
NNI binding pocket on HIV-RT much better than its enantiomer [HI-509(S)]. Due to the 
presence of unfavorable steric interactions with the NNI binding pocket residues near the 
Y181 side chain, HI-509(S) adopts an energetically unfavorable eclipsed conformation, 
which reflects in its higher IC50 value. These assumptions could  also  apply in favor of HI-
510(R). As a relevant data concerning  this study, it is worthy to mention that the methyl 
group on  chiral carbon of HI-509(R) and HI-510(R) probably promotes the strong binding 
to the NNI binding pocket via van der Waals with residue V179. 
The substitution of the pyridyl ring of HI-509(R)  and HI-510(R) by a thiazolyl ring 
(compound HI-513(R)) resulted in 10-fold higher IC50 values in cell free RT inhibition 
assays, as the unsubstituted thiazole could be better accommodated by the binding site than 
the unsubstituted pyridine (in combination with the bulky cyclohexylethyl group) as a 
whole molecule. Nevertheless, halogen substitution on pyridine adds a considerable 
number of favorable interactions at Wing 1 region, which improves the final interaction 
score for the substituted pyridine thiourea compounds. 
While studying the effect of stereochemistry on  anti-HIV activity of chiral thiourea 
compounds, Venkatachalam and  collaborators (Venkatachalam et al., 2004)  synthesized 
two new series of PETT compounds: β-methyl phenylethyl thiourea (β-MPT), and α-methyl 
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Fig. 5. β-MPT and α-MBT series. 
These derivatives were evaluated against HIV-1 strain HTLVIIIB , and also against NNRTI-
resistant strains. Upon analysis of  these results, the authors  expressed critical positions  
regarding SAR of this class of compounds (Fig. 6).  
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Fig. 6. Complementary SAR study of chiral thiourea compounds. 
Among all synthesized compounds, the derivative 15 (Table 12), namely the R isomer 5-
chloropyridyl (β-MPT Series), was 380-fold more active than nevirapine, 2-fold more active 
than trovirdine and 190-fold more potent against A17 than delavirdine. The compound 15 
was also  >200-fold more potent against A17V than nevirapine, trovirdine or delavirdine.  In 
view of these results, the authors  postulated that β-MPT compounds may be useful 
candidates  to further development as anti-HIV agents, especially due to their  remarkable 














rRT HTLVIIIB RT-MDR A17 
A17 
variant 
15 0.1 <0.001 0.02 0.3 0.5 
TRV 0.8 0.007 0.02 0.5 >100 
Table 12. Anti-HIV activity of thiourea derivative 15. 
Besides the modifications on the pyridyl ring, Sahlberg and collaborators (Sahlberg et al., 
1998) decided to investigate the replacement of thiourea by urea moiety in PETT derivatives. 
Furthermore, they have prepared compounds with an ethyl linker (Series I) and other 
conformationally restricted cyclopropyl analogues (Series II, Table 13).  
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variant 
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Table 12. Anti-HIV activity of thiourea derivative 15. 
Besides the modifications on the pyridyl ring, Sahlberg and collaborators (Sahlberg et al., 
1998) decided to investigate the replacement of thiourea by urea moiety in PETT derivatives. 
Furthermore, they have prepared compounds with an ethyl linker (Series I) and other 
conformationally restricted cyclopropyl analogues (Series II, Table 13).  
  





















R3Series I Series II
16-21 22-28  
 
Compound R1 R2 R3 R4 ED50 (µM)
a
wt wtb T181C L100I 
16 H F F Cl 0.03 0.85 >32 32 
17 NMe2 F F Br 0.5 N.D. >25 >25 
18 OMe F OMe Cl 0.011 0.09 3 17 
19 OEt F OMe Cl 0.13 N.D. >27 14 
20 COMe F OMe Cl 0.2 N.D. >27 >27 
21 OEt Cl F Br 0.07 N.D. 8 15 
22 H F F Cl 0.006 0.01 N.D. N.D. 
23 OEt Cl F Cl 0.016 0.06 N.D. 0.1 
24 OEt Cl F CN 0.01 0.02 0.53 0.27 
25 OEt F F Cl 0.008 0.03 0.27 0.75 
26 OMe F OMe Cl 0.012 0.1 2.7 1.6 
27 OEt F Cl Cl 0.008 N.D. 0.1 0.1 
28 OEt F Br Br 0.025 0.8 N.D. N.D. 
TRV ---- ---- ---- ---- 0.02 5 >5 0.8 
a The cell culture assay used MT4 cells infected with HIV-1IIIB. 
b The assay contains 15% human AB serum. 
Table 13. Inhibition of HIV-1  by urea-PETT compounds. 
Cyclopropyl compounds  use to be more potent than the ethyl linked  ones, especially on 
mutants (Table 13). The authors hypothesized that, in comparison with the most restricted 
cyclopropyl analogues, the most flexible ethyl derivatives might  present inconvenient  in 
adopting conformations that fit in the mutant enzymes. 
When compared with thiourea analogues,  urea derivatives are less active (Fig. 7), although 
these compounds might have better toxicological and pharmacokinetic properties. In 
addition,  it was  verified later that, in cell culture and in the presence of added human 
serum, urea-PETT compounds keep their antiviral activity in standards that are much 
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Fig. 7. Anti-HIV activities of thiourea and urea derivatives.  
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Following this study, Högberg and collaborators (Högberg et al., 2000) have proposed 
several bioisosteric substitutions of  both thiourea and urea moieties of PETT compounds  
by sulfamide, cyanoguanidine and guanidine groups (Series III, Fig.8). Furthermore, they 
have promoted the replacement of the phenetyl group  by benzophenethyl group, in an 
attempt to  evaluate the influence of said modifications on the antiviral activities of this class 
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n= Ethyl  or  cis-cyclopropyl  linker
R1= OMe or Cl or H
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Fig. 8. Structures of two series of PETT analogues, obtained through bioisosteric modifications. 
The biological results showed that thiourea and urea moieties play an essential role  in the 
optimal activity of PETT compounds,  as all the proposed bioisosteric replacements  lead to a 
reduction (compounds with guanidine group) or to the complete loss of activity (sulfamide 
and cianoguanidine derivatives). Moreover, the benzoylethyl derivatives were reasonably 
potent inhibitors of wild-type HIV-1 RT and HIV-1 virus in cell culture. However, these 












Compound Ar Y X IC50 HIV-1 RT (µM)a ED50 (µM)
b 
29 phenyl S Br <0.027 0.036 
30 2-F- phenyl S Br 0.004 0.009 
31 2-Cl- phenyl S Br 0.010 0.100 
32 2-OMe- phenyl S Br 0.003 0.076 
33 2-F- phenyl O Br 0.054 0.201 
34 3-OMe- phenyl S Br 0.080 0.911 
35 4-F- phenyl S Br 0.047 0.300 
36 2,5-F- phenyl S Br <0.025 0.067 
37 2,6-F- phenyl S Br 0.006 0.028 
38 2,6-F- phenyl S Cl 0.003 0.050 
39 2,6-F- phenyl* S Br 0.001 0.010 
a HIV-1 RT assay which used (poly)rC.(oligo)dG as the templae/primer.  
b Anti-HIV activity assay, using MT4 cells (human T cell line) infected with HIV-1IIIB 
*Phenylethyl, instead of benzoylethyl linker.  
Table 14. IC50 and ED50 values for Series IV. 
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Table 14. IC50 and ED50 values for Series IV. 
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3.1.2.3 PETT derivatives as anti-HIV microbicides 
D´Cruz and  collaborators  started to develop a vaginal microbicidal contraceptive, which 
was potentially  able to prevent HIV transmission. Thus, they  decided to evaluate two 
potent anti-HIV PETT derivatives (HI-240 and HI-236, Table 5), that had been previously 
identified by Venkatachalam and collaborators (Vig et al, 1998; Mao et al., 1998), in an 
attempt to verify a possible  dual-function, namely its anti-HIV and spermicidal activity. 
After proceeding with the analysis of  the results, they observed that only the derivative HI-
240 showed a spermicidal activity, although the underlying mechanism involved in such a 
function remains  unknown. Moreover, HI-240  inhibited the sperm motility, in a 
concentration-and time-dependent way (D´Cruz & Venkatachalam et al., 1999).  
Subsequently, the authors  investigated the cytotoxic characteristics and selectivity of this 
compound, and, then, compared their  results to nonoxynol-9 (N-9), which is the most widely 
used vaginal spermicide. This substance immobilizes sperm, as a result  from a detergent-type 
action on the sperm plasma membrane.  Due to its membrane-disruptive properties, a 
continued use of N-9 has been shown to be likely to damage the cervicovaginal epithelium, 
causing an acute tissue inflammatory response, and thus enhancing the probability of HIV 
infection by heterosexual transmission. When compared with N-9, HI-240 was selectively 
spermicidal, without  detergent-type  toxicity against membrane of the female genital tract, 
which may present significant clinical advantages. Another important feature of HI-240 may 
still be pointed out, namely the possibility for spermicidal NNI to remain stable as protonated 
species, even within  the acidic environment of the vagina, due to the presence of pyridine 
ring,  containing a basic nitrogen atom. Furthermore, the vaginal concentrations of this 
substance required for dual-action anti-HIV and spermicidal activity are well below the 
systemic concentrations achieved by the oral dosages that are generally prescribed for NNIs.  
In view  of these promising results, D´Cruz and  collaborators (D´Cruz et al., 2000)  decided to 









HI-232: R1=3,4 OMe; R2= Br
HI-236: R1=2,5 OMe; R2= Br
HI-237: R1=2 OMe; R2= Br
HI-239: R1=3 OMe; R2= Br
HI-240: R1=2 F; R2= Br
HI-241: R1=3 F; R2= Br
HI-242: R1=4 F; R2= Br
HI-243: R1=4 Br; R2= Br
HI-244: R1=4 Me; R2= Br
HI-256: R1=4 OH; R2= Br
HI-253: R1=2 Cl; R2= Br
HI-254: R1=3 Cl; R2= Br
HI-255: R1=4 Cl; R2= Br
HI-275: R1=H; R2= Br
HI-308: R1=H; R2= CF3
HI-310: R1=2,5 OMe; R2= CF3
HI-311:R1=2 F; R2= CF3








HI-142 (TRV): Ring =Pyridyl; R2= Br
HI-172: Ring =Piperidinyl; R2= Br
HI-258: Ring =Piperazinyl; R2= Br
HI-230: Ring =Pyrrolidinyl; R2= Br
HI-207: Ring =Pyridyl; R2= H
HI-309: Ring =Pyridyl; R2=CF3
HI-344: Ring =Piperidinyl; R2= CF3







HI-244: Ring =Cis-Myrtanyl*; R2= Br
HI-541: Ring =Cyclohexenyl; R2= Br
HI-346: Ring =Cyclohexenyl; R2= H
HI-445: Ring =Cyclohexenyl; R2= Cl




Fig. 9. Structures of thiourea derivatives, evaluated as spermicidal microbicides. 
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Among all these substances, they  identified several dual-function of thiourea compounds, 
such as the phenyl ring-containing derivatives HI-240 (2-fluoro), HI-253 (2-chloro) and HI-
255 (4-chloro) and the cyclohexenyl ring-containing derivatives HI-346 and HI-445, which 
were identified as potential lead compounds for the development of clinically useful dual-
function anti-HIV spermicides (Table 15). In this study, the authors also demonstrated that, 
at a spermicidal concentration, the dual-function thiourea derivatives were selectively 
spermicidal, without cytotoxic effects  against human vaginal, ectocervical and endocervical 
epithelial cells .  
 
Compound 
IC50 (µM) EC50 (µM) 
SIA p24 rRT 
HI-240 <0.001 0.60 147 ± 18 
HI-253 <0.001 0.70 70 ± 8 
HI-255 0.001 2.50 160 ± 16 
HI-346 0.003 0.6 42 ± 9 
HI-445 0.003 0.5 57 ± 5 
HI-142 (TRV) 0.007 0.8 >500 
Table 15. Effect of PETT derivatives on p24 antigen production in HIV-infected PBMC, as 
well as enzymatic activity of HIV-1 RT and human sperm mobility. 
Considering that the most promising dual-function microbicides PETTs were HI-346 and 
HI-445, which are cyclohexenyl ring-containing derivatives, D´Cruz and  collaborators  
decided to investigate other cyclohexenyl thiourea (CHET) compounds,  in order to examine 
the way how heterocyclic rings and their functionalization affect the  anti-HIV and SIA 
potency of these substances (D´Cruz et al., 2002a). Furthermore, some urea compounds were 
also evaluated, in an attempt to  determine the role of thiourea moiety in  the biological 
activity of these series (Table 16).  
In view of the data obtained, the authors  concluded that, among the thiazolyl-ring 
containing CHET compounds, only the 4-methyl-substituted derivative (42) showed a 
significant anti-HIV activity. As a matter of fact,  compounds containing benzothiazole-ring  
generally present poor anti-HIV activities. Among the compounds containing N-pyridyl 
nucleus, the functionalization at 5-position with bromine, chlorine and methyl groups led to 
a potent anti-HIV activity of CHET compounds. The thiourea moiety was essential  to 
trigger said anti-HIV activity, as its replacement by urea group either abolished (44) or 
reduced (45) the biological activity.  
Among 15 derivative compounds that were evaluated for  spermicidal potential,  12  
showed an improvement of spermicidal function, when analyzed at micromolar 
concentrations. The authors  observed that compounds with methyl group at 4- or 6-postion 
were non-spermicidal, even at concentrations >500µM. The pyridyl-ring containing CHET 
compounds with bromine or chlorine attached  to 5-position showed an excellent SIA 
activity, in addition to their remarkable anti-HIV activity. Interestingly, the urea 
compounds, although having retained SIA, presented a poor anti-HIV activity, . Another 
curious data arises from the comparison between  the values of T1/2 relating to thiourea and 
urea compounds, showing that  urea analogues immobilized sperm 38-fold faster than 
thiourea derivatives. 
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HI-236: R1=2,5 OMe; R2= Br
HI-237: R1=2 OMe; R2= Br
HI-239: R1=3 OMe; R2= Br
HI-240: R1=2 F; R2= Br
HI-241: R1=3 F; R2= Br
HI-242: R1=4 F; R2= Br
HI-243: R1=4 Br; R2= Br
HI-244: R1=4 Me; R2= Br
HI-256: R1=4 OH; R2= Br
HI-253: R1=2 Cl; R2= Br
HI-254: R1=3 Cl; R2= Br
HI-255: R1=4 Cl; R2= Br
HI-275: R1=H; R2= Br
HI-308: R1=H; R2= CF3
HI-310: R1=2,5 OMe; R2= CF3
HI-311:R1=2 F; R2= CF3








HI-142 (TRV): Ring =Pyridyl; R2= Br
HI-172: Ring =Piperidinyl; R2= Br
HI-258: Ring =Piperazinyl; R2= Br
HI-230: Ring =Pyrrolidinyl; R2= Br
HI-207: Ring =Pyridyl; R2= H
HI-309: Ring =Pyridyl; R2=CF3
HI-344: Ring =Piperidinyl; R2= CF3







HI-244: Ring =Cis-Myrtanyl*; R2= Br
HI-541: Ring =Cyclohexenyl; R2= Br
HI-346: Ring =Cyclohexenyl; R2= H
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Fig. 9. Structures of thiourea derivatives, evaluated as spermicidal microbicides. 
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Among all these substances, they  identified several dual-function of thiourea compounds, 
such as the phenyl ring-containing derivatives HI-240 (2-fluoro), HI-253 (2-chloro) and HI-
255 (4-chloro) and the cyclohexenyl ring-containing derivatives HI-346 and HI-445, which 
were identified as potential lead compounds for the development of clinically useful dual-
function anti-HIV spermicides (Table 15). In this study, the authors also demonstrated that, 
at a spermicidal concentration, the dual-function thiourea derivatives were selectively 
spermicidal, without cytotoxic effects  against human vaginal, ectocervical and endocervical 
epithelial cells .  
 
Compound 
IC50 (µM) EC50 (µM) 
SIA p24 rRT 
HI-240 <0.001 0.60 147 ± 18 
HI-253 <0.001 0.70 70 ± 8 
HI-255 0.001 2.50 160 ± 16 
HI-346 0.003 0.6 42 ± 9 
HI-445 0.003 0.5 57 ± 5 
HI-142 (TRV) 0.007 0.8 >500 
Table 15. Effect of PETT derivatives on p24 antigen production in HIV-infected PBMC, as 
well as enzymatic activity of HIV-1 RT and human sperm mobility. 
Considering that the most promising dual-function microbicides PETTs were HI-346 and 
HI-445, which are cyclohexenyl ring-containing derivatives, D´Cruz and  collaborators  
decided to investigate other cyclohexenyl thiourea (CHET) compounds,  in order to examine 
the way how heterocyclic rings and their functionalization affect the  anti-HIV and SIA 
potency of these substances (D´Cruz et al., 2002a). Furthermore, some urea compounds were 
also evaluated, in an attempt to  determine the role of thiourea moiety in  the biological 
activity of these series (Table 16).  
In view of the data obtained, the authors  concluded that, among the thiazolyl-ring 
containing CHET compounds, only the 4-methyl-substituted derivative (42) showed a 
significant anti-HIV activity. As a matter of fact,  compounds containing benzothiazole-ring  
generally present poor anti-HIV activities. Among the compounds containing N-pyridyl 
nucleus, the functionalization at 5-position with bromine, chlorine and methyl groups led to 
a potent anti-HIV activity of CHET compounds. The thiourea moiety was essential  to 
trigger said anti-HIV activity, as its replacement by urea group either abolished (44) or 
reduced (45) the biological activity.  
Among 15 derivative compounds that were evaluated for  spermicidal potential,  12  
showed an improvement of spermicidal function, when analyzed at micromolar 
concentrations. The authors  observed that compounds with methyl group at 4- or 6-postion 
were non-spermicidal, even at concentrations >500µM. The pyridyl-ring containing CHET 
compounds with bromine or chlorine attached  to 5-position showed an excellent SIA 
activity, in addition to their remarkable anti-HIV activity. Interestingly, the urea 
compounds, although having retained SIA, presented a poor anti-HIV activity, . Another 
curious data arises from the comparison between  the values of T1/2 relating to thiourea and 
urea compounds, showing that  urea analogues immobilized sperm 38-fold faster than 
thiourea derivatives. 
  












* Time required for 50% sperm mobility loss. 
Table 16. Anti-HIV and sperm immobilization activity of a serie of PETT derivatives. 
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Furthermore, the lead compounds HI-346 and HI-445 were evaluated in their activity 
against NNI-resistant strains (RT-MDR, A17 variant), and  were found to be more effective 
than TRV, delavirdine and nevirapine. These findings established the dual-function 
compounds HI-346 and HI-445 as potent NNI of drug-sensitive, as well as multidrug-
resistant strains of HIV-1. 
Due to the fact that the compound HI-346 is  a broad-spectrum anti-HIV agent with SIA, and 
also to the characteristic of  its urea analogue 44  as an extremely rapid spermicidal, the 
authors  decided to evaluate the in vivo fertilizing ability of sperm exposed to the lead dual-
function CHET compound HI-346, either alone or in combination with its structural analogue 
(compound 44), in the rabbit model. They  observed that the conception was completely 
inhibited after insemination with semen treated with compound 44, or HI-346 plus 44. 
 As to the cytotoxic profile, CHET-NNIs showed high selectivity indexes  against these 
genital tract epithelial cells in vitro. Moreover, in rabbits, the lead thiourea/urea compounds 
are not harmful to vaginal mucosa,   in spite of their  potent spermicidal properties,  when 
added either to human or to rabbit semen. 
These results indicated that the extremely rapid SIA of the urea analogue, as well as the 
broad-spectrum anti-HIV activity of spermicidal CHET-NNIs, together with their lack of 
mucosal toxicity and the remarkable ability to reduce in vivo fertility, appear as features that 
are particularly attractive to encourage the clinical development of a dual-function 
spermicidal microbicide (D´Cruz et al., 2002a). 
The next step performed by D´Cruz and  collaborators was the investigation on subchronic 
intravaginal toxicity of HI-346 in mice. Thus, HI-346 was formulated via lipophilic gel-
microemulsion for intravaginal use as a potential dual-function microbicide. In order to 
evaluate the potential toxicity of short-term intravaginal exposure to HI-346, groups of 15 
female B6C3F1 and CD-1 mice underwent an intravaginal exposure to a gel-microemulsion 
containing 0, 0.5, 1.0, or 2.0% HI-346, 5 days per week, for 13 consecutive weeks.  
Subsequently, the authors concluded that repetitive intravaginal administration of HI-346 to 
yield effective spermicidal and antiviral concentrations is not expected to  lead to local, 
systemic, or reproductive toxicity (D´Cruz et al., 2002b). 
In another study, D´Cruz and  collaborators decided to evaluate the PETT derivative HI-236 
as microbicide,  as, in accordance with a previous work, this compound  had already 
presented a broad-spectrum of anti-HIV activity (Mao et al., 1999).  In view of the above the 
authors demonstrated  that HI-236 showed a high-selectivity index against both human 
vaginal and cervical epithelial cells, without  affecting the human sperm functions. 
Furthermore, HI-236 was able to prevent the HIV systemic infection via  vaginal route. 
Therefore, HI-236 presented a  clinical utility as  non-spermicidal microbicide to curb the 
transmission of HIV via semen: (a) in sexually active women, to allow pregnancy, while 
protecting both mother and her fetus or infant from HIV-1 and (b) as a prophylactic antiviral 
agent for HIV-1 serodiscordant couples, or  for use before assisted reproductive technology 
procedures (D´Cruz & Uckun, 2005).  
3.2 Thiourea derivatives with potential activity against TB 
3.2.1 Isoxyl  
The thiocarbanilide Isoxyl (ISO, thiocarlide, 4,4’-diisoamythio-carbanilide) (Fig.1) was 
synthesized in 1953 by Buu-Hoi an Xuong. In this work, the authors described the 
antimicobacterial activity of several thioureas, among which some  are more active than 
ISO; however, this substance was chosen for subsequent assays, due to its better absorption, 
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and also to its  good tolerance even at the highest therapeutic doses (König, 1970). 
Pharmacological data demonstrated that,  upon this drug ingestion, the human serum 
presented fluctuating levels of ISO,  that exceeded its minimum inhibitory concentration 
(Tousek, 1970). Besides, given  its remarkable characteristics,  this substance has been used 
at the clinical treatment of  TB since the 1960’s. ISO was employed both: in monotherapy 
and in combined therapy, such as: ISO-isoniazid (I), ISO-streptomycin (S), ISO-I-S and ISO-
para-aminosalicylic acid (PAS). These studies reached good  results  (some of which are 
shown at  Table 17), especially in patients with pulmonary TB resistant to isoniazid, 
streptomycin and PAS, as well as in patients with hyper allergic reactions against others 
drugs or hepatitis as a result  from I (Tousek, 1970; Urbancik, 1970). However, when 
compared with other combinatory regimes, such as I-PAS and S-PAS, the results achieved 
with ISO appeared to be quite mediocre, thus culminating with  the introduction of more 
powerful antituberculosis drugs,  such as ethambutol, and with the consequent 
discontinuation of  ISO  administration. Nevertheless, in view of the worldwide 
dissemination  of MDR-TB and XDR-TB (World Health Organization, 2010a), a  re-
evaluation of drugs which were formerly deemed to be effective against TB  is a promising 
strategy for the development of new treatments, so that,  in this context, ISO  may be 
considered as  a strong candidate.   
 
Combination Months of therapy Negative on culture (%)a 
ISO (6 g) 1.5 – 4.5 47 
ISO – I (6 g/600 mg) 4 89 
ISO – I (6 g/10 mg/Kg) 6 75 
ISO – I (6 g/5 mg/Kg) 6 63 
ISO – S – I (4 g/1 g/200 mg) 6 83 
ISO – PAS (6 g/12 g) 6 50 
apercentage of patients  who had presented negative cultures.  
Table 17. Examples of results achieved in clinical trials with ISO (Tousek, 1970) 
In a recent report, Phetsuksiri and  collaborators (Phetsuksiri et al., 1999) evaluated the 
minimal inhibitory concentration (MIC) of ISO against various clinical isolates of 
susceptible and MDR-TB strains (Table 18). The growing of all tested strains was inhibited at 
low concentrations, with a MIC ranging  between 1-10µg/mL, which are  smaller than the 
maximum serum levels observed in humans for ISO (10-13.2µg/mL) (König, 1970). The 
authors also verified the effect of ISO on viable M. tuberculosis in vitro bone marrow 
macrophage assay, where this substance showed an ability to inhibit  bacterial growth 
inside the macrophage,  as well as a bactericidal activity, by reducing the initial inoculum of 
virulent M. tuberculosis. Another interesting result  from this assay  disclosed that ISO 
showed no acute level of  toxicity for mouse macrophages.   
 Together with the early studies performed with ISO in the 1960s, the recent results 
corroborate the capacity  of this substance to be used as an anti-TB drug, particularly in the 
development of new regimes to  MDR and XDR-TB treatment.  Such a characteristic is a 
direct result from ISO mechanism of action,  which  considerably differs from those 
presented by other  known anti-TB drugs. 
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Strain Designation Drug Resistance MIC (µg/mL) 
CSU 15 I 5.0 
CSU 21 I, R, E, S, Rfb 5.0 
CSU 22 I, R, E, S, Kan, Cap, AMK 10.0 
CSU 31 I, R, E 10.0 
CSU 32 I, R, E, Cyc, ETH, Z 10.0 
CSU 37 ----------------------------------------------------- 5.0 
CSU 39 I, R, S, Kan, AMK, ETH 10.0 
CSU 44 I, R, E, S, Kan, Z 10.0 
W 670 I, R, E, S, Kan 5.0 
W 3432 I, R, E, S, Kan, AMK, ETH, Cip 5.0 
BB ----------------------------------------------------- 1.0 
LL I, R, S, Kan, AMK, Z 1.0 
kanamycin (Kan), cycloserine (Cyc), rifabutin (Rfb), ethionamide (ETH), amikacin (AMK), capreomycin 
(Cap). 
Table 18. Minimal inhibitory concentration of ISO against susceptible and MDR-TB strains. 
3.2.2 Mechanism of action  
Similarly to what happens with Isoniazid, a substance used in  the first line treatment of TB, 
and with ethionamide, a second line drug, ISO strongly inhibits the synthesis of mycolic acids. 
However, ISO can also inhibit shorter chain fatty acid synthesis, thus producing an effect that 
had never been observed in other drugs  showing antimycobacterial properties (Phetsuksiri et 
al., 2003). 
ISO interferes in the fatty acid metabolism, through  inhibition of the ∆9 desaturase DesA3. 
This mechanism leads to the inhibition of the of oleic acid synthesis, which is the most 
abundant unsaturated fatty acid in Mycobacterium spp. and a constituent of mycobacterial 
membrane phospholipids. Due to the vital functions of oleic acid, the inhibition of its 
synthesis  leads to cell death. Another membrane phospholipid constituent which is 
indirectly affected during this pathway is the tuberculostearic acid, given that this substance 
is synthesized  through direct methylation of oleic acid by S-adenosylmethionine.   
ISO inhibitory mechanism  in mycolic acids synthesis has not been described. Nevertheless, 
it was already demonstrated that there is no relationship between oleic acid and mycolic 
acids synthesis inhibition (Phetsuksiri et al., 2003).  
Another relevant aspect involved in the ISO mechanism of action concerns the fact that  its 
activation by the flavin-containing monooxygenase EthA is  mandatory to trigger an activity 
against M. tuberculosis (Korduláková, 2007). Based on the LC/MS analyses of the 
compounds formed after ISO treatment  with the partially purified recombinant EthA 
(compounds 53, 55 and 57, Fig. 10), the  following activation pathway was proposed: 
Initially, oxidation reactions  with sulfur atom lead to the formation of intermediary 54, 
which undergoes an elimination reaction, yielding the formimidamide 55. Further reactions 
lead to the formation of carbodiimide 56, which can be hydrolyzed, yielding the urea 
derivative 57 (Fig. 10).  The data obtained from previous  studies with ETH and thiacetazone 
could suggest that ISO would be a prodrug, activated by oxidations reactions catalyzed by 
EthA, and that  carbodiimide 56  would appear as its active form. However, the real function 
of this process and its role in the inhibition of oleic acid and/or mycolic acids synthesis are 
not well understood. Besides, it is worthy  to consider that  EthA could  only serve to retain 
ISO or its metabolites inside the bacterial cell.  
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Fig. 10. Proposed pathway for ISO activation  by EthA. 
3.2.3 ISO analogues 
In spite of the interesting results shown by the prior clinical trials with ISO , this substance 
was found to present some pharmacokinetic disadvantages,  which  limited its clinical use 
as an antimycobacterial agent (Wang & Hickey, 2010).  In view of the above, and in an 
attempt to overcome this kind of inconvenient,  several ISO derivatives have been 
synthesized  throughout the last years, as may be illustrated by the following  examples.  
Phetsuksiri and  collaborators  described the antimycobacterial evaluation of  series of ISO 
analogues (Phetsuksiri et al., 1999). These compounds were prepared through random 
substitutions in the side chains attached to the thiourea nucleus, which it is required for 
animycobacterial activity (Phetsuksiri et al., 2003; Korduláková, 2007). This strategy  led to 
the formation of a pool of new ISO derivatives, which present variations both in the 
symmetric and asymmetric side chains with alkyl, alkoxy or sulfur fuctional groups 
substituted in para and para´ positions (Table 19). 
Said  results show  that the most part of derivatives presented a similar or a better  activity 
(MIC <0.1 to 2.5µg/mL), when compared to ISO (MIC= 2.0µg/mL).  Among some relevant 
aspects concerning SAR, it may be noted that  the replacement of oxygen (58-60)  by sulfur 
(62-64) in the side chain provides a considerable improvement in the antimycobacterial 
activity. Moreover, the introduction of a long alkyl chain plus an ester group leads to the 
formation of inactive compounds (67,68). Bulky groups, such as t-butyl, attached to para and 
para´ position of phenyl ring, also  gave rise to an inactive derivative (65). These results 
suggest that chemical modifications on  thiourea nucleus basis could lead to the constitution 
of an  inhibitor, that would be even more powerful against M. tuberculosis.  
In another study, Bhowruth and  collaborators (Bhowruth et al., 2006)  synthesized and 
evaluated  series of symmetrical and unsymmetrical ISO analogues  against M. tuberculosis 
(Table 20). Several compounds  disclosed by this study present  similar or better activities 
than ISO (MIC <0.1 to 1.56µg/mL). It is  worthy to mention that the introduction of an 
aliphatic C4 chain to either or both R1 and R2-positions increased the potency of the inhibitor 
(76-79, 81). Among them, the derivatives 78 and 79 were the most active, with a significant 
10-fold increase in potency against M. tuberculosis, when compared to ISO. 
 




* MIC99 is defined as the lowest concentration of compound that reduced 99% of the number of M. 
tuberculosis colonies on the plates, in comparison with those at  the control plate free of compound. 
Table 19. ISO analogues prepared by Phetsuksiri and collaborators,  as well as their 
respective MIC values. 
  







































Fig. 10. Proposed pathway for ISO activation  by EthA. 
3.2.3 ISO analogues 
In spite of the interesting results shown by the prior clinical trials with ISO , this substance 
was found to present some pharmacokinetic disadvantages,  which  limited its clinical use 
as an antimycobacterial agent (Wang & Hickey, 2010).  In view of the above, and in an 
attempt to overcome this kind of inconvenient,  several ISO derivatives have been 
synthesized  throughout the last years, as may be illustrated by the following  examples.  
Phetsuksiri and  collaborators  described the antimycobacterial evaluation of  series of ISO 
analogues (Phetsuksiri et al., 1999). These compounds were prepared through random 
substitutions in the side chains attached to the thiourea nucleus, which it is required for 
animycobacterial activity (Phetsuksiri et al., 2003; Korduláková, 2007). This strategy  led to 
the formation of a pool of new ISO derivatives, which present variations both in the 
symmetric and asymmetric side chains with alkyl, alkoxy or sulfur fuctional groups 
substituted in para and para´ positions (Table 19). 
Said  results show  that the most part of derivatives presented a similar or a better  activity 
(MIC <0.1 to 2.5µg/mL), when compared to ISO (MIC= 2.0µg/mL).  Among some relevant 
aspects concerning SAR, it may be noted that  the replacement of oxygen (58-60)  by sulfur 
(62-64) in the side chain provides a considerable improvement in the antimycobacterial 
activity. Moreover, the introduction of a long alkyl chain plus an ester group leads to the 
formation of inactive compounds (67,68). Bulky groups, such as t-butyl, attached to para and 
para´ position of phenyl ring, also  gave rise to an inactive derivative (65). These results 
suggest that chemical modifications on  thiourea nucleus basis could lead to the constitution 
of an  inhibitor, that would be even more powerful against M. tuberculosis.  
In another study, Bhowruth and  collaborators (Bhowruth et al., 2006)  synthesized and 
evaluated  series of symmetrical and unsymmetrical ISO analogues  against M. tuberculosis 
(Table 20). Several compounds  disclosed by this study present  similar or better activities 
than ISO (MIC <0.1 to 1.56µg/mL). It is  worthy to mention that the introduction of an 
aliphatic C4 chain to either or both R1 and R2-positions increased the potency of the inhibitor 
(76-79, 81). Among them, the derivatives 78 and 79 were the most active, with a significant 
10-fold increase in potency against M. tuberculosis, when compared to ISO. 
 




* MIC99 is defined as the lowest concentration of compound that reduced 99% of the number of M. 
tuberculosis colonies on the plates, in comparison with those at  the control plate free of compound. 
Table 19. ISO analogues prepared by Phetsuksiri and collaborators,  as well as their 
respective MIC values. 
  




Table 20. Structures and antimycobacterial activity of ISO derivatives. 
Liav and collaborators investigated the effect of replacement of one of the isoamyloxyphenyl 
ISO moieties by a carbohydrate (Liav et al., 2008a). Said modification aimed at the 
production of ISO analogues with better hydrophilic properties, which could be useful to 
mitigate the inconvenient represented by the poor bioavailability of this drug (Fig.11). 
Among these compounds, only the arabinfuranosyl derivative 90 has a MIC value of 
2.5µg/mL, which is almost more potent than ISO. 
 







































Fig. 11. ISO derivatives containing carbohydrates moieties.  
This promising result  encouraged Liav and  collaborators (Liav et al., 2008b)  to synthesize 
and  evaluate the D-aldopentofuranosyl derivatives (90-93, Fig.12). Arabino analogue (90) 
was re-tested, and found to be  more potent than ISO, while the ribo analogue (91)  
presented a MIC value in the same range of ISO. The D-xylo analogue (92) was rather less 
active, and the D-lyxo product (93)  only acted at a concentration of 50µg/mL. These results 
could suggest that the products are very sensitive to  stereochemical configuration, thus 
indicating that  the carbohydrate group does not only add the required hydrophilicity to the 



































Fig. 12. Other ISO derivatives containing carbohydrates moieties. 
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Thiourea is a very important functional group for anti-HIV and anti-TB drug discovery,  
and, as seen above, literature has already described the promising biological activities of 
several derivatives. In the context of AIDS drug discovery, this scaffold is found in two 
remarkably important classes of compounds, namely among PETT and TIBO derivatives. 
The PETT compound TRV has been exploited as an excellent lead compound, whose  
several derivatives have been described. TIBO derivatives were essential for the 
development of NNRTI, a class of antiretroviral agents that currently present a relevant role 
in AIDS treatment.  In parallel, as refers to  TB drug discovery, ISO was found to present 
promising activities against resistant strains,  especially due to its unique mechanism of 
action. In  view of said data, the development of substances  containing thiourea moiety and 
showing a potential activity against both diseases  could be considered an important 
research field,  which should be particularly orientated towards the improvement  of 
therapeutic options for HIV-TB co-infected patients. 
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1. Introduction 
Assessing the quality of life (QoL) of people living with HIV/AIDS has become increasing. 
From 1995 to 2003, more than 300 papers on the subject were published. This fact encourages 
researchers to question the existence of suitable assessment instruments. Virtually all existing 
instruments until 2003 had been developed in the USA (Skevington & O'Connell, 2003). 
To apply these instruments in countries in which English is not the vernacular language, the 
instruments were subjected to literal translations, without the worry of a cultural 
adaptation. In this wise, came the proposal to develop an instrument from sundry centers, 
located in different countries (Skevington & O'Connell, 2003). 
The fact that there is no consensus on the QoL concept is a major problem in developing 
instruments to assess the QoL, while it is not possible to state clearly what elements these 
instruments are assessing (Fleck, 2008). 
From this premise, the starting point to build the instrument for QoL assessment of the 
World Health Organization (WHO) was to conceptualize QoL. In the concept adopted, QoL 
is understood as “individuals’ perceptions of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns” (The WHOQOL Group, 1998a, p. 25). 
In face of this concept, WHO embarked on building the World Health Organization Quality 
of Life (WHOQOL) instruments, which assess QoL globally, e.g. WHOQOL-100 and 
WHOQOL-bref, and due to specific aspects, e.g. WHOQOL-HIV, WHOQOL-OLD, and 
WHOQOL-SRPB. One of these instruments, the WHOQOL-HIV, used to assess the QoL of 
HIV carriers, is the object of this study. 
Starting from the fact that 95% of people infected with HIV did not live in the USA but in 
developing countries of Asia, Latin America, and sub-Saharan Africa, WHO has developed 
a tool to assess the QoL directed to such audience. The instrument was designed based on 
the premise that a multidisciplinary approach, involving centers in several countries, would 
allow for greater dissemination of the developed instrument (O'Connell, 2003). 
The WHOQOL-HIV is a complementary module for WHOQOL-100 instrument, and was 
also translated into other languages and validated in sundry studies, among which are a 
part of Starace et al. (2002), Zimpel & Fleck (2007), Saddki et al. (2009), Canavarro et al. 
(2011) and Mweemba et al. (2011). 
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Notwithstanding the significant diffusion of the WHOQOL, questions concerning the 
calculation and analysis of the results of those instruments constitute a limitation for its use. 
In this context, we aimed here at clarifying the mechanism predetermined by the 
WHOQOL-HIV Group to calculate the WHOQOL-HIV and WHOQOL-HIV-bref instrument 
scores. Additionally, we proposed an alternative way to perform such calculations. 
2. WHOQOL-100 
The development of an instrument for evaluation of quality of life purposed by WHO was 
conducted in 15 centers simultaneously, based in 14 countries. After developing the project 
WHOQOL, new centers were built. Currently WHOQOL instruments are available in over 
50 languages (WHO Field Center for Quality of Life of Bath, 2008). 
The development methodology of WHOQOL was sectioned into four major stages: clarifying 
the concept of quality of life, qualitative pilot study, development of a pilot and finally, field 
implementation. For the integrated centers, after the completion of the instrument, a protocol 
was established which consisted in its translation, preparation of the test pilot, development of 
the response scales and administration of the pilot (The WHOQOL Group, 1998a). 
All questions of WHOQOL-100 are closed. It was used a five-point Likert scale, ranging 
from 1 to 5. These extremes represent 0% and 100%, respectively. There are four different 
types of response scales, as can be seen in Table 1: 
 
SCALE 0% 25% 50% 75% 100% 
INTENSITY 










nor dissatisfied Satisfied 
Very 
satisfied 








nor unhappy Happy Very happy 
CAPACITY Not at all A little Moderately Mostly Completely 
FREQUENCY Never Seldom Quite often Very often Always 
Source: Adapted from The WHOQOL Group (1998b) 
Table 1. Response scale of WHOQOL-100 
WHOQOL-100 aims at measuring the quality of life globally through six domains: Physical, 
Psychological, Level of independence, Social relationships, Environment e 
Spiritual/Religion/Personal beliefs. To obtain the results of WHOQOL instruments 
applications, the WHOQOL Group recommends the software Statistical Package for the 
Social Sciences (SPSS). 
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2.1 WHOQOL-100 scores calculation 
The results of the WHOQOL-100 implementation are expressed through the scores of each 
facet and domain. The WHOQOL-100 scoring procedure presents the following logic: 
- Verification of all those 100 questions completed with values between 1 and 5; 
- Reversal of the 18 questions whose answer scale is inverted; 
- Scores of facets calculation from the simple arithmetic average of questions that 
compose each facet, followed by a multiplication by four. The multiplication by four is 
used so that, in case of a question has not been answered, the score of a facet 
compensates the invalidation of the question through the product by the number of 
valid questions that the facet should have. It will be computed only those aspects that 
have at least three valid items; 
- Scores of each domain are calculated through the simple arithmetic average of the facets 
scores that compose each area. In domains composed of up to five facets, this will be 
calculated only if the number of facets not calculated is not equal to or greater than two. 
In domains consisting of more than five facets, the domain will be calculated only if the 
number of facets not calculated is not equal to or greater than three. In the case of facets 
in reversed scale (all questions within the facet have reversed response scale), there will 
be an inversion of that facet to proceed the calculation; 
- Scores of domains and facets are converted to a scale from 0 to 100; 
- Total number of items answered by each respondent is counted. In the calculation are 
computed only those respondents who completed at least 80 items correctly (80% of the 
instrument items). 
The WHOQOL-100 results are expressed in two scales, a variant scale between 4 and 20 
points, due to the fact that the facets scores calculation is achieved by multiplying the 
average of questions that constitute each facet by four. Once each domain is calculated by 
the simple arithmetic average of facets that composes it. The results are expressed on the 
same scale of facets. The results are also expressed on a scale from 0 to 100. 
2.2 Questions and facets response scale conversion 
The conversion of questions is used in order to standardize all the answers of the instrument, 
so that the most positive response is 5. Therefore, the most negative response must be 1. Thus, 
all questions of each facet are converted to the same scale, where the gradual increase in 
response is equivalent in the same proportion to the increase in the result of the facet. 
In cases where all four questions that constitute a facet are arranged in inverted scale, that 
same logic is used, but only in the domain calculation. That is, the result of these facets is 
expressed in the original scale: without inversion (the closer to 1, the more positive the 
result; the closer to 5, the more negative the result). However, when calculating the scores of 
areas where such facets are found, the score of the latter is converted. 
For the conversion of the response scale of questions, the minimum value of the inverted 
scale question should be replaced by the maximum value of the normal scale question, and 
the maximum value of the inverted scale question should be replaced by a minimum value 
of the normal scale question. The same should occur with intermediate values, following 
this same logic. Thus, the only value that remains unchanged is the central value, which will 
remain the same in both normal and inverted scales. 
It is necessary to be attentive to this fact, because when comparing the results between the 
facets, the score of a facet with inverted scale cannot be directly compared to the score of a 
  
Global View of HIV Infection 
 
164 
Notwithstanding the significant diffusion of the WHOQOL, questions concerning the 
calculation and analysis of the results of those instruments constitute a limitation for its use. 
In this context, we aimed here at clarifying the mechanism predetermined by the 
WHOQOL-HIV Group to calculate the WHOQOL-HIV and WHOQOL-HIV-bref instrument 
scores. Additionally, we proposed an alternative way to perform such calculations. 
2. WHOQOL-100 
The development of an instrument for evaluation of quality of life purposed by WHO was 
conducted in 15 centers simultaneously, based in 14 countries. After developing the project 
WHOQOL, new centers were built. Currently WHOQOL instruments are available in over 
50 languages (WHO Field Center for Quality of Life of Bath, 2008). 
The development methodology of WHOQOL was sectioned into four major stages: clarifying 
the concept of quality of life, qualitative pilot study, development of a pilot and finally, field 
implementation. For the integrated centers, after the completion of the instrument, a protocol 
was established which consisted in its translation, preparation of the test pilot, development of 
the response scales and administration of the pilot (The WHOQOL Group, 1998a). 
All questions of WHOQOL-100 are closed. It was used a five-point Likert scale, ranging 
from 1 to 5. These extremes represent 0% and 100%, respectively. There are four different 
types of response scales, as can be seen in Table 1: 
 
SCALE 0% 25% 50% 75% 100% 
INTENSITY 










nor dissatisfied Satisfied 
Very 
satisfied 








nor unhappy Happy Very happy 
CAPACITY Not at all A little Moderately Mostly Completely 
FREQUENCY Never Seldom Quite often Very often Always 
Source: Adapted from The WHOQOL Group (1998b) 
Table 1. Response scale of WHOQOL-100 
WHOQOL-100 aims at measuring the quality of life globally through six domains: Physical, 
Psychological, Level of independence, Social relationships, Environment e 
Spiritual/Religion/Personal beliefs. To obtain the results of WHOQOL instruments 
applications, the WHOQOL Group recommends the software Statistical Package for the 
Social Sciences (SPSS). 
Quality of Life Assessment in People  
Living with HIV/AIDS: Clarifying the WHOQOL-HIV and WHOQOL-HIV-Bref Instruments  
 
165 
2.1 WHOQOL-100 scores calculation 
The results of the WHOQOL-100 implementation are expressed through the scores of each 
facet and domain. The WHOQOL-100 scoring procedure presents the following logic: 
- Verification of all those 100 questions completed with values between 1 and 5; 
- Reversal of the 18 questions whose answer scale is inverted; 
- Scores of facets calculation from the simple arithmetic average of questions that 
compose each facet, followed by a multiplication by four. The multiplication by four is 
used so that, in case of a question has not been answered, the score of a facet 
compensates the invalidation of the question through the product by the number of 
valid questions that the facet should have. It will be computed only those aspects that 
have at least three valid items; 
- Scores of each domain are calculated through the simple arithmetic average of the facets 
scores that compose each area. In domains composed of up to five facets, this will be 
calculated only if the number of facets not calculated is not equal to or greater than two. 
In domains consisting of more than five facets, the domain will be calculated only if the 
number of facets not calculated is not equal to or greater than three. In the case of facets 
in reversed scale (all questions within the facet have reversed response scale), there will 
be an inversion of that facet to proceed the calculation; 
- Scores of domains and facets are converted to a scale from 0 to 100; 
- Total number of items answered by each respondent is counted. In the calculation are 
computed only those respondents who completed at least 80 items correctly (80% of the 
instrument items). 
The WHOQOL-100 results are expressed in two scales, a variant scale between 4 and 20 
points, due to the fact that the facets scores calculation is achieved by multiplying the 
average of questions that constitute each facet by four. Once each domain is calculated by 
the simple arithmetic average of facets that composes it. The results are expressed on the 
same scale of facets. The results are also expressed on a scale from 0 to 100. 
2.2 Questions and facets response scale conversion 
The conversion of questions is used in order to standardize all the answers of the instrument, 
so that the most positive response is 5. Therefore, the most negative response must be 1. Thus, 
all questions of each facet are converted to the same scale, where the gradual increase in 
response is equivalent in the same proportion to the increase in the result of the facet. 
In cases where all four questions that constitute a facet are arranged in inverted scale, that 
same logic is used, but only in the domain calculation. That is, the result of these facets is 
expressed in the original scale: without inversion (the closer to 1, the more positive the 
result; the closer to 5, the more negative the result). However, when calculating the scores of 
areas where such facets are found, the score of the latter is converted. 
For the conversion of the response scale of questions, the minimum value of the inverted 
scale question should be replaced by the maximum value of the normal scale question, and 
the maximum value of the inverted scale question should be replaced by a minimum value 
of the normal scale question. The same should occur with intermediate values, following 
this same logic. Thus, the only value that remains unchanged is the central value, which will 
remain the same in both normal and inverted scales. 
It is necessary to be attentive to this fact, because when comparing the results between the 
facets, the score of a facet with inverted scale cannot be directly compared to the score of a 
  
Global View of HIV Infection 
 
166 
facet with normal scale. The answers 1, 2, 3, 4 and 5 are to take the values 5, 4, 3, 2 and 1, 
respectively. The same procedure is used in the conversion of inverted facets, where the 
scores 4, 8, 12, 16 and 20 are to take the values 20, 16, 12, 8 and 4, respectively. 
2.3 WHOQOL-100 questions, domains and facets 
Composed by 100 questions, the WHOQOL-100 is sectioned into 24 groups of four questions 
each, receiving the name of “facets”. The group of facets constitutes a “domain”. Unlike the 
composition of facets, the six WHOQOL-100 domains are not constituted by the same 
number of facets, and may vary from one to eight. 
The questions that compose WHOQOL-100 are not arranged in the questionnaire in a logical 
sequence by domain or facet. They are grouped by type of answer scale. The distribution of 
WHOQOL-100 facets and areas are listed in Table 2: 
 
DOMAINS FACETS 
Domain I – Physical 
1. Pain and discomfort
2. Energy e fatigue
3. Sleep and rest
Domain II – Psychological 
4. Positive feelings
5. Thinking, learning, memory and concentration 
6. Self-esteem
7. Bodily image and appearance
8. Negative feelings
Domain III – Level of 
Independence 
9. Mobility
10. Activities of daily living
11. Dependence on medication or treatments 
12. Work capacity





Domain V – Environment 
16. Physical safety and security
17. Home environment
18. Financial resources
19. Health and social care: accessibility and quality 
20. Opportunities for acquiring new information and 
skills 
21. Participation in and opportunities for recreation/ 
leisure activities 
22. Physical environment 
(pollution/noise/traffic/climate) 
23. Transport
Domain VI – 
Spiritual/Religion/Personal 
Beliefs  
24. Spiritual/Religion/Personal Beliefs 
Source: The WHOQOL Group (1998a) 
Table 2. Domains and facets of WHOQOL-100 
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WHOQOL-100 has a facet that is not included in any domain, the facet Overall Quality of 
Life and General Health Perceptions (The WHOQOL Group, 1998b). This aspect deals with 
a self-assessment of quality of life, where the respondents express their point of view 
concerning their satisfaction with their lives, health and quality of life. 
2.4 Short version of WHOQOL-100 (WHOQOL-bref) 
Aiming at providing a tool that demand less time to its filling out, and with satisfactory 
psychometric characteristics, the WHOQOL Group developed the short version of 
WHOQOL-100, the WHOQOL-bref (The WHOQOL Group, 1996). 
The WHOQOL-bref is composed of 26 questions - two questions on self-assessment of 
quality of life and 24 issues representing each facet of WHOQOL-100. To compound the 
questions of WHOQOL-bref, it was selected the question of each facet that present the 
highest correlation with the average score of all facets (The WHOQOL Group, 1998c). 
After the selection of issues, an analysis was conducted to see if they, factually, represented the 
corresponding facets. In six facets, the question selected was replaced by another question of the 
corresponding facet, for, under the bias of experts, there was another question that could best 
define these six facets (The WHOQOL Group, 1998c). The facets belonging to the domain Level 
of Independence were incorporated into the Physical domain and the facet belonging to the 
domain Spiritual / Religion / Personal Beliefs was incorporated into the Psychological domain. 
Thus, the WHOQOL-bref is composed by four domains: Physical, Psychological, Social 
Relationships and Environment, completing the configuration expressed in Table 3: 
 
DOMAINS FACETS 
Domain I – Physical 
1. Pain and discomfort
2. Energy e fatigue
3. Sleep and rest
4. Mobility
5. Activities of daily living
6. Dependence on medication or treatments
7. Work capacity
Domain II – Psychological 
8. Positive feelings
9. Thinking, learning, memory and concentration
10. Self-esteem
11. Bodily image and appearance
12. Negative feelings
13. Spiritual/Religion/Personal Beliefs




Domain IV – Environment 
17. Physical safety and security
18. Home environment
19. Financial resources
20. Health and social care: accessibility and quality
21. Opportunities for acquiring new information and skills 
22. Participation in and opportunities for recreation/ leisure 
activities 
23. Physical environment (pollution/noise/traffic/climate) 
24. Transport
Source: The WHOQOL Group (1998c) 
Table 3. Domains and facets of WHOQOL-bref 
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facet with normal scale. The answers 1, 2, 3, 4 and 5 are to take the values 5, 4, 3, 2 and 1, 
respectively. The same procedure is used in the conversion of inverted facets, where the 
scores 4, 8, 12, 16 and 20 are to take the values 20, 16, 12, 8 and 4, respectively. 
2.3 WHOQOL-100 questions, domains and facets 
Composed by 100 questions, the WHOQOL-100 is sectioned into 24 groups of four questions 
each, receiving the name of “facets”. The group of facets constitutes a “domain”. Unlike the 
composition of facets, the six WHOQOL-100 domains are not constituted by the same 
number of facets, and may vary from one to eight. 
The questions that compose WHOQOL-100 are not arranged in the questionnaire in a logical 
sequence by domain or facet. They are grouped by type of answer scale. The distribution of 
WHOQOL-100 facets and areas are listed in Table 2: 
 
DOMAINS FACETS 
Domain I – Physical 
1. Pain and discomfort
2. Energy e fatigue
3. Sleep and rest
Domain II – Psychological 
4. Positive feelings
5. Thinking, learning, memory and concentration 
6. Self-esteem
7. Bodily image and appearance
8. Negative feelings
Domain III – Level of 
Independence 
9. Mobility
10. Activities of daily living
11. Dependence on medication or treatments 
12. Work capacity





Domain V – Environment 
16. Physical safety and security
17. Home environment
18. Financial resources
19. Health and social care: accessibility and quality 
20. Opportunities for acquiring new information and 
skills 
21. Participation in and opportunities for recreation/ 
leisure activities 
22. Physical environment 
(pollution/noise/traffic/climate) 
23. Transport
Domain VI – 
Spiritual/Religion/Personal 
Beliefs  
24. Spiritual/Religion/Personal Beliefs 
Source: The WHOQOL Group (1998a) 
Table 2. Domains and facets of WHOQOL-100 
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WHOQOL-100 has a facet that is not included in any domain, the facet Overall Quality of 
Life and General Health Perceptions (The WHOQOL Group, 1998b). This aspect deals with 
a self-assessment of quality of life, where the respondents express their point of view 
concerning their satisfaction with their lives, health and quality of life. 
2.4 Short version of WHOQOL-100 (WHOQOL-bref) 
Aiming at providing a tool that demand less time to its filling out, and with satisfactory 
psychometric characteristics, the WHOQOL Group developed the short version of 
WHOQOL-100, the WHOQOL-bref (The WHOQOL Group, 1996). 
The WHOQOL-bref is composed of 26 questions - two questions on self-assessment of 
quality of life and 24 issues representing each facet of WHOQOL-100. To compound the 
questions of WHOQOL-bref, it was selected the question of each facet that present the 
highest correlation with the average score of all facets (The WHOQOL Group, 1998c). 
After the selection of issues, an analysis was conducted to see if they, factually, represented the 
corresponding facets. In six facets, the question selected was replaced by another question of the 
corresponding facet, for, under the bias of experts, there was another question that could best 
define these six facets (The WHOQOL Group, 1998c). The facets belonging to the domain Level 
of Independence were incorporated into the Physical domain and the facet belonging to the 
domain Spiritual / Religion / Personal Beliefs was incorporated into the Psychological domain. 
Thus, the WHOQOL-bref is composed by four domains: Physical, Psychological, Social 
Relationships and Environment, completing the configuration expressed in Table 3: 
 
DOMAINS FACETS 
Domain I – Physical 
1. Pain and discomfort
2. Energy e fatigue
3. Sleep and rest
4. Mobility
5. Activities of daily living
6. Dependence on medication or treatments
7. Work capacity
Domain II – Psychological 
8. Positive feelings
9. Thinking, learning, memory and concentration
10. Self-esteem
11. Bodily image and appearance
12. Negative feelings
13. Spiritual/Religion/Personal Beliefs




Domain IV – Environment 
17. Physical safety and security
18. Home environment
19. Financial resources
20. Health and social care: accessibility and quality
21. Opportunities for acquiring new information and skills 
22. Participation in and opportunities for recreation/ leisure 
activities 
23. Physical environment (pollution/noise/traffic/climate) 
24. Transport
Source: The WHOQOL Group (1998c) 
Table 3. Domains and facets of WHOQOL-bref 
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The calculation of scores of WHOQOL-bref follows the same logic of WHOQOL-100, 
except for the calculation of scores of facets. In WHOQOL-bref each facet is represented 
by a single question, and therefore the scores of facets are not calculated (The WHOQOL 
Group, 1996). 
3. WHOQOL-HIV 
Aiming at creating a tool for assessing the quality of life directed to people living with 
HIV, researchers from the Joint United Nations Program on HIV / AIDS (UNAIDS) and 
WHO carried out studies in people with HIV in nine different countries. The result of this 
study was the instrument WHOQOL-HIV, an additional module specifically designed for 
people with HIV or AIDS (WHO Field Center for the Study of Quality of Life of Bath, 
2008). 
WHOQOL-HIV evaluates the quality of life from six domains and 29 facets. The domains 
and facets are the same as in WHOQOL-100, with the addition of five specific facets for 
people living with HIV/AIDS. The facet of WHOQOL-100 that evaluates the quality of life 
from the perspective of the assessed person, not included in any domain, remains in 
WHOQOL-HIV. The specific facets for people with HIV, as well as the facets from 
WHOQOL-100, are composed of four questions (O'Connell et al., 2004). The additional 
facets of WHOQOL-HIV are: 
- Symptoms of PLWHA: physical problems that people living with HIV/AIDS (PLWHA) 
could present; 
- Social Inclusion: individual’s acceptance in society that he/she lives; 
- Forgiveness and blame: feeling of blame that the individual has about his/her HIV 
infection; 
- Concerns about the future: fear and worries concerning changes in individual’s lifestyle 
after HIV infection; 
- Death and dying: worries about dead, such as place, reason and suffering before 
dying. 
The additional facets of WHOQOL-HIV are included in the domains already existent in 
WHOQOL-100, featuring the following configuration (Table 4): 
 
DOMAINS FACETS 
Domain I – Physical 50. Symptoms of PLWHA 
Domain IV – Social Relationships  51. Social Inclusion 
Domain VI – Spiritual/Religion/Personal Beliefs  
52. Forgiveness and Blame 
53. Concerns about the Future 
54. Death and Dying 
Source: Adapted from O'Connell et al. (2004) 
Table 4. Domains and facets exclusive of WHOQOL-HIV 
Based on the previously mentioned configuration, questions which constitute additional 
facets of WHOQOL-HIV, with inverted questions written in italics, are: 
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How much are you bothered by any unpleasant physical problems 
related to your HIV infection? 
To what extent do you fear possible future (physical) pain? 
To what extent do you feel any unpleasant physical problems prevent 
you from doing things that are important to you? 
To what extent are you bothered by fears of developing any physical 
problem? 
Social Inclusion 
To what extent do you feel accepted by the people you know? 
How often do you feel you are discriminated against because of your 
health condition? 
To what extent do you feel accepted by your community? 
How much do you feel alienated from those around you? 
Forgiveness and 
Blame 
How much do you blame yourself for your HIV infection? 
To what extent are you bothered by people blaming you for your HIV 
status? 
How guilty do you feel about being HIV positive? 
To what extent do you feel guilty when you need the help and care of 
others? 
Concerns about the 
Future 
To what extent are you concerned about your HIV status breaking 
your family line and your future generations? 
To what extent are you concerned about how people will remember 
you when you are dead? 
To what extent do any feelings that you are suffering from fate or 
destiny bother you? 
How much do you fear the future? 
Death and Dying 
How much do you worry about death? 
How bothered are you by the thought of not being able to die the way 
you would want to? 
How concerned are you about how and where you will die? 
How preoccupied are you about suffering before dying? 
Source: Adapted from Zimpel & Fleck (2008) 
Table 5. Additional questions of WHOQOL-HIV 
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The calculation of scores of WHOQOL-bref follows the same logic of WHOQOL-100, 
except for the calculation of scores of facets. In WHOQOL-bref each facet is represented 
by a single question, and therefore the scores of facets are not calculated (The WHOQOL 
Group, 1996). 
3. WHOQOL-HIV 
Aiming at creating a tool for assessing the quality of life directed to people living with 
HIV, researchers from the Joint United Nations Program on HIV / AIDS (UNAIDS) and 
WHO carried out studies in people with HIV in nine different countries. The result of this 
study was the instrument WHOQOL-HIV, an additional module specifically designed for 
people with HIV or AIDS (WHO Field Center for the Study of Quality of Life of Bath, 
2008). 
WHOQOL-HIV evaluates the quality of life from six domains and 29 facets. The domains 
and facets are the same as in WHOQOL-100, with the addition of five specific facets for 
people living with HIV/AIDS. The facet of WHOQOL-100 that evaluates the quality of life 
from the perspective of the assessed person, not included in any domain, remains in 
WHOQOL-HIV. The specific facets for people with HIV, as well as the facets from 
WHOQOL-100, are composed of four questions (O'Connell et al., 2004). The additional 
facets of WHOQOL-HIV are: 
- Symptoms of PLWHA: physical problems that people living with HIV/AIDS (PLWHA) 
could present; 
- Social Inclusion: individual’s acceptance in society that he/she lives; 
- Forgiveness and blame: feeling of blame that the individual has about his/her HIV 
infection; 
- Concerns about the future: fear and worries concerning changes in individual’s lifestyle 
after HIV infection; 
- Death and dying: worries about dead, such as place, reason and suffering before 
dying. 
The additional facets of WHOQOL-HIV are included in the domains already existent in 
WHOQOL-100, featuring the following configuration (Table 4): 
 
DOMAINS FACETS 
Domain I – Physical 50. Symptoms of PLWHA 
Domain IV – Social Relationships  51. Social Inclusion 
Domain VI – Spiritual/Religion/Personal Beliefs  
52. Forgiveness and Blame 
53. Concerns about the Future 
54. Death and Dying 
Source: Adapted from O'Connell et al. (2004) 
Table 4. Domains and facets exclusive of WHOQOL-HIV 
Based on the previously mentioned configuration, questions which constitute additional 
facets of WHOQOL-HIV, with inverted questions written in italics, are: 
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How much are you bothered by any unpleasant physical problems 
related to your HIV infection? 
To what extent do you fear possible future (physical) pain? 
To what extent do you feel any unpleasant physical problems prevent 
you from doing things that are important to you? 
To what extent are you bothered by fears of developing any physical 
problem? 
Social Inclusion 
To what extent do you feel accepted by the people you know? 
How often do you feel you are discriminated against because of your 
health condition? 
To what extent do you feel accepted by your community? 
How much do you feel alienated from those around you? 
Forgiveness and 
Blame 
How much do you blame yourself for your HIV infection? 
To what extent are you bothered by people blaming you for your HIV 
status? 
How guilty do you feel about being HIV positive? 
To what extent do you feel guilty when you need the help and care of 
others? 
Concerns about the 
Future 
To what extent are you concerned about your HIV status breaking 
your family line and your future generations? 
To what extent are you concerned about how people will remember 
you when you are dead? 
To what extent do any feelings that you are suffering from fate or 
destiny bother you? 
How much do you fear the future? 
Death and Dying 
How much do you worry about death? 
How bothered are you by the thought of not being able to die the way 
you would want to? 
How concerned are you about how and where you will die? 
How preoccupied are you about suffering before dying? 
Source: Adapted from Zimpel & Fleck (2008) 
Table 5. Additional questions of WHOQOL-HIV 
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The syntax for calculation of WHOQOL-HIV domain and facets’ score, correcting the error 
reported by Pedroso et al. (2010), is the following: 
 








RECODE F11 F12 F13 F14 F21 F22 F23 F24 F31 F32 F33 F34 F501 F502 F503 
F504 F41 F42 F43 F44 F51 F52 F53 F54 F61 F62 F63 F64 F71 F72 F73 F74 F81 
F82 F83 F84 F91 F92 F93 F94 F101 F102 F103 F104 F111 F112 F113 F114 F121 
F122 F123 F124 F131 F132 F133 F134 F141 F142 F143 F144 F151 F152 F153 
F154 F511 F512 F513 F514 F161 F162 F163 F164 F171 F172 F173 F174 F181 
F182 F183 F184 F191 F192 F193 F194 F201 F202 F203 F204 F211 F212 F213 
F214 F221 F222 F223 F224 F231 F232 F233 F234 F241 F242 F243 F244 F521 
F522 F523 F524 F531 F532 F533 F534 F541 F542 F543 F544 G1 G2 G3 G4 





RECODE F11 F12 F13 F14 F22 F24 F32 F34 F72 F73 F81 F82 F83 F84 F93 F94 
F102 F104 F111 F112 F113 F114 F131 F154 F163 F182 F184 F222 F232 F234 
F501 F502 F503 F504 F514 F512 F521 F522 F523 F524 F531 F532 F533 F534 
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Source: Adapted from The WHOQOL-HIV Group (2002) 
Table 6. WHOQOL-HIV syntax 
The calculation of WHOQOL-HIV results is similar to the method used in WHOQOL-100. 
However, some criteria used in WHOQOL-100 were not inherited by WHOQOL-HIV. The 
results of the WHOQOL-HIV are presented as follows: 
- Verification of all those 120 questions completed with values between 1 and 5;  
- Reversal of all the questions whose answers scale is inverted. Concerning the facets 
in inverted scale, all the questions pertaining to these facets are individually 
inverted; 
- Scores of facets are calculated from the sum of the four questions of each facet, followed 
by a division by four, being represented in a scale of 1 to 5;  
- Scores of domains are calculated by the sum of the scores of "n" facets that compound 
each area, divided by the number of the domain facets. The result is multiplied by four, 
being represented in a scale of  4 to 20; 
Contrarily to WHOQOL-100, the scores of domains and facets represent the mean of these 
variables only when all the belonging items to these are correctly punctuated. The score of 
facets is calculated since these presents one or more answered question, while the score of 
domains is calculated since these owns at least one facet that has been scored. The scores are 
not converted to a 0-100 scale. The exclusion criterion for individuals who answered 
incorrectly or doesn’t answer more than 20% of total items from instrument does not exist 
on WHOQOL-HIV syntax. 
4. WHOQOL-HIV-bref 
Under the same reason for the development of WHOQOL-bref, the WHOQOL Group 
developed an abbreviated version of WHOQOL-HIV. The WHOQOL-HIV-bref is based on 
WHOQOL-bref, in a way each facet is represented by one single question.  
The 26 questions of WHOQOL-bref are repeated in WHOQOL-HIV-bref, being added to 
these five questions that represent the additional facets of WHOQOL-HIV (The 
WHOQOL-HIV Group, 2002). Contrary to what occurs in WHOQOL-bref, the facets 
belonging to the domains Level of Independence and Spiritual/Religion/Personal Beliefs 
are not incorporated to the Physical and Psychological domains, having, therefore, the 
same configuration of the domains of WHOQOL-HIV, presenting the following 
configuration: 
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The syntax for calculation of WHOQOL-HIV domain and facets’ score, correcting the error 
reported by Pedroso et al. (2010), is the following: 
 








RECODE F11 F12 F13 F14 F21 F22 F23 F24 F31 F32 F33 F34 F501 F502 F503 
F504 F41 F42 F43 F44 F51 F52 F53 F54 F61 F62 F63 F64 F71 F72 F73 F74 F81 
F82 F83 F84 F91 F92 F93 F94 F101 F102 F103 F104 F111 F112 F113 F114 F121 
F122 F123 F124 F131 F132 F133 F134 F141 F142 F143 F144 F151 F152 F153 
F154 F511 F512 F513 F514 F161 F162 F163 F164 F171 F172 F173 F174 F181 
F182 F183 F184 F191 F192 F193 F194 F201 F202 F203 F204 F211 F212 F213 
F214 F221 F222 F223 F224 F231 F232 F233 F234 F241 F242 F243 F244 F521 
F522 F523 F524 F531 F532 F533 F534 F541 F542 F543 F544 G1 G2 G3 G4 





RECODE F11 F12 F13 F14 F22 F24 F32 F34 F72 F73 F81 F82 F83 F84 F93 F94 
F102 F104 F111 F112 F113 F114 F131 F154 F163 F182 F184 F222 F232 F234 
F501 F502 F503 F504 F514 F512 F521 F522 F523 F524 F531 F532 F533 F534 
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Source: Adapted from The WHOQOL-HIV Group (2002) 
Table 6. WHOQOL-HIV syntax 
The calculation of WHOQOL-HIV results is similar to the method used in WHOQOL-100. 
However, some criteria used in WHOQOL-100 were not inherited by WHOQOL-HIV. The 
results of the WHOQOL-HIV are presented as follows: 
- Verification of all those 120 questions completed with values between 1 and 5;  
- Reversal of all the questions whose answers scale is inverted. Concerning the facets 
in inverted scale, all the questions pertaining to these facets are individually 
inverted; 
- Scores of facets are calculated from the sum of the four questions of each facet, followed 
by a division by four, being represented in a scale of 1 to 5;  
- Scores of domains are calculated by the sum of the scores of "n" facets that compound 
each area, divided by the number of the domain facets. The result is multiplied by four, 
being represented in a scale of  4 to 20; 
Contrarily to WHOQOL-100, the scores of domains and facets represent the mean of these 
variables only when all the belonging items to these are correctly punctuated. The score of 
facets is calculated since these presents one or more answered question, while the score of 
domains is calculated since these owns at least one facet that has been scored. The scores are 
not converted to a 0-100 scale. The exclusion criterion for individuals who answered 
incorrectly or doesn’t answer more than 20% of total items from instrument does not exist 
on WHOQOL-HIV syntax. 
4. WHOQOL-HIV-bref 
Under the same reason for the development of WHOQOL-bref, the WHOQOL Group 
developed an abbreviated version of WHOQOL-HIV. The WHOQOL-HIV-bref is based on 
WHOQOL-bref, in a way each facet is represented by one single question.  
The 26 questions of WHOQOL-bref are repeated in WHOQOL-HIV-bref, being added to 
these five questions that represent the additional facets of WHOQOL-HIV (The 
WHOQOL-HIV Group, 2002). Contrary to what occurs in WHOQOL-bref, the facets 
belonging to the domains Level of Independence and Spiritual/Religion/Personal Beliefs 
are not incorporated to the Physical and Psychological domains, having, therefore, the 
same configuration of the domains of WHOQOL-HIV, presenting the following 
configuration: 
  




Domain I - Physical 
To what extent do you feel that physical pain prevents you from 
doing what you need to do? 
Do you have enough energy for everyday life?
How satisfied are you with your sleep?
How much are you bothered by any physical problems related to 
your HIV infection?
Domain II - Psychological 
How much do you enjoy life?
How well are you able to concentrate?
Are you able to accept your bodily appearance? 
How satisfied are you with yourself?
How often do you have negative feelings such as blue mood, 
despair, anxiety, depression?
Domain III – Level of 
Independence 
How much do you need any medical treatment to function in your 
daily life?
H ow well are you able to get around?
How satisfied are you with your ability to perform your 
daily living activities?
How satisfied are you with your capacity for work? 
Domain IV – Social 
Relations 
To what extent do you feel accepted by the people you 
know? 
How satisfied are you with your personal relationships? 
How satisfied are you with your sex life?
How satisfied are you with the support you get from your 
friends? 
Domain V - Environment 
How safe do you feel in your daily life?
How healthy is your physical environment?
Have you enough money to meet your needs?
How available to you is the information that you need in 
your day-to-day life? 
To what extent do you have the opportunity for leisure 
activities? 
How satisfied are you with the conditions of your living 
place?
How satisfied are you with your access to health services? 
How satisfied are you with your transport?
Domain VI -  Spiritual / 
Religion / Personal Beliefs
To what extent do you feel your life to be meaningful? 
To what extent are you bothered by people blaming you for your 
HIV status?
How much do you fear the future?
How much do you worry about death?
Overall Quality of Life 
and General Health 
Perceptions 
How would you rate your quality of life?
How satisfied are you with your health? 
Source: Adapted from The WHOQOL-HIV Group (2002) 
Table 7. Questions of WHOQOL-HIV-bref 
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The calculation of WHOQOL-HIV-bref’s score then follows a different logic regarding 
WHOQOL-bref instrument, consisting of the following command lines: 
 
STEPS WHOQOL-HIV-BREF SYNTAX
Check all 31 
items from 
assessment 
have a range 
of 1-5 
RECODE Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 
Q17 Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28 Q29 Q30 Q31 










COMPUTE Domain 1 = (Q3 + Q4 + Q14 + Q21)/4 * 4
COMPUTE Domain 2 = (Q6 + Q11 + Q15 + Q24 + Q31)/5 *4 
COMPUTE Domain 3 = (Q5 + Q22 + Q23 + Q20)/4 * 4 
COMPUTE Domain 4 = (Q27 +Q26 + Q25 + Q17)/4*4 
COMPUTE Domain 5 = (Q12 + Q13 + Q16 + Q18 + Q19 + Q28 + Q29 + 
Q30)/8 *4 
COMPUTE Domain6 = (Q7 + Q8 + Q9+ Q10)/4 *4 
Source: The WHOQOL-HIV Group (2002) 
Table 8. WHOQOL-HIV-bref syntax 
The WHOQOL-HIV-bref syntax’s textual transcription presents the following configuration: 
- Verification of all those 31 questions completed with values between 1 and 5;  
- Reversal of all the questions whose answers scale is inverted; 
- Scores of domains are calculated by the sum of the scores of "n" questions that 
compound each area, divided by the number of the domain questions. The result is 
multiplied by four, being represented in a scale of  4 to 20; 
As can be realized, just as WHOQOL-HIV, the WHOQOL-HIV-bref's Syntax presents the 
same present fragility found in WHOQOL-HIV regarding the domains and facets score 
calculation, because it's not accomplished the arithmetic mean of domain items. There is not 
also the conversion of domains and facets score for a 0-100 scale. Lastly, and is not existing 
the criteria of exclusion of individuals who doesn't answer or answered incorrectly a 
number of questions higher than 20% from the total instrument items. 
5. Tools for the calculation of scores and descriptive statistics of WHOQOL-
HIV and WHOQOL-HIV-bref instruments 
To obtain the results to apply the WHOQOL instruments, WHOQOL Group recommends 
the use of SPSS software, a statistical software program that requires specific expertise for its 
use and is not for free distribution. 
Looking for the removal of such limitations, tools were built from the software Microsoft 
Excel, a software program for broad accessibility, to calculate scores and descriptive 
statistics for WHOQOL-HIV and for WHOQOL-HIV-bref. Such tools were made in the same 
manner as the tool developed by Pedroso et al. (2009) to calculate scores and descriptive 
statistics of WHOQOL-100. 
  




Domain I - Physical 
To what extent do you feel that physical pain prevents you from 
doing what you need to do? 
Do you have enough energy for everyday life?
How satisfied are you with your sleep?
How much are you bothered by any physical problems related to 
your HIV infection?
Domain II - Psychological 
How much do you enjoy life?
How well are you able to concentrate?
Are you able to accept your bodily appearance? 
How satisfied are you with yourself?
How often do you have negative feelings such as blue mood, 
despair, anxiety, depression?
Domain III – Level of 
Independence 
How much do you need any medical treatment to function in your 
daily life?
H ow well are you able to get around?
How satisfied are you with your ability to perform your 
daily living activities?
How satisfied are you with your capacity for work? 
Domain IV – Social 
Relations 
To what extent do you feel accepted by the people you 
know? 
How satisfied are you with your personal relationships? 
How satisfied are you with your sex life?
How satisfied are you with the support you get from your 
friends? 
Domain V - Environment 
How safe do you feel in your daily life?
How healthy is your physical environment?
Have you enough money to meet your needs?
How available to you is the information that you need in 
your day-to-day life? 
To what extent do you have the opportunity for leisure 
activities? 
How satisfied are you with the conditions of your living 
place?
How satisfied are you with your access to health services? 
How satisfied are you with your transport?
Domain VI -  Spiritual / 
Religion / Personal Beliefs
To what extent do you feel your life to be meaningful? 
To what extent are you bothered by people blaming you for your 
HIV status?
How much do you fear the future?
How much do you worry about death?
Overall Quality of Life 
and General Health 
Perceptions 
How would you rate your quality of life?
How satisfied are you with your health? 
Source: Adapted from The WHOQOL-HIV Group (2002) 
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The calculation of WHOQOL-HIV-bref’s score then follows a different logic regarding 
WHOQOL-bref instrument, consisting of the following command lines: 
 
STEPS WHOQOL-HIV-BREF SYNTAX
Check all 31 
items from 
assessment 
have a range 
of 1-5 
RECODE Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 
Q17 Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28 Q29 Q30 Q31 










COMPUTE Domain 1 = (Q3 + Q4 + Q14 + Q21)/4 * 4
COMPUTE Domain 2 = (Q6 + Q11 + Q15 + Q24 + Q31)/5 *4 
COMPUTE Domain 3 = (Q5 + Q22 + Q23 + Q20)/4 * 4 
COMPUTE Domain 4 = (Q27 +Q26 + Q25 + Q17)/4*4 
COMPUTE Domain 5 = (Q12 + Q13 + Q16 + Q18 + Q19 + Q28 + Q29 + 
Q30)/8 *4 
COMPUTE Domain6 = (Q7 + Q8 + Q9+ Q10)/4 *4 
Source: The WHOQOL-HIV Group (2002) 
Table 8. WHOQOL-HIV-bref syntax 
The WHOQOL-HIV-bref syntax’s textual transcription presents the following configuration: 
- Verification of all those 31 questions completed with values between 1 and 5;  
- Reversal of all the questions whose answers scale is inverted; 
- Scores of domains are calculated by the sum of the scores of "n" questions that 
compound each area, divided by the number of the domain questions. The result is 
multiplied by four, being represented in a scale of  4 to 20; 
As can be realized, just as WHOQOL-HIV, the WHOQOL-HIV-bref's Syntax presents the 
same present fragility found in WHOQOL-HIV regarding the domains and facets score 
calculation, because it's not accomplished the arithmetic mean of domain items. There is not 
also the conversion of domains and facets score for a 0-100 scale. Lastly, and is not existing 
the criteria of exclusion of individuals who doesn't answer or answered incorrectly a 
number of questions higher than 20% from the total instrument items. 
5. Tools for the calculation of scores and descriptive statistics of WHOQOL-
HIV and WHOQOL-HIV-bref instruments 
To obtain the results to apply the WHOQOL instruments, WHOQOL Group recommends 
the use of SPSS software, a statistical software program that requires specific expertise for its 
use and is not for free distribution. 
Looking for the removal of such limitations, tools were built from the software Microsoft 
Excel, a software program for broad accessibility, to calculate scores and descriptive 
statistics for WHOQOL-HIV and for WHOQOL-HIV-bref. Such tools were made in the same 
manner as the tool developed by Pedroso et al. (2009) to calculate scores and descriptive 
statistics of WHOQOL-100. 
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The tools proposed on this study automatically perform all calculations in the incipient 
syntaxes provided by the WHOQOL-HIV Group. The researchers who use it need only to 
fill in the specified cells the answers given by respondents. 
After data insertion, to use the results of theirs research, researcher may copy the individual 
scores for each respondent, results of descriptive statistics, and graphics; however, without 
changing such results. Is allowed to insert and edit values just in the area to tabulate the 
answers of respondents. 
To validate such tools, simulations were performed with real data applications of each of the 
WHOQOL-HIV and WHOQOL-HIV-bref instrument, comparing the results by using the 
proposed tools with those from SPSS. The results from both software programs were exactly 
the same, thus ensuring the reliability of tools, which are object of this study.  
The tools were tested on different versions of the Microsoft Office: 2000, XP, 2003, 2007 and 
2010. It was found that they are compatible with all versions tested, without differences in 
the results. The tools are available for download in the website: 
http://www.brunopedroso.com.br/whoqol-hiv(en). html.  
6. Conclusions 
Although the WHOQOL-HIV and WHOQOL-HIV-bref instruments are respectively 
additional modules for WHOQOL-100 and WHOQOL-bref instruments, the syntax of these 
instruments are not entirely derivative from its precursor syntax. Despite the widespread 
distribution and use of the WHOQOL-HIV and WHOQOL-HIV-bref, the difficulty to 
interpret the instrument syntax limits in choosing to use such tools. 
Additionally, the WHOQOL Group interposition in making the syntax to calculate the 
WHOQOL scores with SPSS (a relatively high cost software program and which requires 
specific expertise for use) encourages another imbroglio, restricting the use of WHOQOL 
instruments. 
Facing this struggle, we here investigate the instruments in question to facilitate their 
interpretation and use. Looking for the removal of the previously described limitations, the 
syntaxes are transcribed textually, detailing all the steps used to obtain the results from 
WHOQOL-HIV and WHOQOL-HIV-bref instrument. Were also built tools from Microsoft 
Excel 2003 software to calculate the scores and descriptive statistics of such instruments, in 
which the researcher is responsible only for data tabulation. The calculation is carried out 
automatically. 
The developed tools were tested and proved compatible in the versions 2000, XP, 2007 and 
2010 of Microsoft Excel. The results returned by the tools were compared by using real 
application data of WHOQOL-HIV and WHOQOL-HIV-bref instruments, with the results 
returned by SPSS, following the parameters established by the WHOQOL-HIV Group. The 
results were identical to both instruments. 
We conclude that, despite being globally disseminated instruments, developed under a 
rigorous methodology, the instruments produced by the WHOQOL-HIV Group show 
limitations. Expecting to facilitate its use, was made an approach with a focus on clarifying 
these instruments. In this wise, we aimed to enable greater accessibility of the results 
promoted by the instruments, object of study here, thus expanding the investigation 
involving QoL empirical reality of people living with HIV/AIDS. 
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